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Abstract 
Several human diseases are reported to be associated with amyloidogenic peptides and 
proteins, for example, 0 amyloid (A13) in senile plaques of Alzheimer's disease and 32 
microglobulin (02M) deposition in dialysis related amyloidosis. The major factor for 
amyloidosis appears to be an increase in the production of amyloidogenic proteins, 
resulting in the amyloid 13 sheet deposits. It is clear that conformational changes in 
amyloidogenic proteins lead to fibril formation and aggregation. Several trigger 
factors may be involved in the initiation and propagation of these amyloid deposits. 
Common components such as serum amyloid P component (SAP), 
glycosaminoglycans (GAGs) may be involved, and metals such as aluminium, copper, 
zinc and calcium have also been implicated. Metals have been shown to induce 
aggregations of amyloid and accelerate amyloid deposition. The present study 
involved the investigation of the effects of inorganic elements on the secondary 
structural integrity of amyloid proteins leading to aggregation and deposition. 
The addition of Cu 2t Zn 2t Ca2 and Al 3 (>50 jiM) to the amyloids, particularly 
A13 ( 1-40) and 132M, showed some changes with a general decrease in a helix 
secondary structure and an increase in P sheets. Both the A13(l-40)  and 02M peptides 
treated with physiological concentration of either A1 31, Ca2t Cu 2 or Zn2 combined 
with the physiological concentrations of various GAGs showed that they had a 
synergistic effect, indicating that GAGs could play a role in conjunction with metals. 
This has not been previously reported in the literature. The binding of GAGs to the 
amyloids could provide further binding sites for metal ions, leading to an alteration in 
the protein conformation. There is evidence in the literature for metals as trigger 
factors in the deposition of the Alzheimer's disease A[3 peptides, but not for the 
dialysis related f32M peptide. Similar changes occurred for the interaction of both 
Af3(l-40) and 132M with metals and also with metals in the presence of GAGs. This 
suggests that similar mechanisms may be involved and that metals may have an 
underlying role in the general process of amyloidosis independent of the type of 
amyloid protein involved. 
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AP beta amyloid from Alzheiiner's disease 
Aj3( 1-40) 1-40 fragment of beta amyloid 
AJ3( 1-42) 1-42 fragment of beta amyloid 
A3(l-43) 1-43 fragment of beta amyloid 
A13(xx - xx) other fragments of beta amyloid 
AA AA amyloid 
Ads-ATR adsorption attenuated total reflectance 
AEF amyloid enhancing factor 
AIAPP islet amyloid polypeptide 
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Al/Al 3 aluminium / aluminium cation 
Aid 3 aluminium chloride 
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APP amyloid precursor protein of Alzheimer's disease 
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BBB blood brain barrier 
BSA bovine serum albumin 
BSE bovine spongiform encephalopathy 
Ca/Ca 2 calcium / calcium ion 
CaCl2 calcium chloride 
CAPD continuous ambulatory peritoneal dialysis 
Cd cadmium 
CD circular dichroism 
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CNS central nervous system 
Co/Co 2 cobalt / cobalt cation 
Cr chromium 
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CSF cerebral spinal fluid 
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Cu/Cu 2 copper / copper cation 
Cud1 2 copper chloride 
DNA deoxyribonucleic acid 
Ill 
DRA dialysis related amyloidosis 
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EAA excitatory amino acids 
ESRD end stage renal failure 
Fe/Fe3 iron / iron cation 
FTIR/TR Fourier transform infrared spectroscopy 
GAG glycosaminoglycan 
Ge germanium 
Gly glycine 
H2SO4 sulphuric acid 
HCI hydrochloric acid 
HD haemodialysis 
HDL high density lipoprotein 
HEP heparin 
HFIP 1,1,1,3,3,3 hexafluoroisopropanol 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
hr hour 
HRP horse radish peroxidase 
HS heparan sulphate 
HSPG heparan sulphate proteoglycan 
IEF isoelectric focusing 
IRE internal reflectance element 
kDa kilo Daltans 
KS keratan sulphate 
Mg2 magnesium cation 
MgCl, magnesium chloride 
Mn/Mn 2 manganese / manganese cation 
Mo molybdenum 
MT metallothionein 
MW molecular weight 
Na2SiO3 sodium silicate 
NaCl sodium chloride 
NaOH sodium hydroxide 
(NH4)2 SO4 ammonium sulphate 
Ni/Ni 2 nickel / nickel cation 
NMR nuclear magnetic resonance 
NOEINOESY nuclear Overhauser effect / nuclear Overhauser 
enhancement spectroscopy 
NP-40 nonylphenoxy polyethoxy ethanol (Tergitol) 
NT neurofibrillary tangles 
iv 
PAGE polyacrylamide gel electrophoresis 
PAR 4-(2-pyridylazo) resorcinol 
Pb lead 
PG proteoglycan 
Phe phenylalanine 
PT-IF paired helical filament 
p1 isoelectric point 
PMSF phenyl methly suiphonyl fluoride 
Pro proline 
PrP* prion protein intermediate 
PrPC prion protein 
PrP conformationally changed prion protein 
r[hu]PrV human recombinant prion protein 
RNA ribonucleic acid 
rpm revolutions per minute 
SAA serum AA amyloid 
SAP serum amyloid P component 
Sb antimony 
SDS sodium dodecyl sulphate (lauryl sulphate) 
Ser serine 
SHaPrP(29-23 1) Syrian hamster prion protein 
SIMS secondary ion mass spectrometry 
SOD superoxide dismutase 
SP senile plaque 
TCBS tween citrate buffered saline 
TEMED N,N,N' ,N'-tetramethylethylene diamine 
TF-ATR thin film attenuated total reflectance 
TFE 2,2,2 
- trifluoroethanol 
Tris tris[hydroxymethyl]aminomethane 
Irp tryptophan 
TUBS tween tris buffered saline 
TTR transthyretin amyloid 
Tyr tyrosine 
UV ultra violet (electromagnetic radiation) 
Val valine 
VIS visible (electromagnetic radiation) 
Zn/Zn 2 zinc! zinc cation 
ZnCI, zinc chloride 
V 
Contents 
Chapter 1. Introduction. 	 i 
1.1 Proteins. i 
1.1.1 Protein introduction. 1 
1.1.2 The importance of protein structure. 2 
1.1.3 Protein folding. 4 
1.1.4 Protein misfolding and diseases. 5 
1.1.5 Protein misassembly. 7 
1.3.6 The binding of metals to proteins. 8 
1.2 Methods for the determination of secondary structure of proteins. 11 
1.2.1 X-ray crystallography. 12 
1.2.2 Nuclear magnetic resonance (NMR) spectroscopy. 13 
1.2.2.1 Physical principles of NMR. 13 
1.2.2.2 Nuclear Overhauser effect. 13 
1.2.2.3 Secondary structure in NMR. 14 
1.2.3 Circular dichroism (CD) spectroscopy. 14 
1.2.3.1 Physical principles of CD. 14 
1.2.3.2 Secondary structure in CD. 16 
1.2.3.3 Secondary structural interpretation. 17 
1.2.3.4 Svnchrotronic radiation. 17 
1.2.4 Fourier transform infrared (FTIR) spectroscopy. 18 
1.2.4.1 Secondary structure in ETIR. 18 
1.2.4.2 Band assignment. 19 
1.2.4.3 Second derivative and deconvolution spectra. 21 
1.2.4.2 Attenuated total reflectance (ATR). 22 
1.3 Amyloidosis. 23 
1.3.1 Classification of amyloid. 24 
1.3.2 Common components of amyloid deposits. 26 
1.3.2.1 Ainyloid P component. 26 
1.3.2.2 Glycosaminoglycans. 26 
1.3.2.3 Amyloid enhancing factor. 27 
1.3.3 Mechanisms of amyloidosis. 28 
1.4. Alzheimer's disease. 29 
1.4.1 Pathogenesis of Alzheimer's disease. 29 
1.4.1.IA/Jproteinformation. 30 
1.4.1.2 A/i deposition. 31 
1.4.2 Aggregation is dependent on certain regions of A. 32 
1.4.2.1 Main Afifragments, A/j/-40) and A/3(1-42).. 33 
1.4.2.2 Other A/ifragments. 34 
1.4.3 The mechanism of A13 amyloid deposition. 35 
1.4.4 Risk factors for Alzheimer's disease. 36 
1.4.4.1 Advanced Glycation End Products. 37 
1.4.4.1 Cations as a triggerfactorfor the deposition of amyloid in AD. 38 
'II 
1.5 Dialysis related amyloidosis. 39 
1.5.1 Pathogenesis of 132M amyloidosis. 
1.5.1.1 /32M deposition. 39 
1.5.2 Aggregation depends on certain regions of 13 2M. 40 
1.5.3 The mechanism of 02M amyloid deposition. 41 
1.5.4 Risk factors for the 02M amyloidosis. 41 
1.5.4. 1 Advanced Glycation End Products. 42 
1.5.4.2 Cations as a trigger factor for /32M deposition. 42 
1.5.4.3 Aluminium and dialysis encephalopathy. 43 
1.6 Other amyloids: The Prion protein and neurodegeneration. 44 
1.6.1 Pathogenesis of PrP amyloidosis. 44 
1.6.1.1 Prion formation. 44 
1.6.1.2 Prion propagation. 45 
1.6.2 The mechanism of prion protein deposition. 46 
1.6.3 Risk factors for PrP amyloidosis. 47 
1.6.3.1 Cations as a triggerfactorfor Prion deposition. 47 
1.7 Levels of trace elements in the human body. 48 
1.7.1 Essential trace elements. 49 
1.7.1.1 Zinc as a trace element. 49 
1.7.1.2 Copper as a trace element. 49 
1.7.1.3 Iron as a trace element. 50 
1.7.2 Other trace elements. SO 
1.7.2.1 Silicon as a trace element. SO 
1.7.2.2 Aluminium as a trace element. 51 
1.7.3 Trace element levels and disease. 52 
1.7.3.1 Metal involvement and oxidative stress. 52 
1.7.3.2 A disruption of metal levels. 52 
1.7.4 Zinc in disease. 53 
1.7.4.1 Zinc levels andAD. 53 
1.7.4.2 Zinc levels in renal dialysis. 54 
1.7.5 Copper in disease. 55 
1.7.5.1 Copper levels and AD. 55 
1.7.5.2 Copper levels in renal dialysis. 56 
1.7.6 Aluminium and silicon in disease. 56 
1.7.6.1 Aluminium and silicon levels in AD. 56 
1.7.6.2 Aluminium and silicon levels in renal dialysis. 58 
1.8 Summary. 60 
1.9 Aims of study. 60 
Chapter 2. Materials and Methods. 
	 61 
2.1. Reagents. 	 61 
2.1.1 Stock Solutions. 	 61 
2.2. Concentrations of trace metals in biological tissues. 	 63 
2.2.1. Detection of trace metals in biological tissues and fluids. 
	 63 
2.2.1.1. Sample preparation - Blood plasma. 	 63 
2.2.1.2. Calibration of the internal standard method. 
	 63 
2.2.1.3 Sample preparation - Human tissue. 	 64 
2.2.2 Measurement of metal levels by ion chromatography. 
	 64 
vii 
2.2.2.1 Validation of the ion chromatographic technique. 65 
2.3 Extraction of amyloid from Alzheimer's disease brain tissue. 66 
2.3.1 Homogenisation and centrifugation of the brain tissue. 66 
2.3.2 Size exclusion of protein extract and purification of the 4 kDa extract. 66 
2.3.2.1 Protein quantification. 67 
2.3.3 Immunoblotting of 13 amyloid proteins. 68 
2.4 Circular dichroism spectroscopy studies of amyloid materials. 69 
2.4.1 Calibration of the CD spectrometer. 69 
2.4.2. Amyloid studies. 69 
2.4.2.1 Amyloid peptide treated with metals. 71 
2.4.2.2 Amyloid peptide treated with aluminium and si/icon. 71 
2.4.2.3 Ainyloid peptide treated with glycosaminoglycans and metals. 71 
2.4.3 The interaction of recombinant human PrPC 
 with the 72 
organophosphorous insecticide, Phosmet and its metabolites. 
2.4.4 Manipulation of the CD data and determination of the amyloid 73 
secondary structure. 
2.5 Attenuated total reflectance Fourier transform infrared 74 
spectroscopy of amyloid materials. 
2.5.1 Modification of ATR attachment. 74 
2.5.2 Measurement using ATR-FTIR. 75 
2.6 Polyacrylamide gel electrophoresis of 132M and Afi(1-40). 76 
2.6.2 Isoelectric focusing of amyloid materials. 77 
2.6.3 Gel Staining. 78 
Chapter 3. The determination of the levels of trace elements in biological 
	 79 
fluids and tissues. 
3.1 Introduction. 	 79 
3.1.1 Present study. 
	 80 
3.1.2 Method. 	 80 
3.2 Results and discussion. 
	 81 
3.2.1 Determination of the levels of copper and zinc in blood plasma. 
	 81 
3.2.2 Determination of the levels of copper, zinc, cobalt, nickel and 
	 85 
aluminium in biological tissues. 
3.3 Conclusions. 	 87 
Chapter 4. The extraction of amyloid from Alzheimer's disease brains. 	 88 
4.1 Introduction. 	 88 
4.1.1 Present study. 	 89 
4.1.2 Method. 	 89 
4.2 Results and discussion. 	 90 
4.2.1 Extraction of A13 peptide from Alzheimer's disease brain tissue. 
	 90 
4.2.2 Purification of the f3 amyloid extract using size exclusion. 	 90 
4.2.3 Immunoblot detection of the amyloid A13(1-40). 	 97 
L!AUI 
Chapter 5. Circular dichroism spectroscopy studies of amyloid materials. 	 99 
5.1 Introduction. 99 
5.1.1 The use of CD in the study of amyloid proteins. 99 
5.1.2 Factors affecting amyloid studies in vitro. 100 
5.1.2.1 Solvent effects. 101 
5.1.2.2 pH effects. 102 
5.1.3 Present study. 103 
5.1.4 Method. 103 
5.2 Results. 104 
5.2.2 Amyloid peptides. 107 
5.2.3 The secondary structural changes of recombinant mouse P rPC 110 
treated with Phosmet and its metabolites. 
5.2.4 Amyloid proteins treated with metals. 112 
5.2.5 Amyloid proteins treated with aluminium. 120 
5.2.6 Amyloid proteins treated with both aluminium and silicon. 121 
5.2.7 Amyloid proteins treated with glycosaminoglycans. 130 
5.2.8 Amyloid proteins treated with glycosaminoglycans and aluminium. 130 
5.2.9 Amyloid proteins treated with glycosaminoglycans with copper and zinc. 131 
5.2.10 Amyloid proteins treated with glycosaminoglycans and calcium. 131 
5.3 Summary of results. 143 
5.4 Discussion. 143 
5.4.1 Comparison of secondary structural values with those in other CD studies. 146 
5.4.2 Extracted A13 may contain different fragments of the Aj3 proteins. 147 
5.4.3 The prion protein interaction with Phosmet. 149 
5.4.4 Amyloids treated with metals. 151 
5.4.5 Amyloids treated with copper and zinc. 151 
5.4.6 Amyloids treated with aluminium. 152 
5.4.7 Amyloids treated with aluminium and silicon. 153 
5.4.8 Amyloids treated with GAGs. 153 
5.4.9 Amyloids treated with GAGs and metals. 154 
5.5 Conclusion. 155 
Chapter 6. Detection of secondary structural changes in amyloid proteins 
using attenuated total reflectance FTIR spectroscopy. 	 156 
6.1 Introduction. 	 156 
6.1.1 The use of ETIR in the study of amyloids. 	 157 
6.1.1 Present study. 	 158 
6.1.2 Method. 	 158 
6.2 Results. 	 159 
6.2.1 Validation of the ATR system. 	 159 
6.2.2 Second derivative spectra. 	 161 
6.2.3 Amyloid peptides. 	 164 
6.2.4 Amyloid proteins treated with metals. 	 164 
6.2.5 Amyloid proteins treated with aluminium. 	 171 
6.2.6 Amyloid proteins treated with both aluminium and silicon. 	 171 
6.2.7 Amyloid proteins treated with glycosaminoglycans and calcium. 	 171 
6.3 Summary of results. 	 181 
FM 
6.4 Discussion. 	 183 
6.4.1 Amyloid proteins and metals. 	 183 
6.4.2 Amyloid proteins treated with both aluminium and silicon. 	 184 
6.4.3 Amyloid proteins treated with glycosaminoglycans and calcium. 	 185 
6.5 Conclusion. 	 185 
Chapter 7. Polyacrylamide gel electrophoresis of amyloid proteins treated 	 186 
with metals. 
7.1 Introduction. 186 
7.1.1 The use of PAGE in the study of amyloids. 186 
7.1.2 Present study. 187 
7.1.3 Method. 187 
7.2 Results. 188 
7.2.1 A13(l-40)  treated with metals. 188 
7.2.2 A0(1-40) treated with aluminium. 188 
7.2.3 A3(1-40) treated with GAGs and metals. 188 
7.2.4 132M treated with metals. 193 
7.2.5 32M treated with aluminium and with aluminium and silicon. 193 
7.2.6 Two dimensional PAGE of 02M treated with aluminium. 194 
7.2.7 f32M treated with GAGs and metals. 194 
7.2.8 A13(l42)  and A0(l-43) treated with metals and with aluminium and silicon. 194 
7.3 Discussion. 201 
7.3.1 Aged amyloid. 201 
7.3.2 Amyloid peptides treated with metals. 202 
7.3.3 Amyloid peptides treated with increasing concentration of aluminium. 203 
7.3.4 Two dimensional PAGE of P2M  treated aluminium. 204 
7.3.5 Amyloid peptides treated with GAGs and metals. 205 
7.4 Conclusion. 205 
Chapter 8. General Discussion. 	 206 
8.1 Common features of amyloids. 206 
8.2 Metals as a possible trigger factor for amyloidosis. 207 
8.2.1 Metal binding sites in amyloids. 209 
8.2.2 Evidence for a histidine binding site. 210 
8.3 GAGs as a possible trigger factor for amyloidosis. 211 
8.4 The interaction of both GAGs and metals with amyloids. 212 
8.5 Conclusions. 215 
8.6 Future work 216 
References 	 217 
Appendix 	 234 
Published papers 
Declaration 
Chapter 1. Introduction. 
1.1 Proteins. 
1.1.1 Protein introduction. 
Proteins are abundant in all organisms and are indeed fundamental to life. Proteins are 
involved in virtually every biological process in a living system. The precise 
orchestration of cellular activity requires that various proteins are present in 
appropriate quantities at the correct times. The shear diversity of the protein structure 
underlies their large range of function. The information required to synthesise proteins 
is stored in DNA. Proteins are synthesised on ribosomes as linear chains of typically 
hundreds of amino acids. 
Most of the chemical reactions that occur in biological systems are catalysed by 
enzymes, which are proteins. The rate of the reactions they catalyse are often 
increased by the order of at least a million-fold. Proteins are involved in the 
transmission of nerve impulses by acting as receptors of transmitter molecules that 
cross the junctions separating nerve cells. Proteins also act as hormone receptors and 
can themselves be hormones. The immune system depends on the production of 
antibodies: proteins, which bind to specific foreign particles such as bacteria and 
viruses. 
Various ions, small molecules and other metabolites are stored in an organism as 
complexes with proteins; for example iron is stored bound to ferritin in the liver. 
Proteins are involved in the transportation of particles ranging from electrons to 
macromolecules. Haemoglobin in red blood cells is important for the transfer of 
oxygen and removal of carbon dioxide from the lungs to other tissues. The formation 
of pores in cellular membranes through which ions pass and the transport of 
molecules across membranes is also dependent on proteins. Some proteins have a 
structural role, providing mechanical support. The 'skeleton" of a cell consists of a 
complex network of protein filaments. Muscle contraction depends on the action of 
large protein assemblies. Other organic materials are also based on protein, for 
instance hair. Collagen is found in all multi-cellular animals, occurring in almost 
every tissue; approximately a quarter of mammalian protein is collagen. 
1.1.2 The importance of protein structure. 
In order to function, protein chains must fold into the unique native three-dimensional 
structures that are characteristic of the individual proteins. The protein shape and 
function are inextricably linked. The importance of protein folding has been 
recognised for many years. In the 1950's, Linus Pauling [I] discovered that proteins 
consist of primarily two regular secondary structures - the a helix and the J3 sheet. 
And in the early 1960's, Christian Anfinsen [2] showed that proteins could adopt their 
native conformation spontaneously. What Anfinsen's experiments didn't show, 
however, was why a particular chain of amino acids folds into one and only one 
shape, i.e. the protein sequence determines its structure. 
The formations of a helix and Ji sheet secondary structures are directly influenced by 
the presence of primary sequence of a protein. In proteins and nucleic acids the 
predominant regular structures are characterised by intra-chain hydrogen bonding 
within the backbone chain. The a helix is a right-hand spiral stabilised by hydrogen 
bonds between each amino acid's nitrogen atom and the oxygen atom of the fourth 
residue along the chain. This means that there are 3.6 amino acids for each turn of the 
helix (Figure 1.1a) [3]. 
The 13 sheet structure is essentially flat, with the side chains sticking out on alternate 
sides. The 0 sheet is also stabilised by hydrogen bonds between nitrogen and oxygen 
atoms. In this case, however, the hydrogen-bonded atoms belong to different amino 
acid chains running alongside each other. The sheets are 'parallel' if all the chains run 
in the same direction and are 'antiparallel' if alternate chains run in opposite directions 
(Figure 1.1b). 
Antiparallel sheets are often, but not always, formed by a single chain looping back 
upon itself [3]. When a single chain loops back on itself to form an antiparallel 3 
sheet, the one to three amino acids linking the two strands are known as a 13-turn 
(Figure 1.1c). All other local arrangements of amino acids are described as 'random 
coil,' although they are random only in the sense of not being periodic. 
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Figure 1.1 
Typical secondary structure: (a) a helix, (b) anti-parallel 0 sheet, (c) 13 turn or hairpin. 
The dashed lines show hydrogen bonding between residues; arrows denote direction 
of 13 strand [3]. 
helix 
-> 
(b)dieets 	 (c)flints 
Tertiary folding is largely determined by the packing of the a helices andlor 13 sheets. 
For many proteins the tertiary structure can adequately be described by one of three 
motifs: an assembly of a helices with a predominantly 13 sheet (ct/13), 13 sheets stacked 
together (13/13), or structures involving a helices (a/a). These arrangements satisfy the 
hydrogen bonding requirements of buried main-chain nitrogen and oxygen atoms 
while shielding a substantial fraction of the non-polar atoms from the solvent. 
Quaternary structure is formed by the combination of two or more chains. The 
interactions between the chains are not different from those in tertiary structure, but 
are distinguished only by being inter-chain rather than intra-chain [3]. 
1.1.3 Protein folding. 
There are nearly 100,000 proteins encoded in the human genome, and there are 
thought to be more than a thousand fundamentally distinct structural architectures into 
which folded proteins can be classified. The number of possible conformations of a 
polypeptide chain is huge, yet the folding of a protein is fast with a typical folding 
time of I s. Protein folding occurs in multiple steps commonly referred to as 
"The folding pathway". 
The distribution of polar (hydrophilic) and non-polar (hydrophobic) residues along the 
polypeptide chain is now known to be a crucial factor in determining the overall fold 
and are important in both intra and inter-binding sites and ultimately their 
stabilisation. Protein folding involves complex mechanisms that depend on the co-
operative action of a vast number of relatively weak non-covalent interactions 
involving thousands of atoms. 
There are several families of cellular proteins whose job is to assist in the folding 
process of the other proteins, for example, molecular chaperones. The efficiency of 
protein folding can be compromised by aggregation of folding intermediates that have 
exposed hydrophobic surfaces. In a cellular environment, molecular chaperone 
proteins bind reversibly to folding intermediates, protecting the incompletely folded 
polypeptide chains from aggregating and promoting correct folding [4]. 
rAl 
The formation of the protein structure that yields the lowest energy state, i.e. the 
'native conformation", is the process that drives the folding pathway. Protein folding 
is thought to start with the formation of elements of secondary structure independently 
of tertiary structure, or at least before tertiary structure is locked in place. First a very 
rapid formation of secondary structure such as a-helices and fi—sheets. The folding of 
these compact shapes are presumed to be driven by hydrophobic collapse, so that 
most of the interior of the protein is occupied by hydrophobic amino acids, which 
have a low affinity for water. The second phase is slower; the secondary structure 
elements interact with each other to form the native tertiary structure. 
The nucleus primarily consists of a few adjacent residues, which have some correct 
secondary structure interactions, but is stable only in the presence of further 
approximately correct tertiary structure interactions. These elements then assemble 
into the tightly packed native tertiary structure either by diffusion and collision or by 
propagation of structure in a stepwise manner. The protein subunits then assemble to 
the quaternary structure to form the final native conformation of the protein [4]. 
1.1.4 Protein misfolding and disease. 
Even after the folding process is complete, however, a protein can subsequently 
experience conditions under which it unfolds, at least partially, and then it is again 
prone to aggregation. When we boil an egg, the albumin protein in the egg white 
unfolds. Upon cooling, the proteins don't return to their original shapes, instead, they 
form an insoluble solid, but tasty nonetheless. 
It is becoming clear that the failure of proteins to fold correctly or to remain folded 
under all appropriate physiological conditions can give rise to a wide range of 
pathological conditions. Defective and misfolded proteins are normally rapidly 
degraded by proteolysis. It may therefore not always be obvious that a protein is 
misfolding, but rather, there seems to be a decrease in that protein. 
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The misfolding of a protein can be caused by: 
• Mutations in the DNA so that the amino acid sequence differs from normal. Many 
single amino acid mutations have little affect on the folding, but in a number of 
cases results in a less efficient, or unstable protein. 
' Lack of enzymes or molecular chaperone needed to fold a protein. 
• Interaction with other misfolded proteins. 
Correctly folded protein becoming misfolded by accumulated damage due to 
oxidation, radicals or other chemical reactions. 
Misfolding proteins can cause diseases in several ways: 
A protein becomes non-functional or ineffective. 
A protein is in short supply caused by a decrease in production or increased 
uptake/removal. 
A protein is unable to get to the right place, due to inability to fold correctly. 
• The presence of protein aggregates, that have a damaging effect on the cell. The 
abnormal protein can, in some cases, propagate further misfolding of normal 
protein as in the prion diseases. 
A number of diseases are caused by amyloid fibrils, in which a normally soluble 
protein deposits as insoluble fibrils. In most cases the exact cause is as yet unknown, 
but the protein involved is certainly misfolded. Examples are: Alzheimer's disease (Ji-
amyloid protein), Primary systemic amyloidosis (immunoglobulin light chains), 
Senile systemic amyloidosis (transthyretin, TTR), Diabetes Type 2 (Amylin, TAPP), 
The prion diseases such as Bovine spongiform encephalopathy and Creutzfeldt-Jakob 
disease (prion, PrP). The resulting deposition of aggregated amyloid protein disrupts 
the normal function of tissue in which it is deposited [5]. 
Inherited diseases have examples of all types of consequences of misfolded protein: 
Emphysema is due to a lack of ci-anti-proteinase. Osteogenesis imperfecta is due to an 
unstable fold. Cystic fibrosis, and familial hypercholesteremia may be due to a 
misfolded protein that cannot take up its proper position. Familial amyloidosis, 
Creutzfeldt-Jakob disease, and Alzheimer's disease involve aggregation of misfolded 
no 
proteins [5]. In Huntington's disease, the mutated gene codes for a protein that 
produces an increasing number of consecutive residues of the amino acid glutamine. 
When the number of residues expands past 40, the protein becomes insoluble, causing 
the protein to misfold. 
1.1.5 Protein misassembly. 
Various terms encompass protein misassembly [4]: 
Precipitation arises as a consequence of solvent changes, decreasing the solubility 
of the protein in a reversible manner. 
• Denaturation refers to reversible, as well as irreversible structural changes in 
native proteins leading to altered solubility that does not change the primary 
structure. 
• Coagulation occurs as a result of an increase in particle size caused by 
denaturation of a protein with subsequent gelation. 
• Aggregation is used to describe the association or assembly of proteins that may 
involve quaternary structural changes or involve sidechain interaction [4]. 
Proteins may undergo a wide range of specific structural changes during their normal 
function. The biological activity of proteins is closely linked to its native structure, 
which is retained only if critical factors such as temperature, pH, solvent and 
concentration are kept within narrow limits. The relative reactivity of a protein often 
depends upon the nature of the solvent-protein interaction. Solvents such as di-
chloroacetic acid, trifluoroethanol and formic acid can influence the secondary 
structure of the protein [4]. 
Protein folding can be studied in the test tube by dissolving a purified protein in 
aqueous solution and denature it using chaotropic agents which are polar and/or 
charged molecules (e.g. urea and guanidine-HCI), detergents (e.g. sodium dodecyl 
sulphate), heat, metals, reagents which cleave disulphide bridges (e.g. dithiothreitol, 
mercaptoethanol) and acids or bases which cleave salt bridges. Removing the 
denaturant by dialysis induces a spontaneous refolding of the polypeptide into its 
original, native fold. 
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Different denaturants can lead to different denatured states but common to all states is 
a reduction in solubility. Denaturants cause alterations in the conformation of the 
polypeptide chain, which can be reversed on their removal. Essentially the 
'denaturation - renaturation' step is a two-state process involving a native protein 
state and an unfolded state. There are other intermediates but these are generally 
thermodynamically unstable. The increase in nucleus radius with increasing protein 
concentration leads to a gain in conformational entropy that drives the aggregation. As 
the concentration of denatured protein increases then the pool of component 
molecules that favour aggregation increases [4]. 
1.1.6 The binding of metals to proteins 
The solubility of proteins may be pictured as a balance between attractive and 
repulsive forces involving on the one hand the interaction of protein molecules with 
the solvent, and the interaction between the protein molecules. The balance of these 
forces determines the degree to which the protein molecules tend to disperse and 
surround themselves with other protein molecules. Some of the factors affecting this 
solubility include coulombic forces, hydrogen bonding between protein-protein and 
protein-solvent and the presence of hydrophobic groups in the protein. 
The binding of ions depends on the intrinsic affinity of the ligand groups available for 
interaction that allows binding of ions non-specifically. The folding of a peptide chain 
means that side groups such as carboxyl, imidazole, or sulphydryl are usually more 
important than terminal amino or carboxyl groups. In general ion binding sites are 
composed of protein moieties, such as the carboxyl group, that interact simultaneously 
with the ion producing a co-operative affect that may afford some specificity. The 
amino acid groups in a polypeptide chain are restricted by intra- or inter-hydrogen 
bonding and steric hindrance and are not free to move and cluster around a metal ion 
in the way free amino acids and small peptides can. Proteins bind to particular ions 
due to the specific arrangement of residues. 
The protein molecule normally bears a considerable number of positive and negative 
charges whose net potential field favours or hinders the approach of the metal ion. 
The effect of the counter ion depends on its size and ionic strength. At low ionic 
strength, weak interaction of soluble organic molecules with proteins may lead to 
increased protein solubility (salting in). At high ionic strength, e.g. high salt 
concentration, the opposite holds and the solubility decreases (salting out). 
Most of the groups available to bind to metal ions also bind to hydrogen ions and in 
general there will be competition for sites in the protein. Competition for hydrogen 
can be readily detected by a shift in pH following the addition of metal salts. The 
binding of metal ion may be mediated by the unfolding or denaturing of the protein, 
exposing ligands and chelatable sites. There is a linear relationship between the 
logarithm of solubility and ionic strength, i.e. the Hoffmeister effect. Decreased 
solubility favours aggregation and coagulation. These effects may be explained by 
competition for water of hydration between protein and excess electrolyte []. 
There are three separate ways in which metals could interact with proteins that may 
alter the solubility. It must also be highlighted that full saturation of metal ions may 
not be possible due to steric and electrostatic effects. The binding of metal to a protein 
could occur as in Figure I.2a and may also form a chelate complex (Figures 1.2b - 
1.2c). 
The first form is probably encountered frequently in metal protein precipitates and 
may affect solubility in two ways: the charge effects are similar to that of H* 
 (i.e. 
changing the net charge of the protein) and effects between protein-metal complex 
and the solvent. In the second mechanism, the aggregation occurs by cross linkages 
across metal ions. The cross-linking can occur when several ligands are exposed and 
the metal cation is able to chelate across either inter or intra protein molecule. Even if 
intermolecular cross-linking is the main mechanism which renders the protein 
insoluble, relatively few cross linkages may be necessary [4]. 
rF 
protein surface 
a 
	
b 	 C 
Figure 1.2 - Diagrams showing the possible interactions between protein ligand (A) 
and metal (M): (a) simple binding (b) inter and (c) intra chelate complex formation. 
The two amino acids, which combine most strongly with metal ions, are the histidine 
and cysteine residues. Histidine may combine with a metal ion through all of its 
exposed donor groups, imidazole as well as the a amino group and carboxyl groups. 
Cysteine combines with metals strongly via the sulphur group. Ions tend to bind to 
groups for which they have some intrinsic affinity. Ca 2 ions bind to oxygen atoms, 
Zn 2 ions bind to imidazole rings of histidine residues. Fe 2 /Fe3 ions bind to sulphur 
atoms on cysteine residues, and Cu 2 ions bind to thiol or imidazole groups. 
'III 
1.2 Methods for the determination of secondary structure of 
proteins. 
Techniques for protein structural elucidation include X-ray crystallography, NMR and 
fluorescence labelling and other spectroscopic methods. The complete three-
dimensional structure of a protein at high resolution can be determined by X-ray 
crystallography. This technique requires the molecule to form well-ordered crystals, 
which may not be possible for all proteins. Nuclear magnetic resonance (NMR) 
spectroscopy has the advantage over crystallographic techniques in that experiments 
are performed in aqueous solution as opposed to a crystal lattice. However, the 
physical principles that make NMR possible limits the application of this technique to 
macromolecules of less than 30 kDa [6]. The interpretation of the NMR spectrum of 
large proteins is very complex and NMR peaks of larger proteins can be difficult to 
resolve and assign. In NMR, the secondary structures are localised to specific 
segments of the polypeptide chain and can thus provide a wealth of information about 
dynamics. However, obtaining secondary structural information from NMR data 
requires considerably concentrated solutions (15 mg ml' for a 15 kDa protein) [7 & 
8]. These limitations have led to the development of alternative methods that are not 
able to generate structures at atomic resolution but provide structural information on 
proteins (especially secondary structure). Therefore, the use of circular dichroism and 
vibrational spectroscopy to determine the structure of biological macromolecules has 
been increasingly used. 
Circular dichroism (CD) spectroscopy can be used to gain information about the 
secondary structure of proteins in solution. The advantages are that it is a non-
destructive technique using small sample sizes of relatively low protein concentration 
(200 pA of a 0.5 mg ml' solution in standard cells). Relative changes due to the 
influence of the environment on the sample (pH, denaturants, temperature etc.) can be 
monitored very accurately. The major disadvantage is that a CD spectro-polarimeter is 
relatively expensive, and also some interferences occur with solvent absorption in the 
UV region which means that buffers used should be dilute and non-absorbing below 
200nm [9].  Fourier transform infrared (FTIR) spectroscopy can be applied to the study 
of the secondary structure of proteins in aqueous solution [10-12]. The technique of 
FTIR spectroscopy requires only small amounts of proteins in a variety of 
environments. The main strength of ETIIR spectroscopy is the ability to investigate 
biological systems under non-invasive conditions. Therefore, high quality spectra can 
be obtained relatively easily without problems of background fluorescence, light 
scattering and those related with the size of the proteins. The ever-present water 
absorptions can be mathematically subtracted. Methods are now available that can 
separate sub-components that overlap in the spectrum of proteins. Since the potential 
sources of error in CD and ETIR analyses of secondary structure content are largely 
independent, the two methods are highly complementary and could be used in 
conjunction to increase accuracy. Despite limitations in the quantitative assessment of 
protein secondary structure content, FTIR and CD spectroscopy provide good tools to 
monitor conformational changes in polypeptides and proteins. The various techniques 
are described below. The spectroscopic methods of CD and FTIR, which were used in 
the actual studies, are discussed in more detail below. 
1.2.1 X-ray crystallography. 
The understanding of protein structure and function has been greatly enriched by X-
ray crystallography, a technique that can reveal the precise three-dimensional 
positions of most of the atoms in a protein molecule. Crystals of the protein of interest 
are needed because the technique requires that all molecules be precisely orientated. 
Crystals can often be obtained by slow drying, or by adding ammonium sulphate or 
another salt to a concentrated solution of protein to reduce its solubility. A narrow 
beam of X- rays strikes the protein crystal, part of it penetrates through the crystal; the 
rest is scattered in various directions. Current detection methods include solid-state 
electronic detectors such as CCD instruments that can collect larger areas than single 
point scintillation counters. The molecular image obtained from x-ray crystallography 
is called an electron density map, because it is an image of the electron clouds of the 
molecule under study. Hence, the electron density map can give three-dimensional 
information about the structure of the protein [8]. If the sequence of amino acids in 
the protein is known, an accurate model can be obtained by fitting the atoms of the 
known sequence into the electron density map, calculations are carried out on 
sophisticated graphics computers. 
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1.2.2 Nuclear magnetic resonance (NMR) spectroscopy 
1.2.2.1 Physical principles of NMR. 
Nuclear magnetic resonance is a spectroscopic method that is used to observe nuclear 
spin reorientation in an applied magnetic field. Sub-atomic particles possess a 
characteristic spin angular momentum. Many important nuclei ('H, 31 P, 13C) have a 
spin equal to a ½ giving rise to two energy states in the presence of a magnetic field. 
A transition from the lower (a) to the upper (13) state occurs when a nucleus absorbs 
electromagnetic radiation of appropriate frequency. NMR spectroscopy is a very 
informative technique because the local magnetic field around all the nuclei in the 
sample is not identical within the applied field B 0, because of shielding from the 
electron density around each molecule. Consequently, nuclei in different 
environments absorb energy at slightly different resonance frequencies, an effect 
termed the chemical shift. Thus each proton should, in principle, be characterised by a 
unique chemical shift. In practice, this is never observed as some protons, such as the 
three protons of each side chain, methyl group of Thr, Val, Leu, lie, and Met and most 
pairs of equivalent (2,6 and 3,5) aromatic ring protons are found to have degenerate 
chemical shifts. Other protons (OH, SH, and NH3) are in rapid chemical exchange 
with the solvent and thus have chemical shifts indistinguishable from the solvent 
resonance [6 & 71. Near complete amino acid chemical shifts assignments are often 
possible [13]. 
1.2.2.2 Nuclear Overhauser effect. 
The structural information of a protein can come from through space dipole-dipole 
coupling between two protons, called the nuclear Overhauser effect (NOE). The 
intensity of a NOE is proportional to the distance separating the two protons. Thus the 
NOE is a sensitive probe of short intramolecular distances. A two dimensional nuclear 
Overhauser enhancement spectroscopy (NOESY) spectrum graphically displays pairs 
of protons that are in close proximity [7]. The three-dimensional structure of a protein 
can be reconstructed from a large number of such proximity relations. This raises the 
problems complexity when analysing proteins and other biological macromolecules 
[6-8]. 
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1.2.2.3 Secondary structure in NMR. 
Secondary structure determination by NMR techniques does not require a full three-
dimensional structural analyses as X-ray crystallography does. Comparison of X-ray 
structures and amide proton chemical shifts for well characterised proteins reveals a 
simple correlation between chemical shift and secondary structure [7]. The a proton 
of all 20 naturally occurring amino acids has been shown to have a strong correlation 
with secondary structure [14]. Conformationally dependent chemical shifts of 
' 3 C" 
and 13CO nuclei can also be used to identify regular a helix or P sheet regions in 
proteins. While obtaining the sequential resonance assignments is a time consuming 
task, the NMR method is perhaps the most powerful and certainly the most accurate 
method of secondary structure determination [6]. 
1.2.3 Circular dichroism (CD) spectroscopy 
Circular dichroism spectroscopy is a form of light absorption spectroscopy that 
measures the difference in absorption of right and left circularly polarised light by a 
substance. CD is a useful technique to determine the conformation of proteins and 
other biological macromolecules that exhibit chirality. Proteins are optically active 
because they are asymmetric. Amino acid residues other than glycine are intrinsically 
optically active because of the configuration about their a carbon atom. Threonine 
and isoleucine possess an additional chiral centre. Circular dichroism is very sensitive 
to the secondary structure of a polypeptides due to the dis-symmetric environment, 
which affects the electronic transitions to the excited state [15]. The electronic 
interaction between residues also contributes to the optical activity e.g. an a helical 
conformation results in a large contribution [8]. CD spectra rather than optical 
rotatory spectra are measured because CD spectra are more sensitive and simpler to 
interpret. The magnitude of Ac is x10 3 less than the ordinary molar absorption 
coefficient e, corresponding to an ellipticity of a few 1/100th of a degree, hence 
sensitive instrumentation is required to measure CD [8]. 
1.2.3.1 Physical principles of CD. 
Electromagnetic radiation is a complex waveform that can be considered as two 
components, a magnetic (B) and an electric (E) wave at right angles to each other 
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(Figure 1.3a). The differential absorption of radiation polarised in two directions as 
function of frequency is called dichroism. When applied to plane polarised light, it is 
called linear dichroism, and for circularly polarised light, it is called circular 
dichroism. After passing through an optically active sample, circularly polarised light 
will be changed in two aspects. The two components are still circularly-polarised, but 
the molar absorption coefficients for right- and left-polarised light now differ causing 
the E-vector to trace an ellipse (actually an elliptical screw) instead of a circle. There 
will also be a rotation of the major axis of the ellipse due to differences in refractive 
indices [16]. The synchrotronic light is circularly polarised in a photo elastic 
modulator (PEM) before passing through the sample chamber and detected using a 
photomultiplier tube (PMT) (Figure 1.3b). 
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Figure 1.3 - Schematic diagrams of (ai) of linearly polarised light (X - wavelength, B 
- magnetic and E - electric components), (au) of right-handed circularly polarised 
light [16] and (b) the layout for CD Station 3.1 at Daresbury Laboratories. 
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1.2.3.2 Secondary structure in CD. 
Circular dichroism is particularly powerful in monitoring conformational changes. 
The far-ultraviolet CD spectrum of a protein is sensitive to its main-chain 
conformation. For proteins, the absorption in the ultraviolet region of the spectrum 
arises from the peptide bonds (symmetric chromophores) and amino acid side chains 
in proteins. Protein chromophores can be divided into three classes: the peptide bond; 
the amino acid side chains, and any prosthetic groups. The region of 178 - 260 nm can 
be monitored to observe effects of backbone conformational changes (Figure 1.4). 
160 	 210 	 260 	 160 	 210 	 260 
Wavelength (nm) 	 Wavelength (nm) 
Figure 1.4 
- The circular dichroism spectra of (a) secondary structural components; a 
helix (green), 0 pleated sheet (magenta) and a random coil (blue) of a model 
polypeptide and (b) the CD spectrum of combined secondary structure [8]. 
The protein microenvironment in solution, including solvent effects, influences 
secondary structural determination of peptides and proteins. The change in solvent 
environment can cause a change in the transition energy that leads to blue or red shifts 
of the CD maxima These shifts contribute to a discrepancy in the determined 
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secondary structure [16]. The analysis of CD spectra can therefore yield valuable 
information of the secondary structure of biological macromolecules. Measurements 
of synthetic polypeptides and proteins of known structure define the a helices, 13 sheet 
structure and random coils motifs. The a helices have a dominant contribution with a 
negative band between 208 and 222 nm and a positive band at 192 nm. 13 sheets give a 
minimum around 218 nm and a maximum around 196 nm. A randomly arranged 
polypeptide chain has a negative CD band centred at 200 nm [8 & 16]. 
1.2.3.3 Secondary structural interpretation. 
The secondary structural computer programs used to analyse the spectra may give 
differing values due to the program used for secondary structural calculations. 
Various methods including linear combination (LIINCOMB), multi-linear regression 
(MLR), convex constraint analysis (CCA), neural network program single-value 
decomposition (SVD), CONTIIN program for rigid regression analysis, and the self-
consistent method (SELCON) to obtain secondary structural information from CD 
data [16-20]. Secondary structural analysis using the primary sequence has been 
improved by incorporating CD using a least-squares fit or best fit. Unfortunately, 
extraction of a secondary structure using the best fit does not necessarily give 
appropriate secondary structural elements of P sheet or P turn structures. It is 
generally accepted that the a helical secondary structural values are reliable. 
1.2.3.4 Synchrotronic radiation. 
The use of synchrotronic light allows CD measurements below 200 nm in far UV 
region, within the peptide backbone region of 178 - 260 nm. Conventional light 
sources diminish below this range, whereas the flux obtained from a synchrotronic 
light remains high. The synchrotronic light is produced as a result of loss of energy 
from electrons as they decelerate in a magnetic field. The electrons are held in an orbit 
in storage dipole magnets and accelerated to a velocity approaching that of the speed 
of light. Polarised synchrotronic radiation is emitted at a tangent and consists of a 
continuous spectrum of radiation ranging from the X-rays to the microwave region. 
The synchrotron radiation source (SRS) was housed at CLRC Daresbury Laboratory, 
Daresbury, UK. 
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1.2.4 Fourier transform infrared (FTIR) spectroscopy. 
Fourier transform infrared (FTIR) spectroscopy has been used to evaluate structural 
characteristics of proteins, including secondary structure, hydrogen-deuterium 
exchange, thermal denaturation, and other properties. The hydrogen-deuterium 
exchange method can also be used to probe protein conformation, hydrogen bonding, 
exposed exchangeable hydrogens, and membrane-bound conformations. FTIR spectra 
of biological samples are usually complicated with numerous vibrational bands; 
therefore, a difference spectrum would be useful to observe changes purely due to the 
sample. 
The 0-1-1 bending peak at 1644 cm 1 overlaps with the conformational sensitive amide 
I band. The high molar absorptivity of the 0-H bending vibrations of water 
(-1640 cm') and problems associated with non-linearity. This limits the path length 
used in studies of proteins dissolved in water to 10 pm or less. Longer path lengths 
result in significant distortions of water absoprtions, making background subtraction 
impossible. Therefore, digital subtraction of buffer and water spectra can generate the 
spectrum due to the protein. Adequate subtraction will only be obtained if the 
spectrum of the protein solution and water (or buffer) are recorded at the same 
temperature, due to the strong dependency of water absorptions on temperature. An 
alternative approach is to use 2H20 as a solvent. The water bend is shifted some 
400 cm 1 
 to a lower frequency thus leaving a useful window free of absorptions in the 
amide I region of the spectrum. Much longer path lengths may then be used (50 jim is 
standard, although path lengths of 100 jim or more may be used), which allow a 
significant reduction in the concentration of samples (0.1 to I mg mr'). 
1.2.4.1 Secondary structure in FTIR. 
The infrared spectra of polypeptides exhibit a number of 'amide bands' that represent 
different vibrational modes of the peptide bond. There are up to 9 characteristic bands 
named amide A, B and I through to VII. Amide I and amide II bands are two major 
bands of the protein infrared spectrum. The amide I band (between 1600 and 1700cni') 
is mainly associated with the C=0 stretching vibration (70-85%) and is directly related 
to the backbone conformation. Amide 11(1510 and 1580 cm') results from the N-H 
1I 
bending vibration (40-60%) and from the C-N stretching vibration (18-40%). This 
band is conformationatly sensitive. Amide IH and IV (1350 - 1450 cm') are very 
complex bands resulting from a mixture of several co-ordinate displacements. The 
out-of-plane motions are found in amide V, VI and VII bands (200- 800 cm'). 
Overall, the amide I bands are most useful primarily, because they arise 
predominantly from one type of vibration [21]. 
A critical step in the interpretation of JR spectra of proteins is the assignment of the 
amide I component bands of different types of secondary structure. Amide I bands 
centred around 1650-1658 cm 1 are generally considered to be characteristic of cx 
helices. Unordered structure and turns also give rise to amide I bands in this region 
which complicates analysis. The P sheets give rise to highly diagnostic bands in the 
region of 1620-1640 cm 1 . There is a weaker band associated with antiparallel 3 
sheets around 1680 cm1 [22-24] (Table 1.1). 
Secondary structure Amide I frequency (cm ) 
Antiparallel f3 sheets/ aggregated strands 1675 - 1695 
cthelix 1648- 1660 
unordered 1640- 1648 
P sheet 1625- 1640 
Aggregated strands 1610 
- 1628 
Table 1.1 
- shows the typical amide I frequencies corresponding to the secondary 
structural features [23 & 24]. 
1.2.4.2 Band assignment. 
Band assignment depends on the nature and environment of the protein. For real 
proteins, the situation is much more complex than that discussed above, which 
assumes the presence of only one major structural motif. All proteins contain more 
than one secondary structural motif, and, consequently, give rise to more that one 
amide absorption. Unfortunately, the width and separation of these absorptions is such 
that they overlap and produce a composite, often featureless absorption profile as in 
Figure 1.5. It is also assumed that the absorptions arise from amide C=O groups 
involved in secondary structures. 
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Figure 1.5 - A typical spectral profile for a protein containing a degree of secondary 
structure. The individual bands due to the secondary structure contribute to the overall 
featureless spectral envelope shown as the dotted black line. 
In fact significant absorptions in this region of the spectrum may arise from amino 
acid side chains, including tyrosine, phenylalanine, glutamine, arginine and lysine 
[25]. In proteins containing significant amounts of these amino acids a nontrivial 
contribution from the side chains may in fact make up 10 - 15% of the total intensity 
of the amide I. Another source of error lies in the assignment of particular amide I 
absorptions to specific secondary structures, e.g. myoglobin is predominantly a 
helical in structure, with little or no P sheet structure present. However, the IR spectra 
exhibits a maximum at 1653 cm 1 , characteristic of an a helix and also a strong 
shoulder at 1632 cm 1 which may be mistaken for 13 sheet secondary structures. In 
fact, this most likely arises from turns within the protein. Although different types of 
secondary structures produce distinct band frequencies in the amide I region, it is 
difficult to distinguish between different parts of the protein that have the same 
secondary structure. 
Information may be obtained by analysis of the frequency of the composite amide I 
spectral envelope along with any visible shoulders. However, changes in the positions 
of these maxima could make interpretation difficult. For example, a shift to a lower 
b 
3 
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wavenumber of a peak may mean that one or more of the underlying absorptions has 
shifted to a lower frequency. Alternatively, such a shift may be produced by an 
increase in intensity of a component band, resulting in a redistribution of intensities 
without any actual change in the frequency of the peak [23]. Analysis of the spectral 
envelope alone cannot be used to identify secondary structure and could lead to 
misinterpretation 
1.2.4.3 Second derivative and deconvolution spectra. 
Methods such as deconvolution and derivation coupled with curve fitting can be used 
to assign specific bands. Deconvolution or derivation is performed on the original data 
to obtain an estimate of the number of discrete absorptions that make up the complex 
amide I band profile. Deconvolution or derivation are techniques used to obtain an 
estimate of the number of discrete absorptions that make up a complex spectral 
profile. Most of the band positions that are in the amide I band are easily found in 
second derivative spectra. Some difficulties arise in absorption bands showing as 
shoulder peaks in the derivative spectra. Deconvolution is an estimate of the number 
of components in the envelope, their width, height and shape. Therefore the bands 
overlap and can not be distinguished in the amide envelope. These parameters are then 
used as input parameters in an iterative least squares routine that attempts to 
reproduce the experimentally obtained amide I band profile by varying these 
parameters. 
The most common method of quantitation of protein secondary structure involves 
curve fitting of the amide I region [26] of proteins in a variety of matrices and 
environments [27]. Curve fitting methods based on techniques such as singular value 
decomposition [28], factor analysis [29] and partial least squares analysis [30] of JR 
spectra are analogous to methods used for quantitation of CD spectral, i.e. comparison 
of spectra with spectra of known peptide structures. Although quantitative estimates 
of protein secondary structure are sought by many investigators, each of the 
techniques currently used suffers from significant shortcomings. Despite limitations in 
the quantitative assessment of protein secondary structure content, FT-IR provides a 
good tool to monitor conformational changes in polypeptides and proteins [31]. 
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1.2.4.4 Attenuated total reflectance (ATR). 
Attenuated total reflectance FTTR is a versatile and powerful technique for infrared 
sampling and is a method widely used in the study of proteins. Attenuated total 
reflectance spectroscopy can be used to analyse protein structures in different forms, 
including surface adsorbed proteins, membrane bound proteins, turbid solutions and 
proteins in biological samples [32]. The technique is ideal for rapid quantitative and 
qualitative analyses, as no sample preparation is required for most samples. The major 
advantage of ATR-FTIR over conventional ETIR is that proteins can be in aqueous 
solutions that can also be non transparent. 
The ATR attachment comprises of a crystal of a material that is transparent to mid 
infrared. The internal reflectance element (IRE) has a refractive index such that 
incident radiation is internally reflected inside the crystal. Types of material used as 
the IRE include ZnSe and Ge. The refractive index of ZnSe is 2.4 whereas for Ge it is 
4. The most common IRE is ZnSe and can be used at pH 5-9 whereas, Ge is 
recommended for use with acids; either can be used with bases. 
Factors which affect the results obtained in an ATR experiment are: the wavelength of 
infrared radiation; refractive index of the IRE and sample; depth of penetration; 
effective path length; angle of incidence and sample contact with the ATR crystal 
material [33]. An evanescent wave is set up which actually penetrates the crystal 
surface by up to 5 jim dependent on the type of crystal and angle of incident of the 
infrared radiation. The attenuation of the internally reflected radiation results from the 
penetration of the electromagnetic radiation field into the matter in contact with the 
reflection surface. The consequence of this is that a sample in contact with the crystal 
can interact with the evanescent wave, which is then attenuated by absorption by the 
sample, hence the name attenuated total reflectance. The penetration depth is related 
to the effective path length. The effective path length can be used to approximate 
comparisons between transmission and ATR spectra [33]. 
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1.3 Amyloidosis. 
Amyloidosis is the generic term for the classification of diverse but specific 
conditions in which insoluble amyloid fibrils deposit. Amyloid deposits are observed 
in many different diseases including chronic renal dialysis, rheumatoid arthritis, 
B-cell malignancies, diabetes and Alzheimer's disease [34]. The term amyloid means 
"cellulose or starch like" derived from the first diagnostic tests and was first 
developed by Virchow [35]. The term has remained in use despite the fact that 
cellulose is not a constituent of amyloid. 
At least 15 apparently unrelated types of proteins have been described as being 
responsible for amyloid deposition. These deposited proteins are diverse in nature but 
are, nevertheless, grouped together under the term amyloid. These include primary 
amyloid (AL), amyloid A (AA), transthyretin (FUR), Islet amyloid polypeptide 
(AIAPP), 132 microglobulin (132M) and Alzheimer's amyloid 13 protein (Aj3) [36]. 
Although the protein deposits are chemically heterogeneous, they share common 
morphology, being fibrillar in nature with a 13 pleated sheet conformation. They stain 
with specific dyes such as Congo Red, and have a characteristic red-green 
birefringence appearance in polarised light. Amyloid fibrils are small (<30 kDa) and 
are about 7-10 nm in diameter. They are insoluble under physiological conditions and 
resistant to normal degradative processes in vivo [37]. In tissues, they are always 
associated with plasma extracellular matrix constituents such as glycosaminoglycans 
and proteoglycans. 
The accepted overall mechanism in amyloidogenesis is thought to involve specific 
protein precursors that are produced in excess quantity. The processor proteins are 
subjected to genetic mutations or specific amino acid substitutions or are altered by 
proteolytic cleavage resulting in the generation of proteins or peptide fragments [38]. 
These amyloidogenic proteins self aggregate into fibrils with or without trigger 
factors. 
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1.3.1 Classification of amyloid. 
The various amyloids can be classified according to their clinical setting or by the 
type of amyloid protein present. The most common forms of amyloid are shown in 
Table 1.2. 
Type 	 Clinical disease 
	
Type of amyloid protein 
Primary 	 Primary amyloidosis appears de 	 Consist of variable region 
amyloidosis 	 novo and is not associated with any 
	 of light chains deposited as 
underlying disease [39]. 
	
the primary amyloid (AL). 
Secondary 	 Amyloids that appear secondary to a 
	 The AA amyloid protein, 
amyloidosis 	 disorder e.g. chronic inflammatory 
	 derived from a naturally 
disorders, renal cell carcinomas and 
	 occurring serum protein 
Hodgkin's disease [40]. 
	 (apo SAA). 
Hereditary 	 Present in dominant autosomal 
	 Most result from a variant 
amyloidosis 	 disease 	 such 	 as 	 Familial 	 of transthyretin (TTR). 
Amyloidotic Polyneuropathy (FAP) 
and Familial Mediterranean Fever 
(FMF) [4 I]. 
Isolated 	 Localised deposits of amyloid in 
	 e.g. 	 Dialysis 	 related 
amyloidosis 	 endocrine, lung, heart and cerebral 
	 amyloid 132  microglobulin 
in the case of Alzheimer's disease. 
	 (132M) and Alzheimer fi 
amyloid (Au) 
Table 1.2. . Classification of amyloid according to clinical setting. 
AL amyloid protein is common to most primary amyloids such as systemic 
amyloidosis associated with myeloma, monoclonal gammopathy, and occult 
dyscrasia. AL amyloidosis is a disease of ageing that is influenced by gender, two 
thirds of patients are male with a median age of 62 [42}. Generally, AL fragments are 
deposited systemically, although deposits have been found in the heart, kidney, liver, 
spleen and in other organs. AL amyloid fibrils are derived from monoclonal 
immunoglobulin light chains, usually of X type, which are produced by an abnormal 
clone of plasma B cells. AL deposits can consist of light chains of either K or A region 
of the light chain or the entire light chain [40]. The presence of light chain fragments 
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in amyloid deposits represents clear evidence that in situ proteolysis is a major 
mechanism predisposing to fibril formation. 
The AA amyloid protein is a reactive systemic amyloid associated with acquired or 
hereditary chronic inflammatory disease. SAA consists of 76 amino acid residues with 
a molecular weight of 8500 Da, which corresponds to the terminal two thirds of a 
naturally occurring serum protein, apo SAA [43]. The apo SAA is an acute phase 
protein carried by plasma high density lipoproteins (HDL) in concentrations of I tg 
mr' but which increases by 1000 fold during an inflammatory process [44 & 451. 
Multiple isoforms of AA are deposited but it is SAA production and its structure that 
are critical factors in AA amyloidogenesis [36]. 
The transthyretin (TTR) was also termed pre-albumin, as it migrates ahead of albumin 
in electrophoresis. Transthyretin consists of a 55 kDa non-glycoslyated plasma 
protein consisting of four 125 amino acid subunits. TTR serves as a transporter of 
retinol (Vitamin A alcohol). TTR amyloidosis may involve a variety of other proteins, 
for example apolipoprotein, gelsolin, cystatin C, fibrinogen Aa, and lysozyme. 
Mutant forms of this protein cause it to deposit with a predilection for peripheral and 
autonomic nerves [46]. 
Other forms of amyloid include localised deposits of amyloid that tend to involve a 
single organ including the lung, heart and various joints [40]. Islet amyloid 
polypeptide (AIAPP) is involved in endocrine amyloid deposits in the Islet of 
Langerhans in type II diabetes mellitus and insulinoma [47]. 132  microglobulin is 
present in patients on chronic renal dialysis as dialysis-associated amyloidosis and is 
seen to precipitate into amyloid fibrils in various joints and other organs [48]. In 
Alzheimer's disease (AD), a 4 kDa amyloid P protein (Af3) is deposited in 
cerebrovascular and intra-cerebral plaques. This form of amyloidosis can be sporadic 
or occur in a familial form and is also seen in Down's syndrome patients [49]. The 
prion protein (PrP) found in Creutzfeldt-Jakob disease and Gertsmann-Staussler-
Scheinker disease deposit as amyloid plaques and the brain pathology in these 
diseases resembles that of AD [50]. 
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1.3.2 Common components of amyloid deposits 
Chemical analysis of solubilised amyloid fibrils obtained from different types of 
amyloid deposits has shown that amyloid fibrils are formed from two main 
components [51]. The first has a very high molecular weight consisting of a variety of 
macromolecules, including extracellular matrix proteins, fibronectin and 
proteoglycans [52]. The second protein constituent is a distinct fibril subunit with a 
low molecular weight ranging from 3 to 30 kDa, and is specific to each variety of 
amyloidosis. Amyloid fibrils may consist of two or more filamentous subunits of 3 
nm diameter, which are polymerised with each other in an anti-parallel fashion giving 
a f3 sheet conformation [36]. This conformation is common to all amyloid proteins 
such as immunoglobulins, TTR, 132M and Afi 
1.3.2.1 Amyloid P component. 
Regardless of the nature of the fibril protein, the majority of the amyloids are 
associated with glycosaminoglycans (GAG) and a specific protein known as the 
serum amyloid P component (SAP) [47]. The SAP is a normal serum plasma 
glycoprotein synthesised by the liver and formed as 25 kDa subunits [53]. The SAP 
has the ability to bind to different ligands and proteoglycan (HSPG) and to the GAGs 
such as heparan sulphate. Although fibrils can be formed in vitro without SAP, it 
seems that SAP and heparan sulphate proteoglycans are universal constituents of 
amyloid deposits formed in vivo. Their constant association with amyloid may be 
essential to establish or maintain appropriate conditions for amyloid fibril formation 
and deposit accumulation i.e. prevent resorption of fibrils [54]. Much more has to be 
learned about the significance of this association in the amyloidogenic process. 
1.3.2.2 Glycosaminoglycans. 
The presence of sulphated glycosaminoglycans has been reported in a range of 
amyloidogenic diseases including systemic amyloidosis and the cerebral amyloid 
plaques of AD, Down's syndrome [55], and transmissible spongiform encephalopathy 
(TSE) [56], Creutzfeldt-Jakob disease (CJD), Gerstmann—Straussler syndrome, Kuru, 
and experimental hamster scrapie [57]. GAGs have now been demonstrated in at least 
five distinct forms of amyloid and heparan sulphate appears to be one of the most 
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common glycosaminoglycans present [58]. Heparan sulphate as opposed to the other 
GAGs, increases 13 sheet structure in serum amyloid. In murine SAA the HSPG gene 
is over expressed in early amyloidosis and GAGs are reported in situ before the start 
of amyloidosis of AA fibrils [59]. There is high binding affinity of the SAP to heparan 
sulphate and dermatan sulphate. This indicates that the association of SAP and 
amyloid may be mediated by GAGs. 
Glycosaminoglycans are linear polysaccharides composed of a repeating disaccharide 
unit of a N acetylated galactosamine or glucosamine and a uronic acid. They are 
negatively charged species with at least one sugar in the repeating unit having a 
negatively charged carboxylate or sulphate group. Proteoglycans (PG) are proteins 
containing one or more covalently linked glycosaminoglycans chains. They are 
present on cell surfaces and in the extracellular matrix of animals. Their main function 
is in the formation of basement membranes [40]. Proteoglycans are extracellular 
matrix components and also serve as ligands or receptors for mediators of cell 
adhesion, migration, and proliferation [60]. These highly negatively charged 
molecules can directly influence either the processing of the precursor, or the protein 
folding. GAGs and PGs may form templates to which the fibril protein precursors 
attach and multiply. 
1.3.2.3 Amyloid enhancing factor. 
Another factor that may influence amyloid deposition is the so called amyloid 
enhancing factor (AEF). AEF is a non inflammatory, non amyloidogenic substance 
that dramatically shortens the time necessary for the experimental induction of AA 
amyloid deposition in mice to within 24 - 36 hrs [61]. Amyloid enhancing factor was 
originally described in the context of AA amyloidosis. The activity has now been 
isolated from at least four forms of amyloid: AA, AL, transthyretin, and Alzheimer's 
amyloid, all of which vary considerably in terms of the protein subunit that is 
responsible for each amyloid [62]. Preliminary observations indicate that AEF is a 
protein-carbohydrate complex containing large quantities of GAGs or PGs, primarily 
heparan sulphate; the concentrations of AEF increases markedly during inflammation 
[63]. AEF activity cannot be destroyed by either nucleases or lipases, but can be 
destroyed by denaturing techniques and proteolytic enzymes [63]. 
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1.3.3 Mechanisms of amyloidosis. 
The pathogenesis of amyloidosis is thought to involve two key steps: (i) the over 
synthesis of specific amyloid protein as a result of point mutations in the genes coding 
of the amyloid precursor proteins [38] and (ii) the abnormal proteolysis of the 
precursor proteins to form amyloidogenic peptides. The general scheme in Figure 1.6 
shows the possible events that can lead to fibril formation, various components of 
amyloid deposits are common to all amyloidosis. The formation of amyloidogenic 
peptides can self aggregate to form fibrils which then aggregate to form amyloid 
deposits. The aggregation can occur with or without the participation of GAGs, SAP, 
other co-factors or trigger factors. The characteristic feature of the deposits is a large 
quantity of intra- or inter- crossed P pleated sheets. 
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Figure 1.6 
. The possible events leading to the deposition of amyloid adapted from 
Campistol et al. [64]. 
Amyloid deposition is a nucleation dependent process by which protein monomers 
add together to form the fibrils [65]. The fibril formation requires time because the 
nucleus forms via a series of association steps that are rate dependent. The lag phase 
is the period required for the formation of the nucleus, during which time, the protein 
appears to be soluble. The formation of the nucleus is thus the rate determining step. 
Once the nucleus has formed, further addition of monomers becomes 
thermodynamically favourable because monomers can add to the growing polymer at 
multiple sites, resulting in rapid polymerisation [66]. 
1.4. Alzheimer's disease. 
Alzheimer's disease (AD) [67] is the fourth most common cause of death in the 
developed world. It accounts for over 60% of cases of dementia and its prevalence 
increases with age [68]. It is a degenerative condition caused by the progressive loss of 
brain neurones. AD is manifest with loss of memory, disorientation, impairment of 
intellect and changes in behaviour. Ultimately the sufferer becomes bedridden, doubly 
incontinent, and the deterioration leads to death [69]. 
1.4.1 Pathogenesis of Alzheimer's disease. 
AD can be identified at post-mortem by two characteristic features; the neurofibrillary 
tangle (NT) and the senile plaque (SP), both of which are located in the brains of 
sufferers. The formation and contribution of these pathological structures in relation to 
the progression of the disease are largely unknown. Neurofibrillary tangles are found 
within affected neurones in the grey matter and surrounding the SP. They are composed 
of highly insoluble protein polymers, consisting of paired helical filaments (PHF). The 
PHF are seen to occupy most of the nerve cell cytoplasm, displacing cellular organelles 
[70]. The main component of the PHF is the microtubule associated protein tau, which is 
abnormally phosphorylated. Calcium regulated phosphorylation of tau may be 
involved in the formation of the PHF [71]. 
The senile plaques consist of roughly spherical deposits of extracellular amyloid 
fibrils and are 5-200 nm in diameter. They are surrounded by dystrophic neurites, 
microglia and astrocytes in the cerebral cortex, amygdala, hippocampus and in other 
brain regions [72]. The protein subunits are folded in a P pleated sheet conformation. 
Amino acid sequencing of the SP amyloid protein reveals a 39-42 amino acid peptide 
fragments, with a molecular mass of 4 kDa (A13),  similar to cerebrovascular amyloid 
found in the brains of Down's syndrome sufferers [73]. The major component of the 
senile plaques is a 1-40 fragment, the A(l-40) peptide [74]. Diffuse plaques are also 
seen deposited in AD. They seem to lack astrocytes and surrounding dystrophic 
neurites and are predominantly comprised of the A13(l-42)  peptide [75]. 
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1.4.1.1 AD protein formation. 
Molecular cloning of A13 fragment has shown it to be derived from a much larger 
amyloid precursor protein (APP) formed by proteolytic cleavage [76]. APP is a 
membrane glycoprotein that exists in various isoforms, APP-695, APP-75 1 and APP-
770 (Figure 1.7). The APP-695, which lacks the Kunitz type serine protease inhibitor 
domain, is the most abundant in the CNS. APP has been shown to regulate cell growth 
and neurite length, participates in cell matrix adhesion, acts as a cell surface receptor, 
and is a protease inhibitor [77 & 78]. Normal proteolytic cleavage by the a secretase 
pathway at positions Lys 16- Leu 17 generates a soluble non-amyloidogenic APP 
ectodomain and a 10 kDa C-terminus domain that is further degraded to a 3 kDa and a 
7 kDa peptide [79]. Abnormal processing by a secretase releases a 39-43 intact 
amyloidogenic A13  fragment. 
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Figure 1.7 - Schematic diagram in shows the various pathways of metabolism of 
APP, the AP region is the hatched shaded area [72]. 
A13  is released from many cells but its specific function has yet to be found and may be a 
metabolic by-product having no particular role [75]. Experiments with synthetic 
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fragments of A13 indicate that the liberated peptide can spontaneously aggregate to form 
amyloid fibrils and this property may reside in the 25-35 region that also shows 
homology with tachykinin [80]. The hydrophobic C-terminus of the tachykinin 
neuropeptides is required for high-affinity receptor binding and biological activity; 
however the fragment A(25-35) does not interact with tachykinin receptors. The 
precise mechanism of neurotoxicity is unknown, one hypothesis is that AJ3 and 
interferon-y (INF-y) acts synergistically in triggering an increased release of tumour 
necrosis a-factor from microglia which mediates the release of reactive nitrogen species, 
both are involved in neuronal damage [81]. Among the possible metabolic consequences 
of A13 accumulation and aggregation, altered ionic homeostasis, particularly excessive 
calcium entry into neurons could contribute to selective neuronal dysfunction and cell 
death [82 & 83]. 
1.4.1.2 Aj3 deposition. 
AJ3 is found in the brains of individuals affected by AD and Down's syndrome as 
dense extracellular deposits of twisted P pleated sheet fibrils in the senile plaques and 
within cerebral blood vessels (amyloid congophilic angiopathy). The A13  deposits are 
combined with other inflammatory proteins such as proteoglycans [84], amyloid 
P-component, and apolipoprotein E [85]. The deposition of Au,  however, is not 
confined to the brain parenchyma, having been detected in amyloid deposits within 
the muscle, blood vessels, the kidneys, lungs, skin, subcutaneous tissue, and intestine 
of AD patients [86-89]. A0 also aggregates to form diffuse amorphous deposits not 
only in AD but also following head injury [90] and in healthy aged individuals [91]. 
Cerebral A13 deposition occurs in other aged mammals that have the human A13 
sequence [921 but is not a feature of aged rats [93]. 
Relatively large amounts of amorphous amyloid accumulate in healthy older brains 
and in Down's syndrome patients. This amyloid is presumably in a random coil form 
and is not associated with degeneration. Some additional event is required to 
transform this to the 0 sheet conformation [94]. The deposition of amyloid is thought 
to involve the seeding of a nucleus. The initial formation of a nucleus is slow and is 
the rate determining step and may result in a lag time in the disease [66]. Once the 
nucleus has been formed and the critical chain length has been reached addition of 
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further monomers is rapid as there are now several sites where the monomer can add 
to, resulting in aggregation [66 & 951. As is the case with other amyloid proteins, A13 
originates as a normally soluble and constitutive protein found in biological fluids and 
tissue. According to recent in vitro studies the A13(l-40)  is continuously produced and 
secreted as a soluble peptide during normal cellular metabolism but the peptide has 
not been detected intracellularly. These results suggest that A1 3  is not simply an 
unwanted degradation product of a larger precursor molecule but may play a 
biological role by itself. The question then arises under which conditions an 
aggregation of this normal" A13 can be induced [96-99]. 
1.4.2 Aggregation is dependent on certain regions of Af3 
Studies on A13  peptides are diverse with respect to peptides size, region, and solvent 
conditions, but the initial formation of an intermediate with a high 3 sheet content 
appears to be the determining step in the A3 self assembly. The 3-amyloid protein 
(39- 43 amino acid residues) is the major constituent of the amyloid deposits found in 
the brain of patients with Alzheimer's disease (Figure 1.8). It has been shown that the 
first 28 residues constitute an extracellular domain whereas residues 29-40 anchor the 
peptide in the lipid membrane. The region lle3 I to met35 of the A( 1-40) peptide has 
been shown to be involved in formation of a helices in solution. The fibril formation 
could be accompanied by an ci helix to 0 sheet transition in the region 1le3 I to met35 
[ZOO]. Also Lys16 to Va124 and Lys28 to Va140 have been postulated on theoretical 
grounds [101]. 
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Figure 1.8 - The Aj3 sequence, the shaded region is the cell membrane [102]. 
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A number of endogenous A13  peptides exist in AD brain tissue, the two most studied 
being A13 ( 1-40) and A13 (l -42), which differ by the position of their C-terminal 
cleavage from APP. More recently a number of AI3 variants have been identified in 
AD brain amyloid, including variants with modified aspartyl and glutamyl residues 
and shorter C-terminal forms such as the 13  peptide. The relationship of the relative 
abundance of these different peptides in brain, may be important in the development 
of AD neuropathology [102]. 
The solid state IR of the A13 (l -28 ), A13 ( 12-28 ), A13 ( 14-28 ), AJ3(6-25), A13 (l -38 ) and 
A13 (l -40) peptides have all been shown to form amyloid-like fibrils in vitro [103-105]. 
Although the smaller synthetic peptide analogues of the Af3 peptide form amyloid-like 
fibrils in vitro, the solubility properties of these assemblies differ significantly from 
those reported from isolated brain senile plaques and cerebral vascular area [103, 104 
& 106]. Based on X-ray diffraction and ETIR studies, Halverson et al. [107] proposed 
that the C-terminal residues of A[3 form a stable antiparallel 0 fibrillar core. 
1.4.2.1 Main A[3 fragments: A[3(1-40) and A[3(1-42). 
The relative formation of A[3(l-40) and A[3(l-42) appears to be critical to the 
pathology of AD. Both A[3(l-40) and A[3(l-42) have been widely studied to determine 
the influence of factors such as pH on their ability to form the [3 sheet structure of 
amyloid [108-110], the relative extent of deposition [66], and neurotoxicity [Ill]. 
Af3(l-42) forms 0 sheet structure and amyloid fibrils much more readily than does 
A[3(l-40) [112 - 1151. The increased polymerisation rate can be explained by 
increased hydrophobic interaction, first by the formation of a longer intra-molecular 13 
sheet in the C terminus and second by the folding of this sheet over the core of the 
dimer [109]. The A[3(l-42) peptide also deposits earlier than Af3(I-40) in the disease 
process [116]. The aggregation behaviour of A[3(l-40) bears a close resemblance to 
that observed for the fragment A[3(25-35) [117]. 
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1.4.2.2 Other A13 fragments. 
The synthetic A13 peptide fragment having the same sequence as the N-terminal 28 
residues, formed fibrils that share both antigenic and structural features with native 
A13 amyloid filaments [103 & 104]. The 3-amyloid peptide has been shown to fold 
into two antiparallel 0-strands with a 13-turn at residues 26-29 and with the nine N-
terminal residues adopting a random coil configuration [118]. The A3(l 1-25) peptide 
is observed to possess the capability of a helix to 13  sheet transition [119]. 
It has previously been shown that amino acid residues 16-20, are essential for A3 
polymerisation. Peptides with substitutions of the 16-20 residues and peptides that 
bind to the Aj3(16-20) motif, prevent A3 fibril formation [120]. A3(16-20) binds to 
the regions corresponding to 17-21 residues or/and 18-22 residues of adjacent AJ3 
forming antiparallel 13 sheet structure [120]. However, the 16-20 residues themselves 
are not sufficient for polymerisation, when Af3(16-20) was incubated with full-length 
A3, only amorphous aggregates, not fibrils were formed [120]. Synthetic peptides 
consisting of residues 18-28 formed assemblies that showed extensive stacks of 13 
pleated sheets. The Af3(19-28) peptide also retains the ability to form amyloid-like 
fibrils with the characteristic cross-3 conformation [103 & 1041. 
The most interesting property of A3(25-35) is its reversible f3 sheet - random coil 
transition at pH 4.0 and 5.5. Concentrated solutions of A3(25-35) contain microfibrils 
with 13-structure which upon dilution disintegrate into random coil monomers [117]. 
The hydrophobic A3(29-42) peptide adopts exclusive intermolecular 3 sheet 
conformations in aqueous solution despite changes in temperature or pH. The A3(34-
42) segment adopts anti-parallel 3 sheet structures forming filaments that are virtually 
insoluble in aqueous media [107]. This peptide is derived entirely from the 
hydrophobic transmembrane domain and the ability of this peptide to form stable 13 
structure indicates that the C-terminal region could also be amyloidogenic [107]. 
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1.4.4 The mechanism of AJ3 amyloid deposition. 
The polymerisation of the amyloid P peptide into protease resistant fibrillar deposits 
within the brain parenchyma and vasculature is a significant step in the pathogenesis 
of Alzheimers disease [121]. The nucleation may occur, resulting from seeding of A3 
onto non amyloid peptide elements, such as GAGs and amyloid P component, present 
in the cellular milieu [122] or it may involve the self-assembly of Af3(1-40) or A13 
fragments [113]. 
The A13(l-40)  could be seeded by small amounts of the variants A13(l-42)  or 
A(l-43), which nucleate very rapidly and seed the aggregation of AJ3(l-40) (Figure 
1.9). AJ3(l-42) and A13(l-43)  could be produced in trace amounts by an abnormal 
C-terminal proteolysis [113]. This may occur in families with mutations in APP, that 
results in increased amounts of longer A13(1-42)  or other stable aggregates [123 & 
124]. Alternatively, the A3(l-40) can self aggregate with or without the presence of 
other components. In either case, once the slow lag phase of A0 nucleation has 
occurred, a more rapid phase proceeds with the seeding of other A13 peptides leading 
to fibril formation as shown in Figure 1.9. 
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Figure 1.9 - The possible mechanism of Aji deposition based on initial formation of 
nucleus and subsequent seeding [113]. 
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The polymerisation starts with the formation of dimers, which in turn form tetramers 
and higher order oligomers. The existence of dimers and tetramers is supported by gel 
electrophoresis studies [125 - 127]. Since seeded polymerisation can be largely 
concentration dependent, a small increase in Af3(1-40) could significantly increase the 
rate of amyloid formation it could support continued growth [128], which may explain 
some cases of early onset AD. 
1.4.5 Risk factors for Alzheimer's disease. 
Several neurobiological abnormalities have been associated with AD. These include 
abnormalities in cytoskeletal proteins of neurons and in the biology of the amyloid 
precursor protein and its proteolytic cleavage product, A1 3 . The multifactorial puzzle 
of the disease includes a combination of age-related degenerative changes with 
additional genetic pre-dispositions and environmental factors, leading to increased 
vulnerability of the individual [68]. Genetic loci on chromosomes 14, 19, and 21 have 
been implicated. Mutations in the gene coding for the amyloid precursor protein on 
chromosome 21, may be the cause of a small number of familial cases of AD. The E4 
allele of Apolipoprotein E(ApoE), on chromosome 19 is linked with an increased risk 
of both sporadic late onset and familial forms of AD [129]. A genetic determinant 
may increase susceptibility to amyloid deposition in late onset AD. 
Recent interest in AD plaque development has focused on several proteins associated 
with amyloid accumulation: P component, sulphated glycosaminoglycans [55] and 
complement factors [130]; a-I antichymotrypsin, apolipoprotein F. It is also suspected 
that there is an environmental component in the aetiology of Alzheimers disease that 
could involve damage from chemical agents, which may accumulate over long 
periods of time [80]. Several studies have suggested a possible role of oxidative stress 
in the pathogenesis of AD [131]. 
36 
1.4.5.1 Advanced Glycation End Products. 
Advanced glycation end-products play a significant role in the evolution of vascular 
complications in normal ageing, especially in diabetes and renal failure [132]. Protein 
glycosylation first starts with the non-enzymatic spontaneous condensation of sugar 
aldehyde or ketone group with the free amino acid groups such as c-NI-I 2 groups of 
lysine residues. The resulting adducts then undergo irreversible rearrangement to form 
cross-linked advanced glycation end products such as 3-deoxyglucosone [133 & 134]. 
Factors responsible for the increased cerebral AGE levels in Alzheimers disease are 
not yet fully understood. An increased AGE level in plasma does not accompany the 
increased level of cerebral AGEs in AD patients, indicating accumulation in AD is 
probably a highly selective, brain specific event [135]. Increase in intracellular AGE 
could be due to increase of AGE reactive sugars as the consequence of a disturbed 
glucose metabolism, increase in unchelated copper and iron accelerating the oxidation 
of glycated proteins and depletion of the anti-glycation substances such as carnosine 
and anserine [136]. 
AGE related oxidative stress in AD is evidenced by chemical markers and also by the 
activation of the anti-oxidative defence system, and the up-regulation of heme 
oxygenase [137]. These AGE-mediated effects can be blocked by addition of 
antioxidants, such as probucol, or of antibodies to the AGE-receptor [138]. AGE 
modification and resulting crosslinking of protein deposits has been shown to occur in 
both plaques and tangles which is not unexpected since various long-lived and 
precipitated proteins become modified by AGEs. It has been shown that nucleation-
dependent polymerisation of 0 amyloid is significantly accelerated by crosslinking 
through AGEs in vitro [134]. Susceptibility to AD is correlated with c4 allele of 
apolipoprotein E (Apo E) and consequent substitution of cysteine by arginine creates 
more glycation sites and hence may facilitate the AGE-mediated crosslinking of Apo 
E to the insoluble deposits and hence accelerates plaque growth [139]. This suggests, 
that AGE represent a driving force in the acceleration of 0 amyloid deposition and 
plaque formation. 
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1.4.5.2 Cations as a trigger factor for the deposition of amyloid in AD. 
Deficiency or excess of a number of trace elements has been reported in the tissues of 
patients with dementia. Some of these trace elements, both normal and abnormal 
levels, may be shown to have effects on cognition in experimental animals and 
possibly in man [140]. However, the relevance of the observed trace element 
imbalances, to the cognitive problems occurring in human neurodegenerative 
diseases, particularly Alzheimer's disease (AD), is uncertain. Aluminium has been 
consistently implicated as a risk factor for AD [94]. There is some evidence to show 
that the aluminium can be absorbed by normal individuals when present in excessive 
quantities. The high incidence of amytrophic lateral sclerosis in the Pacific island of 
Guam again shows a link between aluminium exposure and dementing disease [141]. 
Aluminium has been found associated with both SP and NF1' in AD brains [142]. 
High levels of silicon have been reported to be associated with both isolated and in 
situ senile plaque rims using both chemical and X-ray microanalysis [143]. High-
resolution solid-state nuclear magnetic resonance studies have detected the presence 
of aluminium and silicon co-localised as an aluminium silicate in the senile plaque 
cores [142]. 
Several metals Al, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Mo, Cd, Sb, and Pb have been 
detected in senile plaques using inductively coupled plasma mass spectrometry [144]. 
Zn 2t Cu2 , and Fe3 
 are highly concentrated in the neocortex, regions most affected in 
AD. All three metal ions are significantly elevated in senile plaque deposits [145]. 
These metals could result from accumulation of physiological levels by AD patients 
over long periods of time. The presence of proteoglycans and glycosaminoglycans in 
the SP could also contribute to the accumulation of these metals. For instance heparan 
sulphate has an affinity for zinc [146-148]. Cations could act as a cofactor in several 
stages of SP formation. They could accelerate the proteolytic processing of APP and 
alter axonal transport and APP accumulation. APP contains multiple cysteine and 
carboxylic acid residues capable of binding metals ions in a non-specific manner. Zinc 
has been seen to have a binding site in the ecto domain (18 1-188) of APP 
(Kd = 764 nM) within exon 5 at the end of the cysteine rich region. [149]. APP has a 
high affinity copper binding site (10 nM at pH 7.5) located within residues 135-155 of 
the cysteine rich domain of APP 695 that is present in all APP splice isoforms [ISO]. 
It has been shown that APP can reduce copper Cu 2 to Cu [1511. 
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1.5 Dialysis related amyloidosis 
Dialysis-related amyloidosis (DRA) is a serious complication of chronic dialysis 
therapy [152 & 153]. The protein deposited has been identified as a modified form of 
2 microglobulin, levels of which are universally elevated in dialysis patients. 02M 
amyloidosis is predominantly localised to osteoarticular tissues causing carpal tunnel 
syndrome, chronic synovitis, and progressive bone destruction [154 & 155]. Systemic 
deposition and visceral organ involvement have also been described. Older age at the 
onset of dialysis and the duration of dialysis are two important risk factors for 
development of this disease [156]. 13 2M has clearly been identified as playing a central 
role as the amyloidogenic protein [157] but other factors must also be required, as the 
serum 32M level is not predictive of the development of DRA. 
1.5.1 Pathogenesis of 132M amyloidosis. 
The 32M is a protein of low molecular mass, first isolated from the urine of patients 
with tubular proteinuria. It has about 30% homology to the immunoglobulin constant 
region domain [158] and is present on the surface of nucleated cells as a part of the 
HLA class I antigen complex and is also found in non HLA associated forms [158]. 
132M consists of 99 amino acid residues and has a molecular weight of 11.8 kDa. Its 
circulating pool in plasma and other body fluids is derived largely from the shedding 
of this protein from the surfaces of nucleated cells, where it is noncovalently 
associated will other molecules, notably class I histocompatibility antigens. The 
plasma concentration of 132M is less than 2 mg r' and approximately 150-250 mg is 
cleared daily by glomerulofiltration [152]. Levels of 132M are increased in diseases 
that impede glomerular filtration or re-absorption by the kidney and in chronic 
inflammatory diseases and malignancies, where synthesis is increased. 
1.5.1.1 P2M  deposition. 
In patients with chronic renal failure, 132M is massively increased to more than 25-35 
times the normal range because of the severe reduction in glomerulofiltration and 
levels of up to 60 times have been reported in anuric individuals due to the prolonged 
half life. Regardless of the serum 132M concentration some subjects require very long 
periods of time to develop 32M amyloidosis, while others do not [159]. It seems that 
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an increase in serum 02M is not sufficient to induce amyloidosis but at least some 
degree of retention is required. It is likely that other factors could interact with the 
13 2M and accelerate the development of J32M deposition [160]. The full amino acid 
sequence of monomeric 132M has been identified in deposits of amyloid and has been 
shown to polymerise in tissue without apparent degradation. Aggregates of intact 
13 2M, consisting of dimers and tetramers have been isolated. The 32M amyloid 
deposits are co-localised with SAP and are surrounded by macrophages. Electron 
microscopy shows the amyloid deposits consist of tightly packed bundles of parallel 
fibrils of 8-10 nm widths in a curvilinear configuration. The 02M has a 13 sheet 
structure fibrillar configuration which may contribute to its deposition [161]. 
However, the genesis of DRA cannot be fully explained solely on the basis of simple 
precipitation of intact 02M in body tissues. Other polypeptides, all of which originate 
from fi2M, have also been isolated from affected tissue samples. Two isoforms of 132M 
the 5.7, 5.22 p1 have been found with a single amino acid replacement Asn by Asp at 
the 17th 
 amino acid residue in the 5.22 p1 isoform [161]. These more acidic isoforms 
of 132M are modified with advanced glycation end products [162] and are suggested to 
be more amyloidogenic [163]. Proteolysed forms of 132M have been found in the 
amyloid deposits, mainly associated with intact 132M but complete sequence of the 
02M purified from the amyloid deposits and found to match with intact 132M [157], 
indicating that proteolysis may not be necessary for amyloid formation. These results 
strengthen the view that DRA, although mainly consisting of j32M, is not uniquely due 
to structural modifications of this protein. Rather, this condition probably has a multi-
factorial pathogenesis, in which anti-proteases and other factors may play a role. 
1.5.2 Aggregation is dependent on certain regions of 02M. 
132M has predominantly a P pleated sheet structure (>50 %) and has the basic fold of 
an immunoglobulin constant domain, where two antiparallel P sheets are closely 
packed face to face [164]. This 3 structure is most likely involved in the 
amyloidogenic properties of 02M [165]. 132M is a non glycosylated single chain 
polypeptide consisting of 99 amino acid residues with an inter-chain disulphide bridge 
between the haif-cysteine residues in positions 25 and 80 [166]. Studies have shown 
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02M isolated from amyloid deposits to be composed of the monomer, dimer and 
higher polymers of intact 132M. Two-dimensional gel electrophoresis studies have 
shown the presence of two or more isoforms of 132M with p1 co-ordinates (5.3-5.7) 
[157]. Acidic isofornis of 132M have also been found with deaminated Asn at position 
17. The presence and relevance of acidic J32M isoforms in the pathogenesis of 132M 
amyloidosis have been reported [167]. Tryptophan, tyrosine and methionine residues 
are also important in the protein folding of 132M [163] and the 6 tyrosines of the 32M 
are within the P sheet sandwich [168]. 
1.5.3 The mechanism of 02M amyloid deposition 
Increased levels of (32M most likely contribute to the formation of fibrils although 
(32M alone is not the sole factor. It is likely that other factors could interact with the 
(32M causing deposition [160 & 169]. Triggering of inflammatory processes due to 
stress could cause an increased production of f32M [170]. It is also possible that the 
(32M amyloid itself acts as a foreign material and thus initiate an inflammatory 
reaction. Deposits of 02M are strongly associated with a heavy macrophage response 
[171]. A three-step molecular mechanism has been proposed by which these proteins 
form amyloid fibrils. The first step involves the association of two monomers to form 
a non-covalent dimer [172]. The second step leads to the formation of the pro-amyloid 
filament formed by head-to-tail interactions between dimers and polymerisation into 
tetramers or higher order complexes [172 & 173]. The final step results in the docking 
of two filaments creating a fibril assembly with enhanced stability through the 
multiple intra- and inter-filament interactions. As the nucleus size increases, the added 
monomers can interact at several interfaces on the fibril making it more 
thermodynamically stable. The formation of dimers, as well as aggregates, is a 
reversible process until the nucleation centre has formed [66]. 
1.5.4 Risk factors for the 02M amyloidosis. 
Several risk factors for (32M deposition are already known, including that of age, 
duration of chronic renal failure, residual loss of renal function and the number of 
years on dialysis. Other factors such as water quality, purity of dialysate, and 
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membrane may have a contributory factor in 02M clearance. Since 132M does not seem 
to be the only factor influencing the occurrence of 132M amyloidosis, a role for other 
proteins in amyloidogenesis has been hypothesised. In addition glycosaminoglycans, 
amyloid P component and apolipoprotein E have also been identified in P2M amyloid 
deposits [161]. It is unknown whether these factors participate in amyloid deposit 
formation, its persistence, or are merely co-deposited. 
1.5.4.1 Advanced Glycation End Products. 
Advanced glycation end products have been demonstrated associated with the f32M in 
amyloid fibrils [174]. The advanced products of the Maillard reaction, including 
NE_(carboxymethyl) lysine and pyrraline are present on surface of most AGE- 
modified proteins and may be involved in the 132M dimer deposition [123]. 32M 
amyloid fibrils are often surrounded by macrophages and it is known that AGE-
modified proteins are chemotactic for monocytes, and that macrophages possess 
receptors for the endocytic uptake of these modified proteins [175 & 176]. Although 
this evidence strongly suggests that AGE modified J32M is a major constituent of DRA 
[176], another possibility that needs to be ruled out is that the deposited 02M 
undergoes secondary AGE modification. Circulating 132M can also bind to AGE-
modified collagen types I, II, and III present in osteoarticular tissue. The 32M itself 
may be modified with AGE in situ to form crosslinks with the AGE-modified 
collagen. This complex could then trap other constituents of the 132M amyloid 
deposits, such as amyloid P component, PGs and/or GAG - regulating the distribution 
and arrangement of these 32M amyloid fibrils [158]. 
1.5.4.2 Cations as a trigger factor for f32M deposition. 
Some studies have suggested that kidney haemodialysis patients could be at risk from 
either moderate copper deficiency or copper toxicity [177 - 179]. There are many 
conflicting factors between these studies such as dietary copper intake, dialysis 
procedure, drug intake etc. [180]. Reduced zinc levels is common in patients with 
end-stage renal disease (ESRD) treated with continuous ambulatory peritoneal 
dialysis (CAPD). Other factors rather than zinc loss in dialysis effluents could result 
in redistribution of zinc from the extracellular to intracellular compartments. 
Decreased zinc nutritional intake, reduced absorption and hypoalbuminemia may be 
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factors affecting circulating levels of zinc [180]. In the past, patients with dialysis 
related amyloid deposition have been shown to have higher plasma and osseous levels 
of aluminium due to the transfer of aluminium in the dialysate during haemodialysis 
and through the use of oral aluminium preparations employed as phosphate binders 
[181]. Silicon levels were elevated in plasma and various tissues in chronic renal 
failure in man [182] and were found to be significantly higher both before and 
immediately after dialysis in the aluminium overload patients. 
Calcium deposits have been found associated with 02M in ectopic calcification of the 
heart [183] and in synovial amyloid deposits [184]. An association between 32M 
amyloid deposition and aluminium, aluminosilicate and iron deposits has been 
reported in amyloid deposits in joints [185 - 187]. Recently, aluminosilicates have 
also been detected with secondary ion mass spectrometry [188]. These metals are 
thought to result in tissue damage mediated by the generation of oxygen free radicals. 
Another factor, which may favour 32M amyloid deposition are the metallic particles 
derived from wear and tear of metal prosthesis. They may similarly act to produce 
tissue damage leading to leukocyte activation with associated 132M amyloid formation 
and deposition. The relationship between the blood zinc, copper, and selenium 
concentrations and P2M levels are widely considered as a marker of the disease 
progression such as with HIV [189 & 190]. Therefore changes in metal levels could 
be an indication of disease. 
1.5.4.3 Aluminium and dialysis encephalopathy. 
Dialysis patients under-going treatment for chronic renal failure were exposed to 
increased aluminium from dialysis fluids and from aluminium containing phosphate 
binders prescribed to prevent hyperphosphataemia [181]. They developed dialysis 
encephalopathy leading to mortality [191]. Strong positive correlations between the 
duration of the dialysis treatment and the index of the encephalopathy were apparent 
[192 & 193]. Patients with dialysis encephalopathy exhibited changes in proteins 
specifically characteristic of AD [194]. Thus there may be a link between aluminium 
and the expression or processing of the A13  precursor protein in both dialysis 
encephalopathy and AD [195] in which eventually, in a complex cascade of events, 
leads to the extracellular deposition of the AP protein in senile plaques. 
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1.6 Other amyloids: The Prion protein and neurodegeneration. 
The human prion diseases, Creutzfeldt-Jakob disease (CJD) and Gertsmann- 
Straussler-Scheinker disease are characterised by the slow onset of neurodegeneration 
[196]. Earlier terms used to describe the prion diseases include: transmissible 
encephalopathy and spongiform encephalopathy. Brain pathology in these diseases 
resembles that of AD [196] and is characterised by aggregation of a normal cellular 
prion protein (PrPC) (rather than the f3 protein as in amyloid plaques) [50]. New 
variant CJD with a new specific neuropathological profile and with an early age of 
onset has been linked to exposure to bovine spongiform encephalopathy (BSE) 
infected food [197]. 
1.6.1 Pathogenesis of PrP amyloidosis. 
Prions cause a group of human and animal neurodegenerative diseases, which are now 
classified together because their aetiology and pathogenesis involve modification of 
the prion protein. Prion diseases are manifest as infectious, genetic and sporadic 
disorders [196]. The diseases can be transmitted among mammals by the designated 
prion. Despite intensive searches over the pass three decades, no nucleic acid his been 
found within prions; yet, a modified isoform of the host-encoded PrPC 
 designated 
PrP is essential for infectivity. In fact, considerable experimental data argue that 
prions are composed exclusively of PrP protein [198]. 
While our understanding of the pathogenic role of PrP has grown, the normal 
physiological function of PrP c still remains unclear. The normal cellular PrPC 
 begins 
its metabolic cycle in the endoplasmic reticulum where the prion is anchored to the 
cell surface by the phospatidylinositol moiety. Possible roles of the PrPC 
 include a role 
in cell recognition, activation of lymphocytes and lymphoid cell and the control of the 
proliferation of astroglial cells. 
1.6.1.1 Prion formation. 
It has been shown that PrPW 
 molecules do not differ from PrV at the level of an amino 
acid substitution or a post-translational chemical modification. It seems likely that it is 
in the secondary and tertiary structure in which the PrP and PrP differ [199]. The 
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analysis shows that PrP 5 " is predominantly composed of 13-sheet, and P turns with a 
smaller amount of a-helix and minimal random-coil structure, which is consistent 
with its amyloid like properties [198 & 200]. Cleavage of the amino acid terminal 
region of PrPW 
 also resulted in all 13 sheet PrP. PrPC contains -45% a helix and little 
[3 sheets. Conversion to PrPW creates a protein, which contains 45% 13  sheet, little or 
no a helix, and 57% 0 turns and random coil [50, 196, 198 & 201]. However, nuclear 
magnetic resonance structure of the autonomously folding PrPC 
 domain comprising 
residues PrPC(121.231) contains a two-stranded antiparallel 0 pleated sheet and three 
a helices. The presence of a [3sheet in PrPC(121231) is in contrast to the model 
predictions of an all helical structure of PrPC, 
 which may have implications for the 
transition from PrPC to  PrPW 
 protein [202]. 
1.6.1.2 Prion propagation. 
Prions show virus like characteristics, with self replication and susceptibility to 
species barriers but is not an infectious pathogen for several reasons. Firstly, prions do 
not contain any nucleic acid, 'genetic coding' for the replication of the infectious 
PrP agent. Secondly, the prion is a modified protein that is encoded by a cellular 
gene. Thirdly, the only, component of the prion is the infectious isoform of the prion 
protein PrP which is pathogenically derived from cellular PrP [196]. The 
fundamental event in prion diseases seems to be a conversion reaction to the PrPsc 
 
involving a dramatic reorganisation of secondary and tertiary structure of the PrP" 
The mechanism by which PrPC 
 is converted to PrP remains unknown but PrPC 
appears to combine with PrPW 
 to form a PrPC.PrP 
 complex with the former being 
transformed into another PrPSC 
 molecule. The two resulting molecules of PrP 
combine with a further two molecules of PrPC 
 forming four molecules of PrP. The 
process continues exponentially with the PrPW 
 precipitating to form the amyloid 
plaques characteristic of transmissible spongiform encephalopathies (TSEs). The 
initial slow step is the conformational change from PrPC 
 to PrP, which could be 
catalysed by the formation of a PrP-PrP 5' heterodimer. Thus, the PrPS 
 monomer 
would be the infectious species. 
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1.6.2 The mechanism of prion protein deposition. 
A similar mechanism to that described in Section 1.4.4 has been proposed for the 
prion diseases which involves a dramatic reorganisation of secondary and tertiary 
structure of the PrP' to the PrP (Figure 1.10) [50]. The PrP' molecules appear to 
combine with PrPW to form a PrPCPrPW complex that initiates further transformation 
of ppC into another PrP molecule. The slow step is the nucleus formation of the 
PrP aggregate that then acts as a seed. Increases in cellular PrPC levels could lead to 
sporadic prion disease. Similarly, PrPC mutations that alter the PrPC 
 to PrPsc  
equilibrium could have a major impact on the nucleation time [113]. 
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Figure 1.10 
- The possible mechanism of prion propagation. The nucleus formation 
step is slow but subsequent seeding is fast [113]. 
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1.6.2 Risk factors for PrP amyloidosis. 
In familial CJD and Gertsmann-Straussler-Scheinker disease, it has been shown that 
there is a mutation in the gene coding ppC The most common form of prion disease 
is the sporadic form of CJD and may result from spontaneous conversion of cellular 
PrPC to PrP but likely other factors are involved. Kuru is a prion disease spread 
amongst people in Papua New Guinea transmitted through cannibalism of human 
brains [203]. Thus the study of prions has shown it to be sporadic, genetic and 
transmissible. 
In the 1980's, cattle were "exposed" to the ectoparasiticide, Phosmet, used to 
eradicate warble fly. The Phosmet was applied as a liquid preparation poured onto the 
back of the cattle. It was hypothesised that this method of application allowed the 
Phosmet to be absorbed into the spinal chord entering the brain after a delayed period. 
The Phosmet would then supposedly reach the brain causing a conformational change 
in cellular PrPC 
 to form the BSE prion PrP that initiated the BSE epidemic [204]. 
However, the most likely cause was contaminated animal feed that originated from 
scrapie infected bone meal. Exposure to BSE infected meat as a foodstuff is 
considered to be the likely cause of the New variant CJD (nvCJD) [197]. 
1.6.2.1 Cations as a trigger factor for Prion deposition. 
It has been shown using tryptophan fluorescence spectroscopy, that copper binds to 
recombinant Syrian hamster prion protein [SHaPrP(29-231)]. The binding sites are 
highly specific for Cu2, 
 and binding of Cu 2 is preferable over other divalent cations; 
Ca2t Co2 , Mg2 , Mn 2t Ni2 , and Zn 2 . Copper may normally bind the PrPC 
 and may 
influence the formation of a conversion of PrPC 
 to  PrPW 
 or the formation of an 
intermediate PrP*. Binding of copper might also modify the second step of the 
conversion reaction where the activated PrP* 
 is transformed into the PrP molecule 
[205]. The binding of copper facilitates the thermodynamically formation of a P sheet 
aggregate [205]. A disturbance of copper binding in these PrP proteins might 
participate in the pathogenesis of prion amyloidosis. 
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1.7 Levels of trace elements in the human body 
The maintenance of normal health requires adequate protein, energy substrates, 
vitamins, and also trace elements. Trace elements in the human body are by definition 
present in tissues at concentrations of less than 0.01% dry mass. The essential trace 
elements are mostly transition elements and include Cr, Mn, Fe, Co, Cu, Zn and Mo 
(Table 1.3). In addition Se, I, and Sn are recognised as essential. Possible essential 
elements include Ni, F, Br, As, V, Ba, Si and Sr [206]. There are many 'non essential' 
elements, for which exclusively negative effects have been found so far. Potentially 
toxic elements include heavy metals such as Sb, Sn, Bi, Zr, and the lanthanides. The 
majority of the trace elements are key components of enzyme systems or proteins and 
are vital for their proper functions. 
Element Function 
Total 
concentration 
(mgk) 
Plasma 
concentration 
(pg F') 
Daily 
intake 
(mg) 
Chromium Deficiency causes glucose <0.09 1.04 0.06 
intolerance 
Cobalt Component of vitamin B12 0.014-0.029 0.59 0.006 
Copper Component of various enzymes 1.4 0.76.1.5C10) 3.0 
Fluorine Present in bone and teeth 37-57 0.1-0.2 0.2-0.6 
Iodine Component of thyroid hormones 0. 14-0.28 0.63 0.15 
Iron Component of haem pigments 57-70 0.56-1.I(. 103) 10-14 
N1angãne Cofactor for several enzymes 0.17-0.23 0.486 2.5-5.0 
Molybdenu Cofactor for xanthine oxidase 0.13-0.23 1.44 0.2 
m 
Nickel Maintenance of membranes <0.14 2.6 
Selenium Glutathione peroxidase 0.3 100-300 0.05-0.2 
Silicon Possibly necessary in cartilage 0.39-1.09 
Zinc Component of various enzymes 14-30 0.65-1.9(10) 15 
Table 1.3- Trace elements and concentrations in the body [182, 207 -213]. 
1.7.1 Essential trace elements. 
1.7.1.1 Zinc as a trace element. 
Zinc is crucial to the normal functioning of over two hundred proteins and enzymes 
[214 & 2151 in their structural, catalytic, and regulatory roles [214]. It is essential for 
the activity of a number enzyme systems such as alkaline phosphatase, alcohol 
dehydrogenase, carbonic anhydrase, superoxide dismutase, collagenase, and leucine 
aminopeptidase. It is important in the binding of DNA and in enzymes involved in 
nucleic acid and protein synthesis. Zinc plays a role in maintaining immunological 
function in the zinc dependent interleukin-113 and tumour necrosing factor-a 
production in peripheral blood mononuclear cells [180]. 
Plasma zinc is mostly transported bound to albumin, a2 macroglobulin and transferrin 
with a concentration in the blood of between 11-23 jiM. Zinc is found throughout the 
mammalian brain, with the highest concentrations found in the neocortical and 
hippocampal areas of the brain [216 & 217]. Zinc concentrations are said to remain 
constant in the normal ageing brain [216 & 218]. The concentration of zinc in the 
neocortex is between 150 and 200 j.tM [217 & 219], three orders of magnitude greater 
than in the CSF (0.15 jiM) [217]. The excitatory nerve terminals of the hippocampus 
and fascia dentata contain the highest concentrations of zinc 220-300 jiM [217]. The 
body does not store zinc to any appreciable extent but non specific proteins such 
metallothionein (MT) can bind Zn 2 as well as Hg2 and Cd 2t Metallothionein is a 
major form of storage of zinc, and is important for cellular zinc metabolism [220]. 
Exogenous zinc has been shown to induce both necrotic and apoptotic death in 
neurons in vivo and in vitro [221 & 222]. 
1.7.1.2 Copper as a trace element. 
Copper is essential for the activity of certain enzymes, notably cytochrome oxidase 
and superoxide dismutase (SOD). Copper is involved in the synthesis of several 
enzymes such as cytochrome oxidase, tyrosine monooxygenase, SOD and dopamine 
monooxygenase [223]. Copper also plays a critical role in the assimilation of iron into 
both microbial and mammalian cells [224]. Copper is primarily bound to 
ceruloplasmin (70%), albumin (18%) and transcuprein (12%) [180]. The 
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concentration of copper in blood is 11-24 !IM. Low molecular weight amino acid 
complexes of copper [223] are the primary components of the exchangeable plasma 
copper pool responsible for the transmembrane transport of copper into the brain 
[225]. The brain contains the highest cellular concentrations of copper in the body 
besides the liver. Copper is most concentrated in the grey matter (60-110 liM) being 
consistently higher than in white matter (25-79 jiM) [145 & 226]. These 
concentrations are about one order of magnitude greater than in CSF (1-8 jiM) 
1.7.1.3 Iron as a trace element. 
Iron is important for oxygen transport and is found in haemoglobin, cytochromes, 
haemoproteins and catalases. Iron occurs in the blood as haemoglobin in erythrocytes 
and as transferrin in the plasma, in a ratio of nearly 1000 to I. Average iron content of 
haemoglobin is 0.34% and functions as an oxygen carrier. Transferrin, a glycoprotein, 
acts as carrier for iron, where it is bound to the 3i  globulin group. Since even small 
quantities of free iron are toxic, the prevention of its occurrence in the plasma can be 
regarded as the function of transferrin. Iron deposits mostly occur in liver, spleen and 
bone marrow where dense hydrated ferric hydroxide form in core of ferritin [207]. 
Iron deficiency, particularly in pregnant women, can lead to anaemia. Iron overload, 
on the other hand, can cause siderosis. Copper deficiency can give rise to anaemia 
even if iron levels are normal as copper in ceruloplasmin is involved in the oxidation 
of Fe2 to Fe3 before it is taken up by transferrin. 
1.7.2 Other trace elements. 
1.7.2.1 Silicon as a trace element. 
Silicon is generally agreed to be an essential trace element in humans. Nevertheless, 
its precise function is not known. It appears necessary for bone and collagen 
formation and growth in the chick and the rat. Silicon is also present in mitochondria 
in the rat liver [227]. Silicon is present in plasma mainly as silicic acid Si(OH) 4 and is 
also present as a complex anion or as a silicate polymer .  The free form of silicic acid 
is able to penetrate biological membranes [182]. Silicon is handled via glomerular 
filtration during normal renal function and levels are elevated in plasma and various 
tissues in chronic renal dialysis. The chemistry of silicon shows it has a relatively 
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unique affinity for aluminium owing to the ionic size and charge and co-ordination 
geometry of the species involved. The two elements are accordingly commonly 
associated with each other in a range of minerals such as aluminosilicates [228]. This 
chemical inter-relationship of silicon and aluminium is of increasing interest in 
biology, particularly as a mechanism for the detoxification of aluminium. Research 
has in fact indicated that silicon may have no direct biological function other than to 
reduce the bioavailability of aluminium species by the formation of 
hydroxyaluminosilicates [211]. 
1.7.2.2 Aluminium as a trace element. 
Aluminium, although ubiquitously distributed in the environment, has no known 
biological function. The reason for this may be the low solubility of A1 3 at around 
neutral pH when it is almost completely present as insoluble hydroxide, Al(OH) 3 , or 
its condensation product A1 203 . The normal healthy individual is exposed to 
aluminium by inhalation of dust, skin contact and oral ingestion of foodstuffs, fluids 
and medicines. It is estimated that the average daily diet contains up to 5 mg of 
aluminium but less than 1% is absorbed [229]. Body uptake of environmental 
aluminium by gastro intestinal tract is complex and known to be influenced by 
numerous dietary factors. Dietary Zn 2 and Fe3 intake and ligands such as citrate and 
maltol increases A1 3 uptake and accumulation in the brain [230]. 
Aluminium is present in blood plasma at a concentration of 10 jtg Ii 
 and present in all 
tissues at a concentration of about 2 mg kg' dry weight and appears to be cleared by 
the kidneys [229]. Aluminium in plasma is almost exclusively bound to transferrin (up 
to 95%) and the rest is bound to citrate [231]. Serum transferrin is only about 30% 
saturated with iron. Transferrin has a high affinity for aluminium and it is likely, A1 3 
competes for Fe 3 for cellular transferrin, although A1 31s not able to displace bound 
Fe3 [232]. Aluminium can be taken up by various tissues including the liver, 
muscles, bone, brain and spleen [229]. 
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1.7.3 Trace element levels and disease. 
Distribution of trace elements in the body is tissue dependent and levels in blood are 
an important factor for determining disruption in trace element status. Deficiencies or 
excess of the trace element may have detrimental effect on the functions of enzymes 
[207]. Clinical and subclinical aluminium, lead and other heavy metal-induced toxic 
syndromes are known to occur in man [140]. Deficiency or excess of a number of 
trace elements has been reported in the tissues of patients with dementia. The 
anatomical functional integrity of the blood brain barrier is essential for heavy metal 
passage into brain tissue [233]. However, the relevance of the observed trace element 
imbalances to the cognitive problems occurring in neurodegenerative diseases, 
particularly Alzheimer's disease, is uncertain. The pathogenic impact of metals such 
as aluminium and lead might be to accelerate deposition of amyloids. The PrP(27-
30) polymeric aggregation and subsequent brain deposition [234] is similar to that 
reported with neurofibrillary tangles in AD patients [233 & 222]. 
1.7.3.1 Metal involvement and oxidative stress. 
Redox-active metal ions are intimately involved in enhancing free radical generation 
via Haber-Weiss and Fenton reactions [235]. The Haber-Weiss reaction can form OH 
in a reaction catalysed by metal ions. The Fenton reaction, in which Fe 2 /Cu reacts 
with molecular oxygen, generates the superoxide anion (01) which undergoes 
dismutation either catalysed by SOD or spontaneously. The formation of H202 can 
generate the highly reactive hydroxyl radical (OH). Cu catalyses this reaction at a 
rate constant magnitudes higher than that for Fe 2 [236]. The generation of free 
radicals and reactive oxygen species (ROS), if not scavenged, can result in lipid 
peroxidation, localised amino acid oxidation, and modifications to DNA [236]. 
Therefore metal disruption such as copper and zinc could lead to oxidative stress. 
1.7.3.2 A disruption of metal levels. 
Imbalances in metal status of an individual may be a contributory factor for metal 
toxicity. Inflammation generally induces local acidity and the mobilisation of both 
Zn 2 and Cu 2 [237 & 238], which are both found in high concentrations in the 
neocortex (-150, --100 j.tM respectively) [239]. Systemic amyloidoses are often 
associated with chronic inflammation [2401 e.g. the deposition of AA amyloid as a 
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consequence of inflammation [241]. Serum copper levels increase during 
inflammation, associated with an increase in ceruloplasmin. The release of reduced 
copper from ceruloplasmin is also greatly facilitated by acidic environments. Such an 
exchange of Cu 2 
 at low pH has been described as mediating the binding of serum 
amyloid P component to the cell wall polysaccharides. Brains from patients who die 
from AD are more acidic (pH 6.6) compared to brains from patients who die with no 
brain diseases (pH 7.1) [242]. Slight changes in the microenvironment of the brain 
may thus alter the solubility of A13  [243]. Further disruption in elemental status occurs 
in conditions such as renal dialysis where clearance of metals is impaired. 
Intracellular concentrations of Zn 2 and Cu2 are approximately 1000- and 100- fold 
higher than extracellular concentrations, respectively [239]. This large gradient 
between intracellular and extracellular compartments is sustained by highly energy 
dependent mechanisms [244]. An energy dependent transport system has been 
described for the re-uptake of zinc into vesicles following synaptic transmission [219 
& 217]. Therefore, alterations in energy metabolism, such as those seen in AD, 
trauma, or vascular compromise, may affect the compartmentalisation of these metal 
ions and possibly promote their pooling in the A1 3  compartment. 
1.7.4 Zinc in disease. 
Zinc deficiency might render an individual more susceptible to oxidative injury 
through reduced Cu/Zn SOD function. Other zinc related disorders have been reported 
with subnormal plasma zinc levels in patients with arterio sclerocis, malignant 
tumours, chronic and acute infections and several liver diseases. The clinical 
manifestations include dermatitis and delayed wound healing. 
1.7.4.1 Zinc levels and AD. 
Studies of zinc in AD brain tissue have produced conflicting results. Studies have 
shown both normal serum zinc and copper levels [245 & 246], decreased serum zinc 
[247] and also decreased zinc concentrations in AD brain [248] particularly in the 
hippocampus [249] and the cortex [250]. Other groups have found no significant 
differences between AD patients and controls in cortical and hippocampal zinc level 
[216]. The highest brain zinc concentrations are found in the hippocampus, principally 
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in the axons of the dentate granule cells which normally synapse with the dendrites of 
the pyramidal cells in the hippocampus [217]. These areas are consistently affected by 
pathological Afi deposition in AD [251]. 
Disruption in the blood brain barrier may result in an increased flow of zinc into the 
brain, as zinc levels in the brain are under homeostatic control. Zinc levels in the 
cerebral cortex, particularly hippocampus, increase from 0.15 to > 300 j.tM during 
glutamate synaptic transmission [251 & 252]. Glutamate is the major excitatory 
amino acid (EAA) neurotransmitter in the hippocampus and cortex. EAAs such as 
glutamate and aspartate have been reported to cause dissociation of zinc from 
metallothionein (MT) in the soluble fraction of rat hippocampus [253]. There must be 
some active removal mechanism as Zn 2 at 300 j.tM concentration is highly toxic 
[254]. Mechanisms of zinc-induced cell death have been observed in neuronal cells 
when exposed to concentrations of 7.5-200 .tM [255] or 50-1000 j.tM [256]. It is 
likely that cellular homeostatic mechanisms that regulate zinc levels would be 
activated to eliminate the excess zinc. Synthesis of MTs to bind the excess ions is one 
such mechanism involved in stabilising levels of Zn 2 . During AD there is increased 
MT levels in the hippocampus [222]. High concentrations (0.15 to >300 tM) of zinc 
have been found in neurones in regions of the brain that are vulnerable in AD such as 
the cortex and the hippocampus during neurotransmission in the hippocampus up to 
300 .tM Zn2 
 is released into the extracellular space [252 & 257]. This elevation in the 
concentration of zinc may be sufficient to induce aggregation of A0. 
1.7.4.2 Zinc levels in renal dialysis. 
Zinc levels have been found to be decreased in patients with end stage renal disease 
(ESRD) treated with continuous ambulatory peritoneal dialysis (CAPD) [177] and 
could result from loss of zinc in dialysis effluents. Factors other than the dialysis itself 
could account for the zinc disruption. The redistribution of zinc from the extracellular 
to intracellular fluid, decreased zinc nutritional intake, absorption, hypoalbuminemia 
and other factors may determine the circulating levels of zinc [180]. The normal 
ranges of serum zinc is 0.65-1.3mg I' [178]. Particular attention has to be focused on 
other factors affecting dialysis such as variations in ambient pH, glucose 
concentrations, osmolality of dialysates and dwell times, and the effect of coexistent 
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conditions such as the uraemic milieu i.e. renal failure. Zinc depletion limits the 
ability of animals to achieve maximum circulating calcitriol hormone levels in 
response to the stress of calcium or phosphorus depletion [180]. Calcitriol levels are 
involved in maintaining calcium and phosphorous levels and may also modulate 
granulocyte and immune cell function of local tissue. Extracellular calcitriol levels 
are, at least in part zinc dependent, and could modulate intestinal zinc absorption, 
thereby perpetuating the cycle. Decreased zinc also causes an increase in interleukin-
1 13, tumour necrosing factor-a production. Zinc reduced serum levels in dialysis 
patients has been associated with disturbances in taste and sexual performance [179]. 
1.7.5 Copper in disease. 
Disorders due to disruption in copper levels include acute leukaemia, Hodgkin's 
disease, leucopenia, haemochromatosis and myocardial infarction. Hereditary 
disorders such as Wilson's disease are characterised by excessive tissue deposition of 
copper, where as Menke's syndrome and fatal amytrophic lateral sclerosis are 
accompanied by changes in copper homeostasis and are characterised by severe 
neurodegeneration [182,205,207-213]. 
1.7.5.1 Copper levels and AD. 
Compared to other tissues, the copper concentration in the brain has been reported to 
be relatively high [258 & 259]. During mild acidosis free copper is released and 
transferred to other proteins such exchange occurs with serum amyloid P component. 
Interestingly, the total copper content of different brain regions varies widely [133]. 
The highest values of copper are found in the locus ceruleus (1.3 mM) and in the 
substantia nigra (0.4 mM). More recently, it has been demonstrated that the normally 
high concentrations of copper in brain parenchyma (350 mM) are elevated in AD 
brain, reaching concentrations of 800 mM [145]. Copper is also further concentrated 
within the core and periphery of Af3 plaques. Copper and zinc are also significantly 
elevated in the serum of AD patients who carry an e4 allele for apolipoprotein E 
(ApoE). Inheritance of the E4 allele of ApoE is known to increase the risk of 
AD [129, 260 & 261]. 
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1.7.5.2 Copper levels in renal dialysis. 
Dialysis patients may be prone to a disruption in copper levels, although there may be 
many conflicting factors between these studies such as dietary copper intakes, dialysis 
procedures, drug intakes, and the prevalence of other health problems. One study 
showed that the mean serum concentration of copper in control patients and in those 
on dialysis are within the normal range of 0.7-1.41 mg 1
-1 [180]. Other studies have 
reported dialysis patients can have disrupted levels of copper and ceruloplasmin, 
ranging from low to high [178 & 2621. 
Serum ratios of copper to ceruloplasmin can be an indication of copper levels as 
ceruloplasmin contains nearly all of the serum copper. Using this indicator, copper 
levels have been shown to be moderately lower compared to the control groups [180]. 
Superoxide dismutase (SOD) levels as an alternative indicator can be misleading as 
moderate copper deficiency could result in above-normal SOD activities via a 
regulatory mechanism. Kidney dialysis patients on HD and CAPD, not dialysed with 
copper based membranes show decreased levels of copper ceruloplasmin [180]. This 
may indicate either increased excretion of copper in patients with renal failure or that 
the dialysis itself is removing copper. 
1.7.6 Aluminium and silicon in disease. 
Aluminium toxicity derives from its small crystal ionic radius of A1 3 (0.051 nm) and 
high positive charge, allowing it to displace magnesium in key metabolic reactions in 
brain cells and to interfere with their calcium utilisation [263]. The unique affinity of 
silicon for aluminium may play a role in biology as a mechanism for the 
detoxification of aluminium [211]. Aluminium is neurotoxic and has been associated 
with Alzheimer's disease and dialysis related encephalopathy. The neurotoxicity of 
aluminium is well established in experimental models [264] 
1.7.6.1 Aluminium and silicon levels in AD. 
Aluminium was one of the first metal ions linked to AD. However, the influence of 
aluminium on the pathogenesis of AD remains controversial. Other researchers have 
been unable to find differences between control and AD brain [265]. Aluminium is 
the only metal which has been found in both plaques and neurofibrillary tangles in 
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brain from AD patients [266]. It has been proposed that the intracellular accumulation 
of A1 3 and also Ca2 
 in tangle bearing neurones is secondary to a defect in brain 
mineral metabolism resulting from a chronic nutritional deficiency of calcium and 
absorption of toxic metals such as aluminium and manganese [267 & 268]. 
Aluminium is neurotoxic and has been associated with AD, induce neuronal 
cytoskeletal abnormalities in vivo, disordered whorls of neurofilaments, affect 
postsynthetis events, neurofilament subunit turnover, post-translational processing, 
axonal transport. Aluminium induces the accumulation of amyloid precursor protein, 
which gives rise to A13,  the main substance of plaques. Aluminium induced build up 
of amyloid precursor protein within the axons and dendrites causes the threadlike 
extensions of nerve cells to thicken [269]. 
Aluminium loaded transferrin is able to pass through the blood brain barrier, into the 
cerebral cortex, hippocampus, septum and amygdala. These areas contain the highest 
level of transferrin receptors and are most prone to AD. The brain is calculated to take 
up 10 jig per annum of aluminium and is consistent with the levels found after 70 
years [270-272]. Aluminium can directly bind to blood brain barrier endothelial cells 
and is capable of disrupting Fe 3 homeostasis. High level of aluminium have been 
found in ferritin isolated from AD brains. A feed back mechanism could 
stimulate over production of ferritin and lead to iron overload causing possible 
oxidative stress from release of Fe 3 [273]. The average AD brain aluminium 
concentrations are greater than 5.5 jig g dry weight compared to control 
concentration of 4.7 jig g' [274 & 275]. Although, other studies have shown no 
elevations in brain aluminium concentration [276 & 277]. Amino acid-Al 
complexes such as D-Asp-Al and L-Glu-Al induce a larger random coil conformation 
in the A13  peptide than the free A1 3 [278]. The acidic amino acids such as Asp and 
Glu are well studied excitatory neurotransmitters present in high concentrations in the 
central nervous system (CNS). It has been demonstrated that aluminium in the form of 
an L-glutamate complex was able to cross the blood-brain barrier and deposit in the 
brain [273]. 
Aluminosilicate, has been reported to be a specific feature of senile plaque core [279 
& 2801 and has been suggested that aluminium accumulation as aluminosilicate 
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complexes in SF. Using solid state NMR spectroscopy aluminium and silicon has 
been shown to be present in senile plaques. Selective increase by 2:3 fold of 
aluminium and silicon in cerebral cortex was detected by secondary ion mass 
spectrometry (SMS) and may be involved in an increased uptake in AD [2811. The 
initial event in the formation of the aluminosilicate deposits is likely to be the 
polymerisation of silicic acid either when its local concentration exceeds 100MM or at 
much lower concentrations in the presence of aluminium [282]. If the total 
concentration of silicon during maturation of AD plaques (30 years) can exceed the 
critical polymerisation concentration >100 jiM then it can precipitate with aluminium 
as aluminosilicates additionally it could react with numerous other protein ligands. 
Usually serum silicon levels are greater than aluminium levels. Levels of silicon have 
been found to be increased by 20 times in the CSF in AD patients, and age dependent 
silicon accumulation has been reported [283]. Elevated concentration of silicon could 
have a protective role in limiting aluminium bioavailability [279]. 
1.7.6.2 Aluminium and silicon levels in renal dialysis. 
Both serum silicon and aluminium are elevated in renal dialysis patients compared 
with healthy controls [284]. In patients with chronic renal failure, aluminium 
accumulates through the use of oral aluminium preparations employed as phosphate 
binders [181] and from the transfer of aluminium in the dialysate during 
haemodialysis and adsorbed metals in the dialysis tubing could also be a possible 
source of metal contamination [285 & 94]. These patients have an increased body 
burden of aluminium due to impaired renal excretion and are at increased risk of 
accumulating the metal in their bodies. Deposition of aluminium, usually in the bone 
and brain, appears to be a major factor in the accumulation of aluminium in the brains 
of dialysis patients [229]. 
A1 3 levels in uraemic patients are greater than 100 jig 1' and even up to 500 jig 
compared to the normal concentration of 47±8 jig 1* Serum A1 3 levels are increased 
in patients with bullous dermatosis recognised as a complication of chronic renal 
dialysis resulting in skin lesions and over photosensitivity [286]. Levels were also 
increased in patients treated with aluminium and calcium citrate phosphate binders, 
indicating an increased absorption with citrate [287]. Highest levels of aluminium are 
found in those on haemodialysis with f32M, 17.4±3.6 tg g 1 in synovial tissues and 
20.2±6.6 Mg g' in cartilage. Controls have 1.7±0.4 Mg g' synovial tissue and 
2.4±0.4 ig g' in cartilage [288]. The use of secondary ion mass spectrometry has 
shown A1 3 
 deposits in articular structures in renal dialysis. The ratio of Al:Si is 1 
providing strong evidence that Al and Si are present as aluminosilicates [188]. 
Silicon levels are elevated in plasma and various tissues in chronic renal failure in 
man, and in patients on renal dialysis [284]. Serum silicon levels were found to be 
significantly higher both before and immediately after dialysis in the aluminium 
overload group. The observations indicate that silicon and aluminium show some 
evidence of association in serum [213]. Several studies show increased levels of 
serum silicon ranging from 0.52 to 2.8 mg F' [182, 213 & 279]. There is also 
evidence showing that an elevated concentration of silicon can limit aluminium 
bioavailability [289]. 
Dialysis patients under going treatment for chronic renal failure can develop dialysis 
encephalopathy leading to mortality [229]. These aluminium-induced dementias were 
associated with elevated aluminium in blood serum, of up to 200 Mg  F', although it 
has been shown more recently that serum aluminium concentrations of 60 Mg  l' are 
associated with impaired cognitive function [193]. Concentration in CNS in 
particular the neocortex, are elevated and aluminium accumulates in lysosomes of 
dialysis patients. The mean aluminium concentration in the frontal cortex in the 
dialysis groups (6.3 Mg g4 dry weight) was significantly elevated compared with 
that in the control groups (2.5 Mg g 1 dry weight) [194]. This encephalopathy was 
reversible if the aluminium burden was detected early enough, either by the dialysis 
regime or by the use of chelating agents such as desferrioxamine [290]. Alternative 
phosphate binders such as calcium compounds are now increasingly used [291]. 
There are profound differences in aluminium bioavailability between people with 
normal kidneys and people with kidney failure that display early AD like brain 
changes [292]. Also, the brains of about 30% of dialysis patients have plaques at 
ages when age matched controls do not [293]. Dynamic secondary ion mass 
spectrometry revealed focal accumulations of aluminium associated with cortical 
pyramidal neurones. 
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1.8 Summary. 
Amyloid deposits have been associated with specific diseases such as chronic renal 
dialysis, prion disease and Alzheimer's disease. A change in the conformation of the 
amyloid proteins to a predominantly 0 sheet conformation results in the aggregation 
of amyloid proteins and their deposition. Trigger factors are required for this 
deposition of amyloid. A genetic determinant may increase susceptibility to the 
deposition of amyloid. Alternately an environmental factor may play a role and could 
involve damage from chemical agents, which may accumulate over long periods of 
time. For instance Phosmet and BSE. A disruption of the inorganic elemental status of 
an individual may be an important factor. Aluminium has been detected co-localised 
with silicon in the cores of senile plaques in Alzheimer's disease. Levels of silicon 
and aluminium in plasma are increased in patients on long term dialysis, who are 
prone to the deposition of amyloid. Glycosaminoglycans (GAGs) have been found 
universally in all amyloid deposits. The highly suiphated GAGs and proteoglycans 
(PG) may form templates to which the fibril protein precursors attach and multiply. 
Where these trigger factors interact in the amyloidosis pathway, and whether they act 
on their own or together is unknown. 
1.9 Aims of study. 
Aims of the present study were to: 
Develop techniques to enable a trace element survey to be carried out in tissues 
obtained from various diseases in which amyloids are deposited and to determine if 
there are any imbalances in the levels of these trace elements. 
Isolate and characterise amyloid materials and to determine the involvement of 
inorganic elements in the formation of these deposits. 
Assess the manner of interaction of trace elements and amyloid materials using 
various methods to detect changes in secondary structure of the proteins. 
Chapter 2. Materials and Methods. 
2.1. Reagents. 
All chemicals and reagents used were of analytical grade, unless otherwise stated. The 
reagents and their suppliers are listed in Appendix A. 
2.1.1 Stock Solutions. 
All solutions were prepared in distilled deionised water (17.6 MQ cm 4 , Barnstead, 
UK) unless otherwise indicated. They were filtered through 0.45 tm Millipore filters 
and degassed. Those solutions asterisked ('p)  were not filtered or degassed. 
17.5% w/v Acrylamide resolving gel: Acrylamide stock solution (17.5% w/v); Tris, 
(1.5 M, pH 8.8); SDS (0.1% w/v omitted for native); Ammonium persulfate (0.05% 
w/v); TEMED (0.25% v/v, added directly before use). 
4% w/v Acrylamide stacking gel: Acrylamide stock solution (4% w/v); Tris, (1.0 M, 
pH 6.8); SDS (0.1% w/v)(omitted for native); Ammonium persulfate (0.05% w/v); 
TEMED (0.125% v/v, added directly before use). 
Bradford reagent: Coomasie brilliant blue 0 (100mg 1 - 5; Ethanol (0.05% w/v); 
Orthophosphoric acid (0.1% v/v). 
Citrate buffered saline (lOx): Citrate (200 mM); NaCl (5 M). 
Coomasie stain: Coomasie Brilliant Blue R (0.025% w/v); Methanol (40% v/v); 
Acetic acid (7.0% v/v). 
Destaining solution 1*: 
 Methanol (40% v/v); Acetic acid (7.0% v/v). 
Destaining solution 11*: 
 Methanol (5.0% v/v); Acetic acid (7.0% v/v). 
Equilibrium buffer (IEF)*:  Tris (0.125 M,H 6.8); SDS (2.0% w/v); Dithiothreitol (4.9 
mM); Bromophenol blue (0.02% w/v); Glycerol (10% v/v). 
Electrophoresis buffer (PAGE)*:  Tris (24.0 mM); SDS (0.1% w/v, omitted for 
native); Glycine (200 mM). 
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Homogenisation buffer*: SDS (1.0% w/v); PMSF (0.1 mM); tris (50 mM, pH 7.4); 
NaCl (150 mM). 
IEF Anolyte solution*: Phosphoric acid (0.85% v/v). 
IEF Catholyte solution: NaOH (20 mM). 
IEF Denaturing tube gel: Acrylamide stock solution (3.3% w/v); Ampholytes (2.0% 
v/v); Urea (9.0 M); NP-40 (2.0% v/v); Ammonium persulfate (0.05% w/v); TEMED 
(0.125% v/v, added directly before use). 
Kreb's Hensleit buffer: NADP (0.4 RM); NADPH (0.4 LIM); glucose-6-phosphate 
(8.0 jiM); glucose-6-phosphate dehydrogenase (0.3 U mi'). 
Lysis buffer (IEF)*: 
 Ampholytes (2.0% v/v); Urea (9.5 M); NP-40 (2.0% v/v); 
Dithiothreitol (5.0% w/v). 
Oxalate buffer*: 
 Oxalic acid (50 mM); Lithium hydroxide (95 mM). 
Post column reagent (transition metals)*: 
 PAR (0.3 mM); Acetic acid (I M); 
Ammonium hydroxide (3 M). 
Post column reagent (aluminium)*: 
 Tiron (30 mM), ammonium acetate (3 M made to 
pH 6.2 with NaOH I M). 
Silver stain solutions*: 
 i) Glutaraldehyde (10% v/v) ii) Dithiothreitol (5 pig lj; iii) 
silver nitrate (0.1% v/v), iv) Glutaraldehyde (0.0185% v/v), Sodium carbonate (3% 
w/v). 
Sulphate buffer*: H2SO4 (0.01 M), (NH4)2 SO4 (0.2 M). 
Treatment buffer (PAGE)*: 
 Tris (0.125 M, pH 8.3); SDS (4.0% w/v, omit for native); 
Dithiothreitol (0.2 M); Bromophenol blue (0.02% w/v); Glycerol (20% v/v). 
Tris buffered saline (lOx): Tris (200mM); NaCl (SM). 
Tris / TFE buffer*: 
 40% (v/v) Tris buffer (10 mM, pH 7.4), 60% (v/v) 
Trifluoroethanol (TFE) 
62 
2.2. Concentrations of trace metals in biological tissues. 
2.2.1. Detection of trace metals in biological tissues and fluids. 
All chemicals were of analytical grade and where possible all analyses were carried 
out in plastic-ware to reduce the risk of contamination during storage, transport and 
analysis. All containers and apparatus were acid washed by soaking in nitric acid 
(10% v/v) (BDH, UK) overnight, rinsed and then soaked in deionised water 
(Barnstead E-Pure, 17.6 MQ cm') overnight. All calibration stock solutions were 
prepared daily from atomic absorption spectroscopy standards (Fisher, UK). 
2.2.1.1. Sample preparation - Blood plasma. 
Blood plasma samples (n=8) from renal dialysis patients were used. Samples were 
obtained from haemodialysis (HD) patients (n=4) and from patients on continuous 
ambulatory peritoneal dialysis (CAPD) (n=4). The age of the dialysis subjects ranged 
between 35-60 and the number of years that they had received dialysis treatment 
ranged between 2-25 years. These samples together with age matched control blood 
samples (n=4) were obtained from the Dialysis Unit, Royal Preston Hospital, Preston, 
UK. 
The blood samples were centrifuged at 5,000 g for 10 minutes and the required 
plasma fractions were removed. The samples were stored in the refrigerator at 4 °C 
before use. The blood plasma (I ml sample) was digested with 3 volumes of 70% v/v 
nitric acid (BDH, UK) in sealed pressurised ISO ml teflon bombs (CEM, UK). The 
samples were microwaved in an MDS 8D microwave (CEM, UK) at 70% power 
(Max temp 250 °C) for a total of 60 minutes in 3 x 20 minute periods. The bombs 
were allowed to cool for 10 minutes between each 20 minute period. After the final 
cooling, the digested material was diluted to a volume of 10 ml with deionised water. 
2.2.1.2 Calibration of the internal standard method 
The developed method used an internal standard to minimise errors due to sample 
loading, column variations etc. A cobalt internal standard was chosen and this was 
added to all of the samples. The standard addition samples were made as follows; four 
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I ml aliquots of the plasma digest were spiked with copper (0, 0.2, 0.4 and 0.8 mg 
and zinc (0, 0.2, 0.4 and 0.8 mg Y) made from atomic absorption spectroscopy 
standards (Fisher, UK). A 0.6 mg Ii 
 cobalt internal standard, made from an atomic 
absorption spectroscopy standard (Fisher, UK), was also added to each sample. The 
solutions were made up to 5 ml with deionised water. These samples were analysed 
immediately with the ion chromatography system. 
2.2.1.3 Sample preparation - Human tissue. 
Liver, kidney, heart and osseus joint (carpal tunnel) tissue samples were obtained at 
post mortem from a renal dialysis patient (n=1) diagnosed as having carpal tunnel 
syndrome from the Renal Unit, Royal Preston Hospital, Preston, UK. Control tissue 
samples of liver, kidney, heart and brain (cerebral cortex) were also obtained from the 
Royal Preston Hospital, Preston, UK. Alzheimer's disease brain tissue (n=4) (parieto-
occipital cortex) was obtained from MRC Neurochemicalpathology Unit, Newcastle 
General Hospital, Newcastle, UK. All the samples were stored in sterile containers 
and were frozen until use. 
A 5 g sample of tissue was digested in 10 ml of 70% v/v nitric acid (for the carpal 
tunnel tissue, 2.5 g was digested in 5 ml 70% v/v nitric acid) in 25 ml teflon beakers 
with loose fitting teflon lids. The samples were allowed to digest for 5 hours on a 
hotplate (250 °C). After complete dissolution of the tissue, the solution was 
evaporated for approximately 2 hours until only about I ml of sample was left. This 
was diluted to 20 ml with deionised water. Levels of copper, zinc, cobalt, and nickel 
and aluminium were directly measured using ion chromatography. 
2.2.2 Measurement of metal levels by ion chromatography. 
Ion chromatography was used to detect levels of transition metals in acid digested 
plasma and in acid digested tissue. Measurements were performed in triplicate on a 
Dionex DX500 ion chromatography system with a gradient pump connected to an 
Acer P100 personal computer running Hewlett Packard 'HP-ChemStation' 
chromatography software. The ion chromatography system also included a Dionex 
AS40 autosampler and postcolumn controller and reservoir (Dionex, UK). The 
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column used was a 25 cm HPJC-CS5 cation exchange column (Dionex, UK) with a 
5 cm HPIC -CG5 guard column (Dionex, UK) with a 25 j.tl sample injection loop. 
The column packing consisted of a crosslinked styrene and vinylbenzene polymer 
with sulphonic functional groups. A Dionex A20 absorbance detector (Dionex, UK) in 
UV/VIS mode was used to detect the separated analytes. All eluents were degassed by 
passing helium gas through the solutions for I hour. 
For the detection of transition metals, the eluent was 50 mM oxalic acid (BDH, UK) 
and 95 mM lithium hydroxide (BDH, UK) at pH 4.8 at a flow rate of I ml min* The 
post column reagent used was 0.3 mM 4-(2-pyridylazo) resorcinol (PAR) (Dionex, 
UK) in I M acetic acid (Sigma, UK) and 3 M ammonium hydroxide (Sigma, UK) 
solution at a flow rate of 0.7 ml min* The PAR metal complex was detected at 520 
nm (VIS mode) using a Dionex A20 absorbance detector. 
For the detection of aluminium, the eluent was 0.01 M H2SO4  and 0.2 M (NH4)2 SO4 
at a flow rate of I ml min. The post column reagent was 3 x 10 M Tiron in 3M 
ammonium acetate (pH 6.2 with NaOH) solution at a flow rate of 0.7 ml min 1 . 
Detection of the tiron-aluminium complex was at 310 nm (UV mode) using a Dionex 
A20 absorbance detector. 
2.2.2.1 Validation of the ion chromatographic technique. 
The ion chromatography method for the detection of transition metals was compared 
to detection by inductively coupled plasma optical emission spectrometry (ICP-OES) 
(Analytical Model P, Spectro, UK) housed at the Sheffield Hallam University, 
Sheffield, UK. Copper was detected at 324.8 nm and zinc at 213.9 nm with a UV 
detector. The sample was introduced into the plasma at a flow rate of I ml min 1 
through silicone tubing via a peristaltic pump. Five replicate measurements were 
made and approximately 0.5 ml of sample was required per sample. The system was 
flushed with deionised water between runs. The samples run on the TCP-OES 
contained the plasma digest spiked with copper (0,0.2, 0.4 and 0.8 mg F') and zinc (0, 
0.2, 0.4 and 0.8mg 1') and 0.6mg F' cobalt internal standard. 
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2.3 Extraction of amyloid from Alzheimer's disease brain tissue. 
A procedure of isolation based on the extreme insolubility of amyloid (A13)  was used. 
The method employed was a slightly modified protocol as used by Naslund et al. 
[294]. Amyloid material was extracted from parieto cortex tissue from Alzheimer's 
disease sufferers from Norway. The brain tissue samples were obtained from the 
MRC Neurochemicalpathology Unit, Newcastle General Hospital, Newcastle, UK. 
2.3.1 Homogenisation and centrifugation of the brain tissue 
Frozen sections of brain parieto cortex (30g of tissue) were thawed and homogenised 
in 5 volumes of homogenisation buffer (1% w/v SDS, 0.1 mM phenyl methyl 
sulphonyl fluoride, 150 mM NaCl and 50 mM tris pH 7.4). The SDS insoluble 
material was centrifuged for 60 minutes at 50,000 g (22 °C) in a Beckman L8 70M 
ultracentrifuge with a 70 Ti rotor (Beckman, UK). The pellet was re-homogenised in 5 
volumes of homogenisation buffer and centrifuged as above. This step was repeated 5 
times. The final pellet was washed with water and extracted with 5 volumes of 
1,1,1,3,3,3 hexafluoroisopropanol (HFIP) (22 °C). The HEW extract was filtered with 
glass wool to remove coarse material and dried using vacuum centrifugation in a 
Jouan RCIO.22 Centrifugal vacuum evaporator, with an RDT 60 Vacuum unit (Jouan, 
UK) and Javac DD 150 high vacuum pump (Jouan, UK). The extracts were 
delipidated by adding 1 ml of a chloroform/methanol mixture (1:2) and centrifuged 
for 10 seconds at 20,000 g in a Jouan AlO centrifuge (Jouan, UK). Water (0.5 ml) was 
added to the supernatant and centrifuged at 20,000 g for 1 minute. Methanol (0.6 ml) 
was added to the aqueous upper phase and centrifuged at 20,000 g for 2 minutes. The 
pellet was dried under a stream of nitrogen and re-suspended in 70% v/v formic acid 
and centrifuged at 5,000 g for 3 minutes. 
2.3.2 Size exclusion of protein extract and purificalion of the 4 kDa extract 
Amyloid proteins extracted from the brains of patients (n=4) with Alzheimer's disease 
were subjected to size exclusion chromatography to remove the 4 kDa amyloid 13 
protein. Approximately 3-4 g of Sephadex (Sigma, UK) G75 was swelled in 40 ml of 
70% v/v formic acid (Sigma, UK). The swelled Sephadex was degassed under 
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vacuum. Approximately 30 ml of the Sephadex was loaded onto a I x 50 cm glass 
chromatography column (Bio-Rad, UK) and allowed to settle for one hour. The 
column was equilibrated with 70% v/v formic acid for 3 hours. The flow rate was 100 
ml mm 1
. Collection volume of each fraction was 250 pA, equivalent to 20 drops. The 
total time for the running of the column was about 12 hours. 
The column was calibrated with molecular weight markers (alcohol dehydrogenase, 
bovine serum albumin, carbonic anhydrase, cytochrome C and vitamin B12, 
(Sigma,UK)) which have molecular weights of 150000, 66000, 29000, 12400, and 
1335 Da respectively. Total protein was approximately 2 mg ml'. Dextran blue (MW 
2,000,000) was also added to determine the 'dead volume'. The fractions were 
collected on a fraction collector. They were monitored by UV absorbance detection at 
280 nm in a 1 mm quartz cuvette (sample volume 250 p1) in a Hewlett Packard (HP) 
diode array UV spectrometer (8452A). The system was connected to a HP Vectra 
QS/20 computer running the HP89531A UV/VIS operating software (Rev A.03.00, 
1990). Collection was terminated when no more protein was detected. 
The crude brain extract (390 mg) was subject to size exclusion using a 30 ml column 
of Sephadex G75 (Sigma, UK) in a I x 50 cm glass packing columns (Bio-Rad, UK) 
with a fraction collector (model 2110, Bio-Rad, UK). Alzheimer brain extract was re-
suspended in 70% v/v formic acid and a small amount of dextran blue was added to 
determine the dead volume. The sample was applied to the column and the eluent was 
70% v/v formic acid. The fractions corresponding to 4 kDa range of protein were 
pooled and vacuum centrifuged to dryness. 
2.3.2.1 Protein quantification, 
Extracted protein concentrations were quantified using the Bradford protein assay. 
The Bradford reagent was filtered in 0.45 pm filter (Millipore, UK) prior to use. The 
aliquot of the extracted protein (0.5 mg) was made up in 0.5 ml of deionised water. A 
range of standard proteins were prepared (1-100 pg using bovine serum albumin 
(BSA) (Sigma, UK). All tests were performed in duplicate. A 3 ml aliquot of the 
Bradford reagent was added to each solution in plastic cuvettes. After 5 minutes the 
absorbance of the solutions (Sarstedt, UK) was measured at 595 nm in a 
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spectrophotometer (Hewlett Packard, UK). A calibration curve was constructed from 
the BSA standards and the values of protein concentration of each extract were 
obtained by interpolation. 
2.3.3 Immunblotting of 0 amyloid proteins. 
The Immuno-Blot enzyme immunoassay kit (Bio-Rad, UK) was used in the detection 
of the amyloid A13 (1-40) specific antigen and the procedure was followed as per kit 
instructions. The Immuno-Blot assay systems used a protein 0 - horseradish 
peroxidase complex that give sensitive detection of specific antigen - antibody 
complex. Protein can be transferred by dot-blotting, Western blotting, filter affinity 
transfers, and in situ colony or plaque lifts. 
Approximately 10 jtg of protein, synthetic A3(l-40), AI 3(l -42), A13(l -43 ), 
APP(125-135), the extracted amyloid and the pre-purified extracts were each 
solubilised in 100 pA of deionised water. The proteins were dot blotted onto a nitro-
cellulose membrane. They were transferred drop wise and was allowed to dry before 
the next drop was added to ensure the radius of the drops were kept small. Following 
binding of each of the antigens, the remaining protein binding sites on the membrane 
surface were blocked with gelatin (3% w/v in tris buffered saline) with gentle shaking 
for 30 minutes. The gelatin will not react with the primary and secondary antibodies. 
The membrane was washed with tween tris buffered saline (TTBS) with gentle 
agitation for 10 minutes at room temperature. The membrane with bound antigens was 
then incubated overnight with the first antibody to A13(1-40)  (Sigma, UK) at a 
concentration of 1:6000. The membrane was washed in tween citrate buffered saline 
(TCBS) to remove unbound antibody for 10 minutes. The solution was changed with 
fresh buffer after 5 minutes. The membrane was then incubated for 2 hours with 
gentle agitation with the conjugate. This was Protein 0 conjugated to horseradish 
peroxidase. The membrane was finally washed in TTBS for 5 minutes, at room 
temperature with agitation. This was repeated. The membrane was then exposed to the 
colour development reagent containing 4-chloro-l-naphtbol and hydrogen peroxidase, 
which yielded purple dots for the reacted antigen. 
2.4 Circular dichroism spectroscopy studies of amyloid materials 
The circular dichroism spectroscopy (CD) was used to detect changes in secondary 
structure of proteins. The CD facility located on Station 3.1 was housed at CLRC 
Daresbury Laboratories, Daresbury, UK. This incorporated a I metre vacuum UV 
monochromator (Seya-Namioka) which was capable of operation between 30 and 
500 nm wavelength range. 
2.4.1 Calibration of the CD spectrometer. 
The CD system was calibrated using (+)-I0-camphorsulphonic acid (CSA) standard in 
water(l mg ml' solution gave an absorbance of 0.149 in a I cm cell at 285 nm). The 
characteristic CD spectrum of camphorsulphonic acid has a positive band at 290 nm 
and a negative band at 192 nm. A I mg ml' solution in a 1 mm cell has a molecular 
ellipticity (AE) of -4.8 M' cm 1 
 at 192 nm. The value at the minimum divided by a 
constant gives a conversion factor for I mg mF' protein in a 0.1 mm cell. 
2.4.2. Amyloid studies. 
The buffer used in the CD studies contained 2,2,2-trifluoroethanol (TFE) and 
tris[hydroxymethyl]aminomethane (tris) (10 mM, pH 7.4) in a ratio of 3:2. The TFE 
acts as a 'secondary structure-inducing' agent. All metal stock solutions (AICI 3 , 
CaCl 2 , CuCl2, ZnCl2 and M902) were prepared in tris/TFE buffer immediately prior 
to use. The silicon, as sodium metasilicate solution, was made in tris buffer and then 
diluted to the required concentration in trisrl'FE (as the silicate precipitated in the 
tris/TFE at the stock concentration of 3 mM). The solutions were vortex mixed and 
allowed to stand at room temperature for 1 hour before analysis. 
The synthetic amyloid proteins used were A1 3(I -40), A13 ( 1-42 ) and 
 A13(l-43).  Other 
proteins used were; amyloid protein extracted from AD brains, 132  Microglobulin and 
the recombinant mouse prion protein (r[mouse} PrPC). 
 The glycosaminoglycans used 
were sodium heparin, heparan sulphate (HS), dermatan sulphate (DS), chondroitin 
sulphate (CS), keratan sulphate (KS) and the proteoglycan used was heparan sulphate 
proteoglycan (HSPG) (Sigma, Poole, UK) and also sodium sulphate. The 
concentrations of the various peptides, metals and glycosaminoglycans used are listed 
in Tables 2.1, 2.2 and 2.3. 
Amyloid peptide Stock solution Final sample concentration (mg m11 (pM)) (mg mr' (pM)) 
Af3(1-40) 0.5 (115.5) 0.25 (57.7) 
132M 0.5 (423) 0.25 (211.5) 
AJ3(142) 0.3 (66.5) 0.15 (33.3) 
Aj3(1-43) 2.0 (433.4) 1.0 (216.7) 
AI3(25-35) 0.25 (235) 0.125 (118) 
Extract 1.0 0.5 
Prr(90.231) 1.0 1.0 
Table 2.1 - The concentrations of amyloid peptides used. 
Stock Working 
Sulphates and GAGs solution solutions 
(mg ml' (mM)) (jig ml') 
Sodium sulphate (Na2SO4) 5.0 (35) 50,500 
Sodium heparin (HEP) 5.0 (0.83) 50,500 
Heparan sulphate (HS) 5.0 (0.67) 50,500 
Heparan sulphate proteoglycan (HSPG) 2.5 50,500 
Dermatan sulphate (DS) 5.0 (0.4) 50,500 
Chondroitin sulphate (CS) 5.0 (0.4) 50,500 
Keratan sulphate (KS) 5.0 50,500 
Table 2.2 - The concentrations of sulphates and glycosaminoglycans. 
Metal studies GAG studies 
Stock Working Stock Working Inorganic element 
solution solution solution solution 
(mg F' (mM)) (pM) (mg 1' (mM)) (pM) 
Aluminium (as AICI3) 135 (5.0) 50, 150, 300, 400 4.3 (0.16) 1.6 
Silicon (as Na2SiO3) 84.3 (3.0) 30,300 39.3 (1.4) 14.0 
Copper (as CuCl2) 63.5 (1.0) 10, 50, 100 63.5 (1.0) 10.0 
Zinc (as ZnCl2) 65.4 (1.0) 10,50, 100 0.65 (0.1) 10.0 
Calcium (as CaCl2) 40.1 (1.0) 100 0.65 (0.16) 16 
Magnesium(asMgCl2) 24.3 (1.0) 100 3.88 (0.16) 16 
Table 2.3 - The concentrations of inorganic elements used in the metal studies. 
70 
Sample were analysed in 0.1 mm cells requiring approximately 80-100 R1  of sample. 
Two scans were taken over ISO to 260 nm range at 0.25 nm increments with a dwell 
time of 3 seconds at each wavelength. The sample was kept at 37 °C using a 
circulating water jacketed 0.1 mm cell (Haake k20 water bath). Buffer scans were 
taken and the buffer spectrum was subtracted from the sample scan to give the final 
spectrum. The buffer scans were taken at regular intervals to correct for the changes in 
the synchrotronic light source output as this deteriorated with time. 
2.4.2.1 Amyloid peptide treated with metals. 
A13(l -40) , A13 ( 1-42 ) ,  Af3(1-43), the extracted amyloid and 132M were treated with 
various metals: Cud2 (100 jiM), Cad2 (100 jiM), ZnCl2 (100 MM). The A13(l-40) 
and 32M were also treated with M902  (100  MM).  The J3(l-40) peptide was treated 
with CuCl2 (10, 50 and 100 MM) and ZnCl 2 (10, 50 and 100 MM) and with combined 
CuCI, and ZnCl2 0 00 MM). 
2.4.2.2 Amyloid peptide treated with aluminium and silicon. 
Various amyloid proteins A13 (I -40) , A13 ( 1-42) , A13 ( 1-43 ) ,  A13(25-35), amyloid extract 
and 132M in the tris/TFE buffer were treated with AId3 (50, 150, 300 and 400 MM). 
The peptides A13(  1-40) and 132M were also treated with various combinations of AICI3 
(50, 150, 300 and 400 MM) and Na2SiO3 (30 and 300 MM) as in shown below in 
Table 2.4. 
Silicon (MM) 	 Aluminium (JIM) 0 	 50 	 150 	 300 	 400 
0 
30 vt' 
300 V vt +* 
Table 2.4 - The various combinations of aluminium and silicon. The + denotes silicon 
added before the aluminium, and * denotes the silicon added after the aluminium. 
2.4.2.3 Amyloid peptide treated with glycosaminoglycans and metals 
Synthetic amyloid peptides 0 2M and Af3(140) peptides were treated with various 
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suiphated glycosaminoglycans, heparan sulphate proteoglycan and sodium sulphate. 
Combinations of these GAGs and various metals were also investigated. Each peptide 
was treated with each of the glycosaminoglycans and also with sodium sulphate to 
investigate the sulphate group on its own. The GAGs were then added with various 
metals at concentrations found in serum: A1 3 , Ca2 , Si044 , Cu 2 and Zn 2 (Table 
2.5). 
SiO4 Ca2 Cu2 Zn2 GAG (1.6 p.M) (14 iil\'I) (16 gM) (10 gM) (10 gM) 
HEP V 
HS V V V V V 
HSPG V V V V 
DS V / V / V 
CS V / V 
KS V V V V V 
Na2SO4 V 
Table 2.5. - The peptides were treated with the various GAGs (500 gg mF') combined 
with the metals. 
2.4.3 The interaction of recombinant mouse PrPC with the 
organophosphorous insecticide, Phosmet and its metabolites. 
A specially designed rectangular cell was custom-made at Daresbury Laboratory. The 
cells consisted of a quartz cuvette (with outer dimensions of 2.5 x 4 x 2 cm) divided 
into two compartments separated by a semi permeable membrane (molecular weight 
exclusion >12 kDa) with a 0.1 mm path length. Due to the extreme toxicity of the 
prion protein these cells were manipulated in a Class III environment in a Class III 
hood (Royal Preston Hospital, Preston, UK) and were destroyed after use by 
incineration. 
The effects of Phosmet and its metabolites on the secondary structure of recombinant 
mouse, r[mouse} PrPC(90.231) 
 was investigated by circular dichroism spectroscopy 
using synchrotron radiation at the CLRC facilities at Daresbury, UK. Spectra were 
recorded at 0.5 nm increments between 185 to 260 nm. The recombinant [ mouse]PrPC 
(I mg mF') in Kreb's Hensleit buffer and phosmet (25 mg F') in Kreb's Hensleit 
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buffer were incubated in a cuvette for 2 hours before the spectrum were recorded. The 
spectrum was taken at 15 minute intervals for a total of 7 hours 15 minutes. The prion 
was treated with the metabolites of Phosmet. The metabolite generating system 
consisting of rat microsomes (2 mg ml') was freshly prepared in Kreb's Hensleit 
buffer [295] and mixed with Phosmet (12.5 mg F') in Kreb's Hensleit buffer. The 
r[mouse]PrPc (1 mg ml') in the Kreb's Hensleit buffer was injected into one side of 
the cell and the phosmet and rat microsomes in Kreb's Hensleit buffer (the metabolite 
generating system) was added to the reservoir. 
The metabolite-generating system was studied by incubating microsomes (2 mg ml' 
of protein) with Phosmet (12.5 mg F') in Kreb's-Hensleit buffer at 37°C for 30 
minutes. Samples (100 Ml) were taken at 15 minute intervals and extracted with 
hexane (500 R1). The hexane was evaporated and the residue dissolved in methanol 
(100 jtl). Aliquots (20 Ml)  of the extract were analysed by high performance liquid 
chromatography (HPLC) with UV detection utilising a Sphereclone ODS 5 .im 
column (250 x. 4.6 mm; Phenomenex, Macclesfield, UK) eluted with methanol 
(I ml min') [296]. 
2.4.4 Manipulation of the CD data and determination of the amyloid 
secondary structure. 
The data were analysed using 'Plotekx' (data analysis program on the Challenge L 
computers at CLRC, Daresbury) and Microsoft Excel (version 97). The buffer data 
were subtracted from the sample data and the resultant values corrected by a scaling 
factor obtained from calibrating the spectrometer with camphorsulphonic acid as 
described in section 2.4.1. The spectrum should tend towards zero after about 240 
nm; this indicates correct buffer subtraction. The spectrum may need to be shifted by 
either a positive or negative constant. The SELCON program was used to determine 
empirically the secondary structures from the CD data by comparing with the peptide 
backbone (190-250 nm) for a set of model polypeptides [17-20]. 
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2.5 Attenuated total reflectance Fourier transform infrared 
spectroscopy of amyloid materials. 
Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy can 
be used to analyse protein structures in different forms, including surface adsorbed 
proteins, membrane bound proteins, turbid solutions and proteins in biological 
samples. Generally the a helical conformation of a protein is located around 1650 
cm 1 
 and the J3 sheet band is around 1630 cm 1 . There is a weaker band associated with 
antiparallel 13 sheets around 1680 cm* Monitoring of the changes in position and 
intensity of these amide I bands allows detection of conformational change within the 
protein. 
Spectra were taken on a Mattson Galaxy series 3000, Fourier transform infrared 
spectrometer (Mattson, USA) connected to a Mitac PC computer running 'First' 
acquisition software. An attenuated total reflectance (ATR) element - model 0001-
171/H133 (Spectratech, Nicolet, UK) was used with a germanium crystal in a 
horizontal mount for the two types of sampling (Spectratech, Nicolet, UK). This type 
of accessory comprises of a parallelogram prism of the internal reflectance crystal 
with mirrored ends. For a solid sampling attachment, the crystal is mounted flush with 
the top plate and the solid is clamped onto the surface by means of a fixing plate. The 
liquid sampling block has a well that holds the liquid sample, which was simply 
cleaned off when the acquisition was completed. 
2.5.1 Modification of ATR attachment. 
To minimise sample volume the solid sampling block was adapted for liquid 
sampling. An acetate cover (approximately 4 x 50 mm) was carefully placed over the 
pipetted sample on the germanium crystal. The liquid covered the crystal as with a 
cover-slip on a glass slide. This reduced the sample volume to 15 R1  compared to 2 ml 
required in a typical liquid sampling block. (Figure 2.1). There was also less 
evaporation of the sample during measurement compared to open liquid sampling. 
/ 
74 
Acetate cover 
Germanium IRE crystal 
Solids block mount 
Figure 2.1 - A horizontal ATR attachment and solid sampling block with acetate 
cover slip (4 x 50mm) to minimise sample volume (15 MD 
2.5.2 Measurement using ATR-FTIR. 
Amyloid proteins A3(l-40) (57.7 j.tM), A13 ( 1-42 ) (33.3 MM), A13(l-43)  (216 j.tM), 13 
amyloid extracted from human brain (0.5 mg ml') and 02M (211 MM) in tris buffer 
(10 mM, pH 7.4) were treated with AId3 (50, 150, 300, and 400 MM), 
Cud 2 (100 jiM), CaCl 2 
 (100 jiM), ZnC12 (100 MM) in tris buffer (10 mM, pH 7.4). 
The Af3(l-40) and 132M were treated with Si04 4 (300 MM), and A1 3 (300 MM). The 
Af3(l-40) and f321V! were also treated with Ca 2 (100 MM) combined with heparan 
sulphate (500 Mg  ml t ) or heparan sulphate proteoglycan (500 Mg  ml'). All the 
samples were left to incubate for 1 hour at room temperature before the ATR 
measurements. 
Firstly, the crystal background was taken at 100 scans at 4 cm 1 resolution. Then three 
repeat scans of the tris buffer were taken. The crystal was wiped with tissue and three 
repeat scans of the sample were taken. The crystal was cleaned with detergent 
(10% w/v SDS), then wiped with ethanol and rinsed thoroughly with water and 
periodically checked for any adsorbed protein by running a blank spectrum which 
would show absorption bands between 1700-1600 cm if protein was still present. 
The spectrum were converted to absorption spectrum and normalised using the 'First 
spectral analysis program (V 1.52, Mattson, USA). The tris buffer scans were 
subtracted from the sample spectrum. 
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2.6 Polyacrylamide gel electrophoresis of 3 2M and A13(1-40). 
Analysis of the amyloid proteins was carried out by polyacrylamide gel 
electrophoresis (PAGE) using a Hciefer SE600 water cooled dual unit gel 
electrophoresis kit (Hoefer, UK) with PS500XT power supply (Hoefer, UK). The gels 
were run either natively (which allows the separation by charge) and/or run as 
denatured proteins (which separates according to the size of the protein). The two 
dimensional analysis was carried out in a SE 6035, 1.5 mm tube gel adapter kit used 
with the above Hoefer SE600 gel electrophoresis equipment (Hoefer, UK). 
Gels were cast according to the manufacturers instructions for the Hoefer SE 600 
series gel electrophoresis unit. Solutions of 4% w/v and 17.5% w/v acrylamide, pH 
6.8 and 8.8 respectively, were prepared from 30% w/v acrylamide, 0.8% w/v 
bisacrylamide stock solutions (Sigma, UK). Two clean glass plates of dimensions 
16 x 18 x 0.03cm (Hoefer, UK) were wiped with 70% v/v ethanol and allowed to dry. 
The plates were assembled with 1.0 mm spacers and clamped together and screwed 
onto the casting base to form a vertical slab gel unit. The 17.5% w/v acrylamide 
solution was syringed into the cavity up to 1 cm below the comb level (the acrylamide 
was initiated by adding TEMED immediately before filling). An overlay of water 
saturated iso-butanol was added and the gel allowed to set for I hour at room 
temperature. The overlay prevents the top edge of the resolving gel from polymerising 
so that the stacking gel can adhere to the main gel. Once the resolving gel had set the 
iso-butanol was thoroughly washed out with deionised water. A comb with 15 teeth 
(0.4 cm diameter) was inserted and the 4% w/v acrylamide solution was added 
making sure no air bubbles were trapped under the comb teeth. This was allowed to 
set at room temperature (about 30 minutes). The comb was then carefully removed 
and the wells washed with PAGE running buffer. 
Synthetic amyloid proteins used were A1 3 ( 1-43 ) (87 tiM), A13(l-42)  (44.4 jiM), A13(l -
40) (92 jiM) and 32M (170 jiM) in tris buffer (10 mM, pH 7.4). All the metals and 
GAGs were made to twice the required concentration in tris buffer (10 mM, pH 7.4). 
The samples were then prepared by combining the solutions in equal amounts and 
were left to incubate at room temperature for 1 hour. 
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The amyloid peptides were treated with various metals; AId 3 (1 mM), CuCl2 0  mM), 
ZnCl2 (I mM), CaCl 2 
 0 mM) and M902 (1 mM) and SDS PAGE gels run. The 
Af3(l-40) and the P2M peptides were also treated with increasing concentrations of 
aluminium (25, 50, ISO, 300 and 400 MM). These samples were run both natively and 
under denaturing conditions. SDS PAGE gels were run of A13(l-40)  and 132M peptides 
treated with glycosaminoglycans (Heparan sulphate, heparan sulphate proteoglycan, 
dermatan sulphate and heparin Na2SO 4 
 (all at a concentration of 500 jtg mr')) and 
also with Na2SO4 
 (500 tg mE'). SDS PAGE of these GAGs also combined with 
various metals; Ca 2 (100 MM), Cu2 (100 MM), Al 3 (300 MM), Si044 (300 MM) and 
Al3 
 (300 MM) combined with Si0 44 (300 MM) were also run. 
A mixture containing 10 M1  of the protein sample and 10 M1  of the treatment buffer 
were denatured by boiling the samples for 5 minutes at 95 °C in a heat block. For SDS-
PAGE the treatment buffer contained SDS and for native PAGE the SDS was omitted. 
The samples were loaded into the wells and 5 M1  of low range molecular weight 
markers (1,060-26,600 kDa) (Sigma, UK) was also loaded. The gels were run in 
electrophoresis buffer (0.025 M tris, 0.192 M glycine) at 10 mA, 120 V for 1-2 hours 
(PS500XT, Hoefer, UK). 
2.6.2 Isoelectric focusing of amyloid materials. 
In two dimensional gel electrophoresis the first dimension gel is the isoelectric 
focused (IEF) gel. This first dimension separates the proteins according to their p1. 
The second dimension will separate the proteins according to their size as above. The 
1.5 mm diameter glass tubes were cleaned and the ends capped by twisting Parafllm 
over the end three times. The tubes were assembled upright in the rack and held in a 
vertical position. The 3.3% w/v acrylamide solution containing ampholytes 
(3.5-10 pH) and urea was first degassed thoroughly and again initiated with 
ammonium persulfate and TEMED before casting. The solution was carefully 
syringed into the tubes, making sure no air bubbles were trapped in the gel and 
leaving about a 2 cm gap at the top. The ends were sealed with Paraflim and the gels 
were allowed to polymerise at room temperature for about 2 hours. 
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The P2M peptide (85 jiM) was treated with aluminium (300 jiM) and allowed to 
incubate at room temperature for 1 hour. The sample was mixed with the IEF 
treatment buffer loaded on to the tubes and focused with the anolyte solution as a 10 
mM phosphoric acid and the catholyte solution of 10 mM sodium hydroxide for up to 
16 hours (PS500XT, Hoefer, UK). The tube gel was carefully removed from the glass 
tube by inserting a syringe over the end and expelling equilibration buffer until the gel 
slides out of the tube. The gel was equilibrated in a buffer containing dithiothreitol 
and SDS for 10 minutes. The tube gels were laid on top of the second dimension gel 
and sealed in place with a 1% w/v agarose melted in the electrophoresis buffer before 
being run as an SDS PAGE, as above. 
2.6.3 Gel Staining. 
Gels were stained with either coomasie blue or silver stain, following standard 
procedures. For coomasie blue stain, the gel was placed in a tray with coomasie blue 
and gently shaken for about 2 hours and preferably overnight. The gel was then 
destained in destain I solution overnight, then in destain II, again overnight. The silver 
stain method is highly sensitive but may also produce a higher background colour. 
Briefly, the gel was first stained with coomasie blue and destained as above. The gel 
was rinsed in destain II and then fixed in 10% v/v glutaraldehyde solution for 30 
minutes. The gel was washed in deionised water for 2 hours with several changes or 
soaked overnight. Again it was rinsed in deionised water and placed in 200 ml of 5 jig 
mU' DTT in deionised water for 30 minutes. The solution was discarded and without 
rinsing, 100 ml of 0.1% w/v silver nitrate solution added and the gel shaken gently for 
30 minutes. The silver nitrate was decanted and the gel washed twice with the 
developing solution and then left to develop in 100 ml of developer. Bands appear 
after about 30 minutes. The development was stopped by decanting the solution and 
addition of 100 ml of destain II. 
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Chapter 3. The determination of the levels of trace elements in 
biological fluids and tissues. 
3.1 Introduction. 
Levels of many trace elements are disturbed in various diseases for instance abnormal 
levels of copper and zinc have been found in patients on renal dialysis [284 & 2881. 
The disruption of trace element status, particularly the effects due to their 
accumulation, depletion or deficiency may have a detrimental effect on the functions 
of many enzymes (2071. Deficiency or excess of a number of trace elements has been 
reported in patients with dementias such as Alzheimer's disease [142] and clinical and 
subclinical aluminium, lead and other heavy metal induced toxic syndromes are 
known to occur in man [140]. 
Determination of a disruption in the levels of trace elements in an individual may 
indicate whether or not these elements play a role in the development of the disease. 
The detection of trace elements in blood is an important factor for determining any 
disruption in trace element status of the body. The method used to determine 
elemental levels needs to be sensitive enough to detect the concentration present in 
blood (c I mg l) and in an all too often limited sample volume [262]. Analysis of 
trace elements in biological samples requires; precise and accurate separation of the 
analyte from the bulk matrix and a suitable means of detection, which is of the 
appropriate sensitivity. Careful consideration of factors such as diet and disease state 
are critical in the assessment of the results before any conclusions can be made about 
cause-effect relationships for the disruption of metal status [262]. 
Atomic absorption spectrometry (AAS) is widely used for the detection of many 
elements. Electrothermal atomic absorption spectrometry (ETAAS) is suitable for the 
detection of metals in biological tissues [297]. Detection limits for ETAAS are 
typically 0.3 .tg F' and 0.1 jig F' for Cu and Zn respectively. However, for most of the 
AAS techniques, only one element can be determined at a time in many routine 
laboratories, although the relatively new Perkin Elmer method of simultaneous multi-
element ETAAS (S[MAA) is able to detect up to 6 elements with the same detection 
limits as conventional ETAAS analysis due to the very low noise of the solid-state 
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detector [298]. Inductively coupled plasma optical emission spectrometry (ICP-OES) 
can be used in the direct analysis of biological fluids. The main advantage is the 
simultaneous detection of several elements in the one sample. The sample is 
efficiently desolvated, vaporised, excited and ionised in the plasma. Many chemical 
interferences are greatly reduced by the high temperature of 7000-8000 K. Typical 
levels of detection range from 0.5-100mg r' for most metals [299]. 
Ion chromatography (IC) has gained wide acceptance over the last twenty years [178]. 
Advances in column technology and detection schemes have led to ion 
chromatography applications in a wide variety of matrices. One of the most important 
applications of IC in clinical chemistry is the analysis of physiological fluids and 
tissues both for inorganic and organic anions and cations. The analysis of 
physiological fluids requires a highly sensitive and selective analytical technique, 
since the matrix is complex and the concentrations of the ions of interest are often 
very low. While high-performance liquid chromatography has become an important 
technique for the determination of biological markers for the diagnosis of diseases, IC 
is being widely used for the analysis of ionic species. 
3.1.1 The present study. 
The current study involved the development of an IC method for the detection of the 
levels of trace metals from biological plasma and in various tissues in various disease 
states where amyloid is seen to deposit. A modified ion chromatographic method was 
used to detect levels of copper and zinc in blood plasma samples from patients on 
haemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). Standard 
methods were employed to detect copper, zinc, cobalt, nickel and aluminium in liver, 
heart, brain, kidney and carnal tunnel tissue [300]. 
3.1.2 Method. 
Details of experimental method, instrumentation, and reagents are listed in chapter 2 
section 2.2. 
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3.2 Results and discussion. 
3.2.1 Determination of the levels copper and zinc in blood plasma. 
The method of standard additions was used to detect copper and zinc. Copper, cobalt 
and zinc were easily resolved by ion chromatography with elution times of 2.9, 4.8 
and 6.6 minutes respectively as shown in Figure 3.1. An unknown matrix component 
may account for the presence of the unidentified large peak. The reproducibility and 
the precision of the standard additions method was further improved by combining 
this with an internal standard. For this method to be reliable, the chosen internal 
standard must be well separated from the components but must appear close to the 
peaks of interest. The cobalt internal standard was subjected to the same conditions as 
the sample hence any fluctuations in the running conditions would be eliminated by 
plotting the absorbance ratio between copper and cobalt against the concentration of 
spiked copper. This was also applied to the analysis of zinc. 
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Figure 3.1 - Chromatograms of spiked blood plasma. Each of the samples was spiked 
with increasing concentrations of copper and zinc (0, 0.4, 0.8 mg 1-1) and with cobalt 
(0.6mg 1-1). Copper, cobalt and zinc eluted at 2.9,4.8 and 6.6 minutes respectively. 
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Cobalt can be used as an internal standard as it is found in serum at levels (c 0.05 
J.tg F') [207] well below the detection limit of IC with VIS. The detection limit for 
IC was calculated as 3 times the baseline signal to noise ratio. The signal to noise 
ratio was calculated as the standard deviation of a 0.05 mg 1
-1 sample of the analyte. 
The detection limits were calculated as 0.09 mg F' for copper and 0.03 mg F' for zinc. 
Sample and Method 
Copper (mg F') 
Average 	 Range 
Zinc (mg F') 
Average 	 Range 
control (n=4) 0.501 ± 0.05 0.45 - 0.67 1.350 ± 0.05 0.73 - 1.83 
IC-VIS 	 CAPD (n=4) 0.549 ± 0.05 0.33 - 0.68 1.576 ± 0.06 0.89 - 1.95 
HD 	 (n=4) 0.594 ± 0.05 0.46 - 0.78 1.348 ± 0.06 0.98 - 1.79 
control (n=4) 0.534±0.03 0.31 -0.62 1.417±0.02 0.79- 1.95 
ICP-OES CAPD (n=4) 0.597 ± 0.02 0.51 - 0.70 1.789 ± 0.03 0.91 - 2.28 
HD 	 (n=4) 0.575 ± 0.02 0.43 - 0.73 1.481 ± 0.02 0.93 - 2.02 
Table 3.1 
- Concentrations of copper and zinc in acid digested blood plasma as 
detected by IC with VIS detection using the standard additions method with a cobalt 
internal standard. 
The levels of copper and zinc in CAPD patients, HD patients and controls are shown 
in Tables 3.1 and Table 3.2. It must be stressed that these individual values represent 
the levels of copper and zinc in different patients and thus the concentrations of 
copper and zinc may vary from patient to patient due to factors such as sex, age, and 
time on dialysis. The normal range for copper in serum is 0.8 - 1.5 mg F' and for zinc 
it is 0.6 - 1.3 mg F' [178]. Overall, the average control copper levels were less than 
the normal levels expected in the blood. The measured copper concentration for this 
study was 0.501 ± 0.05 mg F' and was 1.350 ± 0.05 mg F' for zinc in the control 
samples. 
The combination of the standard additions method and the use of an internal standard 
improved the precision of the measurements. This produced an overall improvement 
in the correlation coefficients of the standard addition plots for copper of 2.98 ± 1.89 
% (in the range -0.3 % and 6 %) and zinc 2.92 ± 2.07 % (in the range -0.8 % and 
5.7 %) as detailed in Table 3.2. The results obtained from the IC-VIS analysis were 
compared with the results with those obtained by inductively coupled plasma optical 
emission spectrometry (ICP-OES). The copper and zinc levels in blood plasma in both 
dialysis groups were not significantly different to the copper and zinc levels in blood 
plasma of the control patients. A student t-test (at 95 % confidence limit) revealed no 
significant differences between the values obtained by the two methods (Table 3.3). 
There was reasonable agreement between both methods, although more samples 
would indicate if a better correlation were possible. The correlation coefficient for 
copper was 0.88 and the correlation coefficient for zinc was 0.89 for the two methods. 
Copper Zinc 
R2 
With IS No IS Improvement With IS No IS Improvement 
0.97 0.92 6.05 0.94 0.95 -0.83 
0.95 0.92 3.35 0.95 0.91 4.64 
CAPD 0.99 0.94 4.76 0.98 0.95 2.70 
0.99 0.95 3.75 0.98 0.92 5.64 
0.94 0.92 2.14 0.95 0.95 0.93 
0.95 0.94 0.82 0.93 0.93 0.43 
HD 0.98 0.95 2.61 0.94 0.90 4.78 
0.98 0.93 5.23 0.95 0.92 3.05 
0.95 0.93 2.41 0.98 0.94 3.33 
0.93 0.92 1.18 0.98 0.95 2.25 
Control 0.94 0.95 -0.33 0.95 0.93 2.31 
0.95 0.91 3.89 0.99 0.93 5.77 
Average 2.98 ± 1.89 2.92 ± 2.07 
Table 3.2 - The percentage improvement in the correlation (R 2) of standard additions 
of copper with and without an internal standard (IS) and zinc with and without an 
internal standard. (CAPD - continuous ambulatory peritoneal dialysis, MD - 
haemodialysis) 
Methods and sample Copper (mg r') Zinc (mg 1 1 ) 
comparison tcalc terit tcalc tcrjt 
IC-VlSI ICP-OES (n = 12) 0.189 1.717 0.265 1.717 
IC- CAPD / control (n = 4) 0.448 1.938 0.747 1.943 
IC- HD /control (n = 4) 0.938 1.938 0.007 1.943 
IC- CAPD I HD (n = 4) 0.427 1.943 0.747 1.943 
Table 3.3 - One tailed t-test for unequal variances was used to compare between the 
means of the dialysis group with the control groups and between the two methods 
(p<0.05). A total of 12 test samples were used in the comparison. 
0.50 
040 
0.30 
c 0.20 
C) 
a) 
0.10 
0.00 
-0.10 
WWWX 
(b) 
- 
I 
. 
. 
- . 
Zero bias 
0, 
V 
0 
C) 
E 
C) 
4S 
C 
C) 
C) 
C) 
.0 
C) 
C 
C 
C) 
0.12 
0.10 
0.08 
0.06 
0.04 
0.02 
0.00 
-0.02 
-0.04 
-0.06 
The Altmann-Bland plot, i.e. the plot of the differences between the two methods 
against the mean of the concentration, shows an overall positive bias for zinc of 0.128 
mg 1* The positive bias for copper can be accounted for from experimental errors. 
This suggests that the results for zinc obtained from the JCP-OES method are higher 
than those obtained with IC-VIS analysis. This could result from interference from 
other elements within the plasma in the ICP-OES method. 
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Figure 3.2 - The Altmann-Bland plots compare the two methods, IC-VIS and ICP-
OES for copper (a) and zinc (b) The plots show a small positive bias for copper and 
larger bias for zinc indicating that the results obtained for zinc with ICP-OES are 
higher than those obtained using IC-VIS. The dotted lines show the mean difference 
between the two methods and the zero bias denotes no differences between the two 
methods. 
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3.2.2 Determination of the levels of copper, zinc, cobalt, nickel and 
aluminium in biological tissues. 
The direct analysis of the acid digested tissues showed little matrix effect with the 
peaks being resolved easily. Copper, cobalt, zinc and nickel eluted at 2.9, 4.8, 6.6, 8.2 
minutes respectively using an oxalate eluent and PAR post column reagent as shown 
in Figure 3.3a. The aluminium eluted at 6.1 minutes using an ammonium sulphate 
and tiron post column reagent as shown in Figure 3.3b. The concentrations of copper, 
zinc, nickel, cobalt and aluminium in acid digested tissues as detected by ion 
chromatography with UV/VIS detection are shown in Table 3.4. 
Concentration of analyte in the sample (mg F') 
Tissue sample Al3 CUZ* Zn2 Co2 Ni2 
Brain (n=4) 0.0294 ± 0.04 0.461 ± 0.04 0.392 ± 0.04 0.214 ± 0.05 0.062 ± 0.04 
Heart (n=1) 0.0221 ± 0.04 0.107 ± 0.05 0.034 ± 0.03 0.615 ± 0.05 0.057 ± 0.04 
Liver (n=1) 0.0120 ± 0.03 0.063 ± 0.04 0.095 ± 0.04 2.936 ± 0.06 0.040 ± 0.05 
Kidney (n=1) 0.0179 ± 0.04 0.033 ± 0.03 0.027 ± 0.04 0.759 ± 0.04 0.029 ±0.04 
€11 (n=1) 0.0155±0.05 0.134±0.04 0.037±0.05 0.371 ±0.06 0.021 ±0.05 
Brain (Control n=1) 0.0261 ± 0.04 0.642 ± 0.04 0.122 ± 0.04 0.930 ± 0.04 0.054 ± 0.04 
Heart (Control n=1) 0.0124 ± 0.04 0.133 ± 0.04 0.055 ± 0.04 0.230 ± 0.03 0.033 ± 0.03 
Liver (Control n=1) 0.0139±0.03 0.051 ± 0.04 0.122 ± 0.03 1.041 ± 0.04 0.037 ± 0.04 
Kidney (Control n=1) 0.0110 ± 0.04 0.055 ± 0.04 0.051 ± 0.04 0.625 ± 0.04 0.043±0.04 
Table 3.4 - Concentrations of copper, zinc, nickel, cobalt and aluminium in acid 
digested tissues as detected by ion chromatography with UV/VIS detection the 
standard deviations quoted relate to the replicate analysis. 
Only one sample was measured for each tissue (except the AD brain) due to the small 
number of samples available. Inter-patient variations could account for the differences 
between the samples and controls. It should be noted that the high level of cobalt 
found in the tissue samples is most likely due to vitamin B12 (cobalamin). Vitamin B12 
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is present in most organs and particularly high levels are found both in the liver and in 
the kidney. Therefore cobalt cannot be used as an internal standard for the detection of 
transition metals in tissues. A suitable internal standard should not be present in 
tissues and it should also be detectable by the current method. 
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Figure 3.3 - (a) Detection of transition metals in heart tissue. Copper, cobalt, zinc and 
nickel eluted at 2.9, 4.8, 6.6, 8.2 minutes respectively using an oxalate eluent and 
PAR post column reagent (VIS mode). (b) Detection of aluminium in heart tissue. 
Aluminium elutes at 6.1 minutes using an ammonium sulphate and tiron post column 
reagent (UV mode). 
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3.3 Conclusions. 
The above studies show that ion chromatography (UV/VJS detection) can be used to 
measure both transition metals and aluminium in a variety of acid digested tissues and 
transition metals in blood plasma. Although, no real conclusions can be made about 
the levels of these metals within each, due to the small number of samples analysed. A 
larger sample set is needed for a thorough investigation of the trace element levels. 
Even with an adequate number of samples, it is still difficult to determine if there are 
any overall disturbances in trace element levels in various disease states. Inter-patient 
variation and other factors such as age, sex, dietary condition, and disease state could 
affect the detected levels of trace elements. 
The method developed method for the analysis of blood used cobalt as an internal 
standard to minimise errors due to sample loading and fluctuations that can occur 
during the running of the column. A suitable internal standard should not be present in 
tissues and it should also be detectable by the current method. Cobalt was successfully 
used as an internal standard for the analysis of blood plasma but high levels of cobalt 
were measured in the tissues samples. Therefore cobalt cannot be used as an internal 
standard for the detection of transition metals in tissues. 
Ion chromatography has been increasingly used for the determination of metals and is 
becoming an alternative to conventional spectrometric methods [178].The most 
obvious advantages of this technique are that multiple elements can be determined in 
one sample of 25 jtl volume and complete analysis can be performed when coupled 
with a suitable detection system or systems. Generally, the sample requires minimal 
sample pre-treatment [178]. The selectivity and peak sharpness in IC can be enhanced 
by the use of complexing agents such as PAR for the detection of cations followed by 
spectrophotometric detection giving a highly sensitive method. The use of the 
standard additions method and of an internal standard can improve the precision of the 
results. 
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Chapter 4. The extraction of amyloid from Alzheimer's 
disease brains. 
4.1 Introduction. 
Amyloid fibrils are known to be highly insoluble in neutral aqueous media of ionic 
strengths commonly used. At present, the examination of amyloid proteins from 
tissues of clinical significance is still based on the classical approach of water 
extraction, which is based on the insoluble nature of the amyloid deposits [301]. 
These techniques are still based on the initial method developed by Pras et al. [301]. 
The extracts were subjected to column gel chromatography, and the isolated proteins 
were analysed immunochemically and chemically. 
Amyloid fibrils were originally isolated from amyloid rich tissue by alternate 
homogenisation in saline and water to obtain a top layer preparation. Further 
purification was achieved by centrifugation of the top layer amyloid material in a 
sucrose gradient. Solvents that the amyloid are soluble in are too harsh and may alter 
the structure of the amyloid material. In other procedures, the final top layer was 
homogenised in water in which some of the fibrils were suspended [76 & 112] 
Various methods of isolation and purification of amyloid from tissue deposits have at 
present been used [112, 302-303]. The majority of these methods are based on the 
insoluble nature of the amyloid protein [301] and have been used to obtain amyloid in 
a reasonably pure and stable state. 
Analysis of the peptides suggests that A13(  1-40) is the major variant in brain tissue and 
that cerebrovascular amyloid is composed primarily of A13(l-40),  and 
 A13(l-42)  [304]. 
The Af3(l-40) was predominant in sporadic AD, whereas A13(1-42)  was predominant 
in elderly controls. The A13(l-40)/A13(1-42)  ratio was seen to differ by 10 fold 
between non-demented controls and sporadic cases [301]. Therefore, a step that 
causes A13 ( 1-42) to aggregate may seed further aggregation of either A13(  1-40) or 
A13 (l -42) [294]. Other variants or fragments of the 3 amyloid such as A13(l  1-42) have 
been isolated in amyloid deposits too. 
A13 fragments of differing lengths show characteristic differences for instance in 
solubility [305] and amyloid fibril formation, since slight differences in structure may 
affect amyloidogenesis. It is, therefore, important to have knowledge of the primary 
structure function and processing of the Afl. This has major importance in the 
extraction and purification of amyloid from tissue. For instance, A13(  1-40) is relatively 
soluble in aqueous media, whereas the C-terminally extended variant A3(1-42) 
rapidly forms fibril like, insoluble structures in aqueous solutions [113]. 
4.1.1 The present study. 
A procedure of isolation based on the extreme insolubility of Afi amyloid was used. 
Amyloid material was extracted from parieto cortex tissue from Alzheimer's disease 
sufferers (Obtained from MRC Neurochemicalpathology Unit, Newcastle General 
Hospital). The method employed was a slight modification to the protocol as used by 
Naslund et al. [294]. The ultra-centrifugation steps were carried out at 50,000 g for 1 
hour compared to Naslund et al. [294] at 100,000 g for 20 minutes. Washings from 
subsequent re-homogenisations were run on a SDS polyacrylamide gel 
electrophoresis. 
Amyloid was extracted by homogenisation with water after preliminary treatments, 
firstly to remove proteins soluble in saline and then to remove salts. The crude extract 
from brain tissue of patients with Alzheimer's disease containing insoluble amyloid 
protein was subjected to size exclusion to remove the 4 kDa amyloid protein. The 
immunoblot of this purified protein using antibody to the Af3(l-40) was then 
performed. 
4.1.2 Method. 
Details of experimental method, instrumentation, and reagents are listed in chapter 2 
section 2.3. 
4.2 Results and discussion. 
4.2.1 Extraction of AJ3 peptide from Alzheimer's disease brain tissue. 
The A3 proteins are insoluble in the 1% w/v SDS lysis buffer, whereas other proteins 
and brain constituents are soluble and are able to be separated by subsequent 
centrifugations and rehomogenisation steps. After each centrifugation step, a sample 
of the supernatant was retained. These were run on SDS PAGE to determine if the 
sample contained A13 peptides. The remaining pellet contains insoluble proteins and 
insoluble A3 peptides. The A13 were further purified by extraction with 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP). The Aj3 amyloids are soluble in this solvent, which is 
a better solvent than trifluoroethanol for >40 residue AP amyloids [305]. The five 
supernatant fractions from the initial homogenisations contained progressively less 
protein as determined by UV spectroscopy at 280 nm. The final supernatant fraction 
recorded 0.01 absorbance units at 280 nm. 
The supernatant from each of the centrifugation steps were run on a SDS PAGE 
together with the extracted peptide and synthetic A13(1-40)  (Figure 4.1). The 
molecular weight markers are shown to the right of the lanes. There was no 
A13  peptide in the supernatant fractions. The SDS PAGE also shows the progressive 
decrease in soluble brain proteins after each subsequent water homogenisation and 
centrifugation steps. 
4.2.2 Purification of the 0 amyloid extract using size exclusion. 
The column was calibrated with standard molecular weight markers: alcohol 
dehydrogenase, bovine serum albumin (BSA), carbonic anhydrase, cytochrome C and 
vitamin B12. The dead time/dead volume was calculated to be the time from initial 
addition of the sample to the top of the size exclusion column, to the actual elution of 
the dextran blue, which is present as a blue coloured band. This was calculated to be 
about 1 hour for a 30 ml G75 column. The fractions were collected and monitored by 
tJV absorbance detection at 280 nm in a I mm quartz cuvette (sample volume 200 pi) 
and collection was terminated when no more protein was detected. 
Figure 4.1 
Samples of the supernatant from each of the centrifugation steps were run on a SDS 
PAGE. The Molecular weight markers are shown to the right of the lanes. There was 
no AP peptide in the supernatant fractions. 
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The log of the molecular weight of the protein is proportional to mobility of the 
protein and hence the elution time, which is related to the length of the column or 
volume of packing. The smaller the protein the longer the retention time. Therefore, 
the column can be calibrated with markers of known molecular weight producing a 
linear plot for the log of the molecular weight against volume eluted as shown in 
Figure 4.2. The elution volumes are given in Table 4.1. The markers used were 
dextran blue, alcohol dehydrogenase, bovine serum albumin, carbonic anhydrase, 
cytochrome C and vitamin B12. 
Dextran blue 
Alcohol dehydrogenas 
 Cytochrome C 
Vitamin B12 
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Figure 4.2 - The calibration plot for 30 ml column (Sephadex G75). The log 
molecular weight is directly proportional retention in the column i.e. the elution 
volume. 
Molecular weight marker 
	 Elution volume log MW 	 MW 
Dextran Blue 0.5 6.30 2000000 
Alcohol dehydrogenase 9.75 5.17 150000 
BSA 11.5 4.81 66000 
Carbonic anhydrase 13.5 4.46 29000 
Cytochrome C 19 4.09 12400 
Vitamin B12 23 3.12 1335 
Extracted protein (4kDa) (calculated) 20.5 3.63 4330 
Table 4.1 - The elution volumes of the standard molecular weight markers. The 
calculated elution volume for the 4 kDa peptide is also given. 
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There are several factors involved in the separation of proteins by size exclusion. The 
major factor in the resolution of size exclusion lies in the pore size of the packing. The 
stationary phase consists of a porous network of crosslinked polymers of 
carbohydrates and acrylamides that swell on absorption of water. The degree of 
crosslinking determines the size of the pores. Solvated molecules larger than the 
largest pores of the swollen gel cannot penetrate the pores of the gel particles and, 
therefore, will pass straight through the column through the spaces between the 
individual particles. Smaller molecules, however, will penetrate the open network in 
the particles to a varying degree, depending on their size and shape. They are 
therefore, retarded to varying degrees and will be eluted in order of decreasing 
molecular size. Dextran blue has a size of 2,000,000 MW and will therefore pass 
straight through the column and is consequently used to calculate the void volume. 
The two sizes of Sephadex (Sigma, UK) used were the 075 and 0150 with 
fractionation ranges of 2,500-40,000 MW and 5,000-100,000 MW respectively. 
Although separation of the proteins is reasonable for both the 075 and G150 the 
running time is almost doubled for the larger pore size Sephadex. Figure 4.3 shows 
the comparison of two 30 ml size exclusion columns using 075 and G150 Sephadex 
sizes. This shows the effect of the choice of Sephadex on resolution of the peaks and 
the running time (or the volume of eluent required to remove all the components of 
the column). The larger pore size means that the proteins are retained for longer 
resulting in a better peak resolution but increasing the running time. 
The length of column (or volume) also affects the degree of separation of proteins. 
The Figure 4.4 shows the results from the three different column lengths of Sephadex 
075. This illustrates that for a longer column there is better separation of proteins 
compared to the shorter column but the time taken to run the column is drastically 
increased. Therefore, the 30 ml column was chosen. 
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Figure 4.3 
Comparison of two 30 ml size exclusion columns using (a) 075 and (b) 0150 
Sephadex sizes. The larger sized pores of the G150 retains the proteins longer 
resulting in a longer running time but better separation hence a sharper resolution. The 
peaks correspond to dextran blue (i), alcohol dehydrogenase (ii), bovine serum 
albumin (iii), carbonic anhydrase (iv), cytochrome C (v) and vitamin B 12 (vi). 
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Figure 4.4 
Comparison of different lengths of size exclusion column made with Sephadex 075 
(a) 20 ml, (b) 30 ml, and (c) 50 ml columns. There is better separation of proteins in 
the longer column but the total time taken to run the column is drastically increased. 
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The crude Alzheimer brain extract (390 mg) was subject to size exclusion using 30 ml 
column of Sephadex G75 (Sigma). The final yield was 280 mg of extract protein, 
which approximated to about 1% weight of the original wet mass of brain tissue. 
Since the molecular weight is proportional to the degree of separation we can 
calculate the volume of elution of a 4 kDa fraction from the slope of the line. 
The 4 kDa amyloid protein was calculated to be eluted in a volume of 20.5 ml. The 
actual volume in which our protein was eluted was about 21 ml (Figure 4.5). This is 
close to the calculated fraction number for a 4 kDa peptide (Table 4.1). The fractions 
corresponding to 4 kDa range of protein were pooled and vacuum centrifuged to 
dryness leaving a white powder. 
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Figure 4.5 - The elution profile for the extracted protein shows a large absorption 
seen at around 21 ml relating to the 4 kDa fraction 
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4.2.3 Immunoblot detection of the amyloid Af(1-40). 
A dot blot of the extracted protein and the crude extract before size exclusion 
chromatography is shown in Figure 4.6. The synthetic A13(l -40), synthetic AJ3(l-42), 
synthetic A(1-43) and synthetic APP(125-135) were also added for comparison. The 
primary antibody was an antibody to the Af3(l-40) (Sigma, UK). 
I Synthetic APP(125-135) I 
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Figure 4.6 - A dot blot of the extracted protein and the crude extract before size 
exclusion chromatography. The synthetic Af3(l-40), synthetic A13(l-42),  synthetic 
AI3(l -43 ) and synthetic APP(125-135) were also added for comparison. The primary 
antibody was an antibody to the A1 3 ( 1-40). 
Amyloid protein was extracted from Alzheimer's brain tissue using an extraction 
method that relied on the extreme insolubility of the amyloid. Several 
homogenisation/centrifugation steps are necessary to remove the majority of soluble 
proteins. It was then necessary to subject the crude extracted amyloid to size 
exclusion to yield the 4 kDa peptide. The purified 4 kDa extracted amyloid peptide 
reacted to the Af3(l-40) antibody on the immunoblot. 
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It can be seen from Figure 4.6 that there is strong reactivity between the A13(  1-40) 
antibody and the synthetic A13 ( 1-40). There was also strong reactivity with the 
extracted 4kDa peptide indicating that the extracted protein contains the A13(l-40). 
There is reactivity with the crude extract before purification by size exclusion. After 
purification the sample dot is more concentrated showing that the size exclusion step 
is needed to purify the amyloid extract. This indicates that the extracted protein most 
likely contains the AJ3(l-40). 
There was no reactivity with the APP(125-135) fragment, which is a portion of the 
parent precursor molecule. There was some cross reactivity with Af3(l-43) and Aji(l-
42) peptides. The anti-Ji amyloid A1 3 (l -40) antibody is known to have weak cross 
reactivity with both A(1-28) and A1 3 ( 12-28) and may also have some reactivity with 
the above fragments. The modification of the Au lysine-16, either by derivatisation 
[306] or by the substitution of alanine reduces its ability to inhibit antibody binding to 
amyloid. Binding of amyloid antibody to Af3(1-40) was found to be inhibited 80% by 
addition of A13(l-28)  and 60% by [Ala'6]A13(l-28)  but not all by Af3(18-28). This 
suggests that the antigenic sites in AD amyloid are exposed in both AIi(l-28)  and the 
[Ala '6]A13(l -28) but is absent in A13(18-28)  [104]. Fragments that contain an exposed 
AJ3(1-28) region will also react with this antibody. Therefore, although the extracted 
amyloid contains predominantly A13(1-40),  it may also contain other Au fragments 
such as Af3(1-43) and/or A13 (l -42) as indicated by the immunoblot assay. 
A13(l -40) is the predominant soluble species in biological fluids while Aj3(l-42) a 
minor species of AP that is more insoluble in vitro is the predominant species found in 
senile plaques and deposits associated with Alzheimer's disease and Down syndrome. 
Af3( 1-40) has been reported to be the predominant AP peptide in cerebral cortical 
extracts from AD brain [307] whereas diffuse SP have been reported as containing 
Af3(l-42) [308]. 
Chapter 5. Circular dichroism spectroscopy studies of 
amyloid materials. 
5.1 Introduction. 
Circular dichroism spectroscopy (CD) is a useful technique for gaining information 
about the secondary structure of proteins and polypeptides in solution. The method 
requires only very small samples and it is non-destructive. Relative changes due to the 
influence of the environment on a sample can be monitored with CD. The technique 
of CD has been used increasingly to observe the conformational changes in the 
various amyloidogenic peptides. 
5.1.1 The use of CD in the study of amyloid proteins. 
A number of papers have used CD to observe conformational changes in the various 
amyloids [108, 117, 289, 309 & 310]. Murine serum amyloid A proteins have been 
shown to consist of a mixture of a helices and P sheets dependent on pH and solvent 
conditions [59]. 
 The refolding of 132M to its native state in vitro has been monitored 
using CD [311]. The interaction of amyloid AI3 peptides with neuronal membranes 
have been studied using CD to show that there was a specific binding of Af3(1-40) to 
ganglioside containing membranes inducing a transition from unordered to 13 sheets. 
[312]. The amyloid peptides A13(1-28), Af3(1-39), A13(1-40) and Af3(1-42) incubated 
with rat neuronal cell lines showed a correlation between the toxicity and increasing 3 
sheet secondary structure of the aged peptides [125]. 
CD has been used to study fragments of A0 showing that the secondary structure is 
dependent not only on the specific fragment but also on experimental conditions. The 
A13(l-42) and A13(29-42), were seen to be predominantly 13 sheet at pH 7.3 in 
phosphate buffer, whereas the A13(l-28) was in random coil and A13(1-39) was a 
mixture of random coil and 13 sheets. In 50% TEE, the Af3(29-42) remained in 0 sheet, 
but the other three formed a helices which is consistent with the stabilising effects of 
TEE [108]. Certain A13 fragments undergo a reversible random coil to 13  sheet 
transition. The A13(12-28) will undergo such a transformation but this is temperature 
dependent [313]. The A13 (25-35 ) is also seen to undergo a reversible transition to [3 
sheets at pH 4.0 and 5.5 [117]. 
The effects of aluminium with A1 3 ( 1-40) and A13(25-35)  have been monitored using 
CD. There was a loss of a helices with addition of increasing aluminium to the 
Aj3(1-40) with a shift to 3  sheets [289]. The effect of aluminium on the A[3(l-42) has 
been shown to be reversed on addition of silicate in a 1:2 ratio. The addition of the 
silicate prevented the aluminium from interacting with the peptide [314]. Af3(1-40) 
and AJ3(l-42) with glycosaminoglycans have also been studied using CD. The 
addition of various GAGs (heparan sulphate, keratan sulphate, chondroitin sulphate 
and heparin) to Af3( 1-42) caused an acceleration in the formation of 13 sheets but did 
not affect the less amyloidogenic A[3(1-40) [315]. 
5.1.2 Factors affecting amyloid studies in vitro. 
Synthetic amyloid proteins in vitro adopt a mixture of 0 sheet, a helix and random 
coil structures with relative proportions of each structure being dependent on 
conditions such as pH [305], length of time in solution [80 & 316], concentration and 
the solvent conditions [108]. Studies have shown that the conformational changes 
play an important role in P sheet aggregation and amyloid formation [317 & 318]. 
Different studies have also employed different amyloid proteins: A13(1-40)  [125, 289 
& 319]; A13(l-42)  [109, 309 & 320]; A13(25-35)  [117]; 
 A13(I-39);  Af3(l-28) [108 & 
109]; and from different origins such as synthetic [108, 117 & 134] and rat [125 & 
314]. There are many different conditions under which amyloids have been analysed, 
e.g. buffers, temperature, and pH. Some studies have conducted analyses at room 
temperature [108, 124 & 3191 whilst others have maintained the temperature at 37 °C 
[289 & 125]. At pH 1-4 and pH 7-10, a helix formation is favoured whereas [3 sheet 
formation is favoured at pH 4-7. Interestingly the maximum rate of aggregation is at 
pH 5.5, which is close to the isoelectric point of Af3 peptide is 6.1 [108 & 3211. The 
composition of buffers used in these studies also varied. In aqueous solution [3 sheet 
structure is favoured, whereas in aqueous solution containing trifluoroethanol (TFE) 
or hexafluoroisopropanol (HFIP) [322] the a helix is favoured [110]. Buffers, which 
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have been used, contain from between 50-100% TFE and have been combined with 
phosphate, tris, acetate or MES. The differing environments in these studies 
underscore the difficulties in assigning relevance to structural studies in peptides 
using CD spectroscopy. 
5.1.2.1 Solvent effects. 
The choice of solvent for the use in in vitro studies is important. The A13(l-40) 
peptide, has been shown to have a limited solubility in aqueous solutions. Organic 
solvents such as trifluoroethanol (TFE), hexafluoroisopropanol (HFIP) and 
chloroform may mimic membranes i.e. the lipid environment. These solvents acts as a 
'secondary structure-inducing' agents as they weaken hydrophobic interactions in the 
tertiary structure. Fluorinated alcohols such as TFE and HFIP favour the production of 
a helices over the formation of f3 sheets and random coil structures. Less of the higher 
fluorinated HFIP is required to stabilise the a helical structure. However, the 
maximum a helical content in HFIP or TFE solvents are nearly the same, showing 
that HFIP does not cause additional a helix formation. This is consistent with the 
current understanding that these solvents do not induce a helix formation, but actually 
stabilisq q helices in the protein regions that have an intrinsic tendency to form helical 
structure [323]. 
The dielectric constants of trifluoroethanol and the interior of biological membranes 
(26.6 and 1, respectively) are very different leading to a strengthening of charge 
interactions. TFE is a weaker proton donor than water and promotes structure 
formation by allowing intramolecular hydrogen bonding to occur, rather than 
intermolecular hydrogen bonding with the solvent i.e. stabilising of the a helix 
structure [108 & 324]. This indicates that hydrophobic interactions are probably 
important for stabilisation and formation of the P sheet conformation but are not 
important for the a helical conformation [108]. 
Trifluoroethanol may also induce P sheet structure. This has been demonstrated with 
CD spectroscopy for the related peptide A13(1-42),  which is even less water soluble 
than Aj3(l-40) [108]. In the concentration range of 10 to 32% TFE, the A1 3 ( 1-42) 
forms f pleated sheet structures, whereas the CD spectrum at 50 to 100% TFE reveals 
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a helices. Sha et al. [325] used CD to show that a 9 amino acid peptide 
(LLEELKEVL) in different solvents adopted different secondary structure. The 
peptide adopted a 0 sheet conformation in water, random coil in PBS buffer, a helical 
in SDS [323]. A 3 sheet conformation was also observed in TFE due to charge 
interactions of the peptide and hydrophobic clustering. Therefore, the use of TFE may 
alter the secondary structure, dependant on the ratio of TFE in the solvent. 
Nevertheless, TFE is widely used as a membrane mimetic solvent. 
5.1.2.2 pH effects. 
The pH has a significant effect on promoting the assembly of all amyloid peptides and 
influences the aggregation in vitro. The length of the hydrophobic carboxyl terminus 
of the Af3 peptide is important in determining the solubility and aggregation properties 
of the AP peptide and that acidic environments, high peptide concentration, and long 
incubation time would be predicted to be important factors in promoting amyloid 
deposition [305]. The A13(l -40) peptide exists in the a helical conformation and is 
stabilised in the pH ranges of pH 1-4 and pH 7-10. The 1-28 region is highly 
amphipathic, tending to stabilise the a helical conformation in the membrane-like 
environments. In the pH range 4-7, the peptide tends to be in P sheet-like 
conformation, e.g. A13(l-42)  is insoluble in the pH range of 3.5-6.5 [108]. Only 
peptides of 42 residues or longer are showed to be significantly insoluble at pH 7.4. 
The solubility of A0 analogues of the A(2-43), A1 3 ( 10-43 ) , and  AI3(12-43)  fragments 
are not dependent on pH in the range of pH 4.5-9.3 [118]. Both A13(1-47)  and 
A(1-52) are soluble in the a helix-promoting solvents such as HFIP [305] but have I 
sheet conformation in aqueous media. 
The refolding conditions of P2M  are also dependent on pH. P2M  was seen to be stable 
at neutral pH where it displays a lower tendency to self-aggregate than in acidic 
conditions. It has been shown that low pH destabilises native P2M.  Aggregation 
studies with guanidine-HCI have shown that a reduction in the pH from 6 to 5 has the 
effect of reducing the stability of 132M, increasing the aggregation [311]. The effect of 
temperature on the aggregation of 02M is also pH mediated and no aggregation is 
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detected at pH 4. At this pH the j32M is positively charged and the electrostatic 
repulsion can prevent protein aggregation [3111. 
5.1.3 The present study. 
The present study extends the work of previous studies [289, 314 & 320], by using 
CD to study other amyloid peptides and with various inorganic anions and cations and 
GAGs. The first series of experiments used large concentrations of metals to elicit 
maximal effects. The later experiments used physiological concentrations for both the 
GAGs and metals. The amyloid materials used were the synthetic Alzheimer's disease 
proteins; A13(25-35 ), A13(l -40), Af3(1-42), AJ3(1-43), and the extracted amyloid from 
Alzheimer's disease brains. The synthetic 132M, as found in dialysis related 
amyloidosis was also used. In a separate experiment, the effect of the organophosphorous 
pesticide, Phosmet on the secondary structure of the recombinant mouse cellular prion 
protein (r[mouse] PrY) was investigated. Any changes in secondary structure were 
detected using CD spectroscopy. 
The use of trifluoroethanol solvent to stabilise a helices was exploited in the current 
CD study. This work used TFE (60% v/v) the same as Exley et al. [289]. Barrow et al. 
[108] reported that the optimum concentration which induced an a helical 
conformation was TFE (60% v/v). In contrast the experiments of Fasman et al. [314 & 
320], used a 100% TFE environment. Any change due to the interaction of metals can 
be detected from the initial conformation of the native peptides in the TFE/tris (3:2) 
buffer. In the present studies, the pH of the amyloid peptide solutions was maintained 
at physiological pH 7.4 with TFE/tris buffer. All other solutions, where possible, were 
also buffered with TFE/tris at pH 7.4. 
5.1.4 Method. 
Experimental methods, instrumentation and reagent details are given in chapter 2, 
section 2.4. 
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5.2 Results. 
Relatively high protein concentration and lowest path length afforded the best results. 
Typically, for a 0.01 cm cell, 50-100 j.tl of a protein concentration of 0.2-0.5 mg mF' 
was needed to record a CD spectrum to 180 nm. Two scans were taken over 180 to 
260 nm range at 0.25 nm increments with a dwell time of 3 seconds at each 
wavelength. To achieve adequate signal-to-noise ratio, a spectrum for secondary 
structure determination required 30-60 minutes to record and an equivalent amount of 
time for the recording of the background. 
Buffer spectra need to be taken regularly because the synchrotronic light source 
diminishes exponentially with time (Figure 5.1). The buffer data were subtracted 
from the sample data to give the resultant spectrum due to the peptide itself. Problems 
may arise if the buffer and sample scans are taken too far apart, ripples may appear in 
the subtracted data. 
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Figure 5.1 - The synchrotronic light output plotted against time. The light source 
diminishes exponentially with time over a 24 hour period. 
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The spectral data was analysed using the SELCON program [17]. This used a self 
consistent method to fit the CD data with a combination of spectral data from proteins 
with known structure. Secondary structural analysis using the primary sequence has 
been improved by incorporating CD data constraints. Several new methods have been 
developed to analyse the secondary structures of peptides and proteins from CD data, 
to obtain secondary structural information from CD data 1117-211.  Most methods were 
developed by comparing the CD experimental curve with the reference protein using a 
least-squares fit or best fit. 
Many interpretation difficulties arise from: ionisation of groups; binding ligands; 
temperature; PH; disulphide bridges; aromatic side rings and 3  turns etc. The 
contributions of the side chains can become significant below 200 nm. It is generally 
accepted that the a helical content, as calculated by data fitting programs, are 
accurate. The 0 sheet structural elements are predicted to give a negative minimum 
near 218 nm and positive maximum around (195-197 nm). A positive maximum at 
192 nm and two negative minima at 207 and 222 nm are characteristic of a helices 
[325]. The SELCON program gives good correlation for the fitting of the secondary 
structures with coefficients of 0.95 for a helix and 0.84 for 3 sheet [326]. 
Interference can occur with solvents that absorb in the region of interest between 170 
and 260 nm. A buffer or detergent or other chemical should not be used unless it can 
be shown that the compound in question will not mask the protein signal. For instance 
imidazole cannot be used below 220 nm because it overwhelms the spectrum from 
then on. Only very dilute, non-absorbing buffers that allow measurements below 200 
nm, should be used. Unfolded protein, peptides, particulate matter (scattering 
particles), and, anything that adds significant noise to the CD spectrum must be 
avoided. The protein itself should be as pure as possible, any additional protein or 
peptide will contribute to the CD signal. 
The error in the CD spectra is shown in Figure 5.2, this was calculated for both repeat 
scans of the prion protein in Krebs Hensleit buffer (n = 20) and the Aj3( 1-40) amyloid 
protein in TFE/tris buffer (n = 6) obtained on different days and different runs. The 
spectra clearly show that there is a large inherent error in the & values at lower 
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wavelengths below 190 nm. The error at low wavelength is greater for the Krebs 
Hensleit buffer than for the TFE/tris buffer and is most likely due to the fact that the 
Krebs Hensleit buffer absorbs more energy than the TFE/tris buffer in that region. 
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Figure 5.2 - A plot of the error against wavelength for the CD spectra for both the 
prion in Krebs Hensleit buffer (n = 20) and amyloid in TFE/tris buffer (n = 6). 
The CD measurements are subject to a number of experimental errors and due to 
errors in the fitting process. The overall accuracy of the secondary structural values as 
calculated by SELCON was determined to have a 3% error for the spectral region 
between 190-260 nm. Experimental values quoted as significant if the changes in the 
secondary structure are greater than 3%. Errors within results obtained between 
different runs on different days and were within the error limits and so it was possible 
for comparison of the results intra- and inter- run. The quoted secondary structural 
values for the amyloid peptides are an overall average of the values over the different 
[UtII!1 
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5.2.1 Amyloid peptides. 
The CD spectra of several of the fragments of the Alzheimer's disease amyloid 
fragment are shown in Figure 5.3a. The spectra for the amyloid peptides clearly 
showed the diversity of secondary structure for the different fragments of the same 
protein. This demonstrates both the unique ways in which certain amino acid residues 
can contribute to the overall structure and the possibility that different parts of the 
molecule may be involved in the deposition of amyloid. 
In the TFE/tris solvent, the longer AJ3(1-43) was predominantly a helical (40.3%) in 
nature, whereas the A13(25-35) fragment is predominantly 13  sheet (5 1.7%) in nature. 
The A13 (25-35) is thought to be involved in the mediation of 13 sheet formation within 
the amyloid deposition [327]. The Af3(l-40) ((x - 36.9%, 13 - 17.6%) had a higher a 
helical and lower 0 sheet content than the AJ3(1-42) ((x - 20.5%, 0 - 24.9%) (Figure 
5.3a). Both are found in senile plaques within Alzheimer's disease brains [74 & 75]. 
The amyloid protein extracted from Alzheimer's disease brains (a - 11.3%, 13 - 
35.5%) shows a larger percentage of 0 sheets than a helices. This indicates that the 
extracted protein had more 13  sheets than either A[3(1-40) or the Aj3(l-42) but less than 
the A[3(25-35). The extracted amyloid could also contain many 13 amyloid protein 
fragments such as the A[3(1-42) or Af3(25-35). The CD method is not able to 
distinguish between a mixture of proteins and the secondary structure from each 
protein within the mixture contributes to the overall spectrum. 
Comparison of the A13(l -40) ,  02M and the prion protein are shown in Figure 5.3b. 
The spectral profiles of the A[3(1-40) and [32M are very similar The A[3(1-40), 02M 
and r[mouse]PrPC 
 prion all have similar percentages of 13  sheet (17.6, 18.2 and 15.2% 
respectively). The CD spectrum (Figure 5.3b) shows that PrP' is predominantly 
composed of a-helix (42.5%). Changes in the secondary structure of PrPC 
 to form 
PrPW lead to the deposition of [3 pleated sheets in a manner similar to amyloid 
deposition [200]. Conversion to ppW 
 creates a protein, which contains 45% P sheet, 
little or no a helix, and 57% [3turns and random coil [50, 196, 198, 201 & 319] which 
is consistent with its amyloid like properties [198 & 3181. 
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Figure 5.3a 
The CD spectra of the AJ3(1-40) (57.7 jiM), A1 3 ( 1-42) (33.3 jiM), A13(1-43)  (216 MM), 
A13 (25-35) (118 MM) and Aj3 extract (0.5 mg mE') in TFE/tris buffer. The percentage 
secondary structures of various amyloid materials are shown below. 
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Figure 5.3b 
The CD spectra comparing A13 ( 1-40) peptide (57.7 RM), 02M (211.5 jiM) and prion 
protein (r[mouse]PrPc) (1.0 mg mr 1 ) in TFE/tris buffer. The percentage secondary 
structures of various amyloid materials are shown below. 
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5.2.2 The secondary structural changes of recombinant mouse PrPc 
treated with Phosmet and its metabolites. 
The exposure of the r[mouse]PrPC (90-231) to Phosmet is shown in Figure 5.4. There 
was no overall change in the CD spectrum over a 7 hour period. This indicates that the 
Phosmet does not change the secondary structure of the prion protein over the 7 hour 
incubation period. 
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Figure 5.4- The CD spectra of r[mouse]PrPC 
 in Krebs Hensleit buffer following 
incubation with Phosmet. The shaded region is the error. 
PrPC exposed to the metabolites of Phosmet generated in situ in the CD cuvette, 
showed no change in the CD spectrum of the protein (Figure 5.5). The exposure of 
r[mouse]PrPC to Phosmet or its metabolites did not result in any changes in the 
conformation of the prion. This indicates that Phosmet does not act as a trigger factor 
for the initiation of PrP. This experiment was designed to ensure a short time period 
between generation of the active Phosmet metabolites and their potential contact with 
the PrPC. 
 This is important because it is likely that the metabolites, which might 
interact with PrPC, 
 are reactive oxidation products that have a short half-life in 
aqueous environments. 
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Figure 5.5 - The CD spectra of r[mouse]PrPC 
 with Phosmet and its metabolites. 
In order to check the Phosmet metabolite-generating capacity of the rat microsomal 
preparation, rat microsomes were incubated with Phosmet and the incubation medium 
solvent extracted and subjected to I-IPLC analysis. The major metabolite (likely to be 
oxo-phosmet) was generated plus at least 2 minor metabolites. The overall metabolic 
conversion of Phosmet was 0.16 MM h' (this is equivalent to 50% Phosmet 
metabolism h' in our experiment). Generation of the oxo-metabolite is important 
because this is very reactive and is a likely candidate for interaction with proteins and 
these experiments show they were available for reaction with PrPC. 
Secondary CanUtI1IUOIflV4flP'+ 4mOUSJPW+ 
structures 
nilabolit€s 
Helix 38 42 42 
Betasheets 19 17 16 
Turn and Others 42 41 42 
Table 5.1 - The secondary structural values for the prion with Phosmet and its metabolites. 
The proportions of the different conformational forms of the prion protein are shown 
in Table 5.1. The secondary structure values show no change in the conformation of 
the prion, irrespective of the treatment to which the PrP' was subjected in our 
experiments. 
5.2.3 Amyloid proteins treated with metals. 
The various amyloid peptides Af3(1-40), A1 3(l -42), Af3(1-43), Af3 extract and 132M 
were treated with the metals Ca 2 (100 jiM), Cu2 (100 jiM), Zn 2 (100 jiM) and Al 3 
(150 jiM). In addition, the A13(l -40) and 132M were also treated with Mg 2 (100 jiM). 
The CD spectrum for the A3(1-43) peptide showed little or no change on addition of 
the metals. The secondary structural values also indicated no change from the native 
peptide values (Figure 5.6a). The CD spectrum for the A13(1-42)  peptide showed a 
general increase in random coil by more than 5% and a decrease in the a helix of 
about 3% for all of the metals. A decrease in the 0 sheets resulted from treatment with 
Ca (L  13%) (Figure 5.6b). The CD spectrum for the extracted amyloid protein again 
showed a general decrease in a helix of less than 4% for all the metals. There was 
also a decrease in the minimum around 220 nm for the Cu 2 treated peptide. This 
related to a large increase in 3 sheet with a corresponding decrease in both P turns and 
random coil secondary structural values (Figure 5.6c). The CD spectrum for the P2M 
amyloid showed small changes in the metal treated protein spectrum. There was a 
small decrease in a helices and random coil together with a small increase in P sheets 
for all the metal treated peptides (Figure 5.6e). 
The CD spectrum for A1 3 ( 1-40) amyloid protein showed little change with Mg2 but 
with Ca2 and A1 3 
 there was a significant decrease in the maximum around 195 nm 
and a decrease in the minimum around 220 nm (Figure 5.6d). The secondary 
structural values for Cu 2t Zn2 and A1 3 treated peptides showed large decreases in a 
helix and random coil with large increases in fi sheet secondary structures. The 
peptide treated with either Cu 2 (100 MM) or Zn 2 (100 MM) caused a complete 
inversion in the minimum and maximum. Ca 2 also showed similar effects but to a 
lesser extent. The Af3(l-40) amyloid peptide was also treated with Cu 2 and Zn 2 (10, 
50, 100 jiM) and with Cu 2 and Zn 2 combined (100 jiM). The results showed that the 
lower concentration of Cu 2 (> 10 jiM) and Zn 2 (> 10 jiM) also elicited large changes 
in the secondary structure of the AI3(1-40)  (Figure 5.6f and 5.6g). The combined 
effect of Cu 2 (100 jiM) and Zn2 (100 jiM) was similar to either Cu 2 (100 jiM) or 
Zn 2 (100 jiM) alone, but interestingly to a lesser degree. 
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Figure 5.6a 
CD spectra of the synthetic A13(I-43)  treated with Ca 2t Cu2t Zn 2 (100 piM) and AI 3 
(150 l.IM) in TFE/tris buffer. The percentage secondary structures are shown below. 
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Figure 5.6b 
CD spectra of the synthetic Aj3(I-42) treated with Ca 2t Cu2t Zn 2 (100 jiM) and A1 3 
(150 }IM) in TFE/tris buffer. The percentage secondary structures are shown below. 
Shaded values are changes greater 3% from the native peptide. 
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Figure 5.6c 
CD spectra of the A3 extract treated with Ca 2t Cu2t Zn2 (100 jiM) and A1 3 (150 
jiM) in TFE/tris buffer. The percentage secondary structures are shown below. 
Shaded values are changes greater 3% from the native peptide. 
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Figure 5.6d 
The CD spectra of f32M treated with Mg 2t Ca2t Cu 2 , Zn 2 (100 j.tM) and A1 3, (ISO 
MM) in TFE/tris buffer. The percentage secondary structures are shown below. 
Shaded values are changes greater 3% from the native peptide. 
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Figure 5.6e 
The CD spectra of Af( 1-40) amyloid peptide treated with Mg21, 
 Ca2 , Cu 2t Zn 2 (100 
jiM) and A1 3 (150 piM) in TFE/tris buffer. The percentage secondary stmctures are 
shown below. Shaded values are changes greater 3% from the native peptide. 
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Figure 5.61' 
The CD spectra of A13(1-40)  peptide with Cu 2 (10, 50, and 100 .tM) in TFE/tris 
buffer. The percentage secondary structures are shown below. Shaded values are 
changes greater 3% from the native peptide. 
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Figure 5.6g 
The CD spectra of A13(1-40)  peptide with Zn 2 (10, 50, and 100 jiM) in TFE/tris 
buffer. The percentage secondary structures are shown below. Shaded values are 
changes greater 3% from the native peptide. 
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5.2.4 Amyloid proteins treated with aluminium. 
The CD spectrum for the A[3(1-43) peptide showed little change on addition of 
increasing concentration of A1 3t The secondary structural values also showed no 
significant changes although there was a small decrease in a helices and slight 
increase in 0 sheets (Figure 5.7a). The CD spectrum for A13(l-42)  with A1 3 showed a 
decrease in both a helices and random coil and a general increase in [3 sheets on 
addition of high concentrations of A1 3 (Figure 5.7b). The CD spectrum of the extract 
with A1 3 
 showed a small decrease in the minimum around 220 nm although the 
secondary structural values indicate no significant changes (Figure 5.7c). 
The spectrum for the A13(  1-40), on the other hand, showed more of a marked change 
on addition of increasing concentration of A1 3 . There was a gradual decrease in the 
maximum around 195 nm coupled with a gradual decrease in the minimum around 
220 nm. There was a decrease in a content and small increases in [3 sheets and 
random coil with increasing concentration up to A1 3 (300 MM). With Al 3 (400 MM), 
there was a slight reversal in the above trend i.e. up to A1 3 (300 jiM) the [3 sheets 
decreased from 36.9% in the native peptide to 15.5% but for the addition of 
Al 3 
 (400 MM) there was an increase back to 18.5% (Figure 5.7d). With the 132M, 
there was a general decrease in a helices and an increase in [3 sheets with increasing 
A1 3 (Figure 5.7e). A1 3 
 may have a similar effect on 02M as with A1 3(l -40) but to a 
lesser extent. On addition of increasing concentration of A1 3 (150, 300 and 400 MM), 
the a helix values decrease to 24.4% and the [3 sheet values increase to 3 1.2%. 
The solution chemistry of aluminium is complex. A variety of aluminium species 
exist as a result of a series of hydrolytic equilibria as Al(H206) 3t Al(OH) 2t 
Al(OH)2 , Al(OH)3 , Al(OH)4, and other polycationic species. The amount of each 
species present is dependent on p1-I, concentration and time [328, & 232]. At pH 7, 
AI 3 
 is almost completely present as insoluble hydroxide, A1(OH)3 [232]. It is this 
insolubility that limits the concentration of aluminium in aqueous biological systems. 
The 5 mM AI 3 stock solution in tris buffer was prepared immediately prior to use 
from AICI3 salts (pH 7.4). The required working solutions were then prepared and 
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added to the samples and allowed to incubate for 1 hour. Flame atomic absorption 
spectroscopy experiments indicated that the concentration of the 5 mM A1 3 in tris 
buffer (pH 4.8) was stable for up to 72 hours. Hence, the concentrations of the 
working solutions made immediately from this 5 mM stock solution were reliable. 
The equilibrium of A1 3 
 in solution is also time dependent and it may be the case that 
the 1 hour incubation period is sufficient to allow a certain degree of A1 3 to transform 
into insoluble species. At the 400 j.tM A1 3 concentration, less of the AI 3 had 
remained in the soluble monomeric state at pH 7.4 and at 20 °C over the incubation 
period. The availability of the aluminium in solution may thus account for a higher 13 
sheet content of AJ3( 1-40) of the 300 I.tM compared with the 400 jjM concentrations. 
5.2.5 Amyloid proteins treated with both aluminium and silicon. 
Addition of A1 3 (150 and 300 jiM) to the A[3(I-40) peptide caused a decrease in a 
helices and an increase in [3 sheet as shown in Section 5.2.4. Addition of 
Si044 (30 jiM) after the A1 3 , had little effect in reversing the changes in secondary 
structure caused by A1 3 (150 and 300 jiM) as shown in Figure 5.8a. A higher 
concentration of Si044 (300 MM) caused a reversal in both the a helices by 5% back 
towards the native peptide for the A1 3 (ISO MM) treated peptide. 
Addition of Si044 (300 jiM) gr A13 (300 jiM) caused similar effects but to a lesser 
extent with a further increase in a helices of 3% compared to A1 3 (300 jiM) alone. 
Figure 5.8b showed that the addition of Si0 44 (300 MM) added before the 
A1 3 
 (300 jiM) further reverses the structural changes with an increase in a helices of 
5% and a decrease in 0 sheets of 4%, back towards the native peptide. The f32M 
showed similar trends to A[3(1-40) though to a lesser degree (Figure 5.8c). Addition 
of Si044 (100 MM) after the A1 3 (300 MM) seems to have little effect on reversing 
the changes due to the A1 3 and when added before the AI 3 increased the a helices by 
4%, towards the native value. However, a higher concentration of Si044 (300 MM) 
added both before and after the A1 3 (300 jiM) resulted in a slight reversal in the 
changes caused by the A1 3 with further increases in a helices (6% for Si04 4 added 
before) and decreases in 0 sheets of (4% for Si04 4 added before). 
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Figure 5.7a 
CD spectra of the synthetic A13(1-43)  treated with A1 3, (50, 150, and 300 jiM) in 
TFE/tris buffer. The percentage secondary structures are shown below. 
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Figure 5.7b 
CD spectra of the synthetic AJ3( 1-42) treated with A1 3, (50, 150, 300, and 400 i.tM) in 
TFE/tris buffer. The percentage secondary structures are shown below. Shaded values 
are changes greater 3% from the native peptide. 
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Figure 5.7c 
CD spectra of the A13 extract treated with Al 3 (50, 150, 300 jiM) in TFE/tris buffer. 
The percentage secondary structures are shown below. 
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Figure 5.7d 
CD spectra of the synthetic A13(1-40)  treated with A1 3, (50, 150, 300 and 400 piM) in 
TFE/tris buffer. The percentage secondary structures are shown below. Shaded values 
are changes greater 3% from the native peptide. 
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Figure 5.7e 
CD spectra of the synthetic 132M treated with A1 3, (50, 150, 300 and 400 j.iM) in 
TFE/tris buffer. The percentage secondary structures are shown below. Shaded values 
are changes greater 3% from the native peptide. 
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Figure 5.8a 
The CD spectra of AJ3(l-40) peptide with A1 3 (150, 300 RM) and Si04 4 (300 IIM) in 
TFE/tris buffer. The percentage secondary structural values are shown below. Shaded 
values are changes greater 3% from the native peptide. 
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Figure 5.8b 
The CD spectra of AJ3(1-40) peptide with A1 3, (300 RM) and Si044 (300 I.LM) in 
TFE/tris buffer added before and after the A1 3 . The percentage secondary structural 
values are shown below. Shaded values are changes greater 3% from the native 
peptide. 
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Figure 5.8c 
The CD spectra of 02M peptide with A1 3 (300 jiM) and Si04 4 (300 M) in TFE/tris 
buffer. The percentage secondary structures are shown below. Shaded values are 
changes greater 3% from the native peptide. 
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5.2.6 Amyloid proteins treated with glycosaminoglycans. 
The AJ3(1-40) amyloid peptide and 132M peptide were both treated with various 
glycosaminoglycans; heparin (FIEP) (50, 500 jig mF'), HS (50, 500 jig ml'), HSPG 
(50, 500 jig ml'), KS (50, 500 jig ml'), DS (50, 500 jig ml'), CS (50, 500 jig ml') 
and sodium sulphate (50, 500 jig ml'). The 02M and A13(l -40) peptides did not 
appear to undergo any significant change in the spectral profiles on binding sulphates 
and GAGs. 
The addition of the lower concentration GAGs (50 jig ml', data not shown) showed 
very similar spectrum to the spectrum of the higher concentration of GAG (500 jig 
m1'). The GAGs on their own seem to have little effect on the secondary structure of 
the A(l-40) and f32M with maximum change of about 5%. The most notable changes 
for A13(l -40) are with Na2SO4 ((x 15% and 0 t3%) and DS (a 14.5%) (Figure 5.9a). 
The most notable changes for 132M are with HS ((x 14%) and KS (a 15%) (Figure 
5.9b). 
5.2.7 Amyloid proteins treated with glycosaminoglycans combined 
with aluminium. 
The CD spectrum in Figure 5.10a showed that the A(1-40) peptide treated with 
physiological concentrations of A1 3 (1.5 jiM) and A(l-40) with the GAGs alone, 
both showed little change in the secondary structures. There was a slight change of in 
both a helices (16%) and 0 sheets (t8%) when the aluminium was combined with HS, 
HSPG or DS. Similar effects were seen with 02M. 132M treated with A1 3 (1.5 jiM) or 
GAGs showed little change with slight changes of about 3% in both a helices and 13 
sheets. There was a change of in both a helices (jlO%) and 0 sheets (i9% ) when the 
A13 was combined with HS, DS or CS (Figure S.lOb). 
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5.2.8 Amyloid proteins treated with glycosaminoglycans combined 
with copper or zinc. 
A13(l -40) peptide with both DS/Cu 2 and HSPG/Cu 2 show little difference in the 
secondary structures compared to Cu 2 (10 j.tM) alone. With HS/Cu 2 there was a 
slight reversal in the changes of secondary structure caused by copper itself (Figure 
Lila). f32M with both DS/Cu 2 and HSPG/Cu 2 seem to enhance the effects due to 
copper itself i.e. further decreases in a helices and increases in 0 sheets. Again, with 
HS/Cu2 
 there was a slight reversal in the changes of secondary structure caused by 
copper itself (Figure 5.11b). Similar results are also seen with 132M and zinc. 32M 
with D5/Zn 2 and KS/Zn2 
 seem to enhance the effects due to Zn 2 (10 iM) itself i.e. 
a further decrease in a helices and an increase in P sheets, where as HS appears to 
have no effect. (Figure 5.11c). 
5.2.9 Amyloid proteins treated with glycosaminoglycans and calcium. 
Af3(1-40) peptide and P2M were treated with combinations of Ca 2 (16 jiM) and HEP, 
Na2SO4, HS, HSPG, KS, DS and CS. The CD spectra of Af3(1-40) peptide treated 
with HSPG, CS, KS and DS with Ca 2 (16 jiM) are shown in Figure 5.12a. The CD 
spectra show that combinations of KS or DS and calcium do not seem to alter the 
secondary structural changes with just the Ca 2 (16 jiM) itself. Both HSPG and CS 
combined with calcium cause further decreases in a helices but only the CS/Ca 2 
caused a further increase in 0 sheets. Where as HEP, HS, and Na2504 with Ca 2 show 
a further increase in a helix and a decrease in f3 sheet compared to Ca 2 itself, i.e. 
decreasing the effects of calcium, as shown in Figure 5.12b. 132M with Na2SO4/Ca2t 
DS/Ca2 and HEP/Ca2 
 cause no further changes with respect to calcium (Figure 
5.12c). With KS/Ca 2 , CS/Ca2t HS/Ca2 and HSPG/Ca 2 there are further decreases 
in a helices and increases in 13 sheets indicating that these combinations enhance the 
effects of Ca 2 (Figure 5.12d). 
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Figure 5.9a 
CD spectra of the A13(l -40) treated with sodium sulphate sodium heparin (HEP), 
heparan sulphate (HP), dermatan sulphate (DS), chondroitin sulphate (CS), keratan 
sulphate (KS) and heparan sulphate proteoglycan (HSPG) (all 500 xg mr') in TFE/tris 
buffer. The percentage secondary structures are shown below. Shaded values are 
changes greater 3% from the native peptide. 
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Figure 5.9b 
CD spectra of the 02M treated with sodium sulphate sodium heparin (HEP), heparan 
sulphate (HP), dermatan sulphate (DS), chondroitin sulphate (CS), keratan sulphate 
(KS) and heparan sulphate proteoglycan (HSPG) (all 500 .tg mi 1 ) in TFE/tris buffer. 
The percentage secondary structures are shown below. Shaded values are changes 
greater 3% from the native peptide. 
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Figure 5.10a 
The CD spectra of A13(1-40)  peptide treated with HS, HSPG and DS with A1 3 (1.5 
jiM) in TFE/tris buffer. The percentage secondary structures are shown below. 
Shaded values are changes greater 3% from the native peptide. 
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Figure 5.10b 
The CD spectra of f32M peptide treated with HS, DS and CS with A1 3 (1.5 pM) in 
TFE/tris buffer. The percentage secondary structures are shown below. Shaded values 
are changes greater 3% from the native peptide. 
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Figure 5.11a 
The CD spectra of A13(  1-40) peptide treated with HS, HSPG, KS and DS with Cu2* 
(JO iM) in TFE/tris buffer. The percentage secondary structures are shown below. 
Shaded values are changes greater 3% from the native peptide. 
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Figure S.11b 
The CD spectra of 02M peptide treated with HS, HSPG and DS with Cu 2 (10 jiM). 
The percentage secondary structures are shown below. Shaded values are changes 
greater 3% from the native peptide. 
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Figure 5.11c 
The CD spectra of 132M peptide treated with HS, DS and KS with Zn 2 (tO jiM). The 
percentage secondary structures are shown below. Shaded values are changes greater 
3% from the native peptide. 
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Figure 5.12a 
The CD spectra of AJ3(l-40) peptide treated with HSPG, KS and DS with Ca 2 (16 
jiM) in TFE/tris buffer. The percentage secondary structures are shown below. 
Shaded values are changes greater 3% from the native peptide. 
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Figure 5.12b 
The CD spectra of A13(l-40)  peptide treated with heparin, HS, Na2SO 4 and CS with 
Ca2 (16 jiM) in TFE/tris buffer. The percentage secondary structures are shown 
below. Shaded values are changes greater 3% from the native peptide. 
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Figure 5.12c 
(c) The CD spectra of 02M peptide treated with Heparin (HEP), HSPG and CS with 
Ca2 
 (16 I.LM) in TFE/tris buffer. The percentage secondary structures are shown 
below. Shaded values are changes greater 3% from the native peptide. 
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Figure 5.12d 
The CD spectra of 13 2M peptide treated with sodium HS, DS, KS and Na2SO4 with 
Ca2 (16 tM) in TFE/tris buffer. The percentage secondary structures are shown 
below. Shaded values are changes greater 3% from the native peptide. 
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5.3 Summary of results. 
The following tables (Table 5.3) show a summary of all the results. 
AD(140) 	 a helix 	 - Random 	 5 sheet 
Ca(lOOpM) U - IT 
Mg(1OOpM - - - 
ut(1jM) I-4 - if 
ct(50pM) U - ttt 
u?(loopM) 114 1 ttt 
Th(1OpM) U - if 
Zn2 (5OpM) U I tif 
Zt(lOOpM) UI I ttt 
Qt/Zt(lOOpM) UI - ttt 
Ar(so1M  
At(JSOpM) U - It 
Al3 (300pM) UI - tIt 
A1'+ (400pM) 141 - tIt 
Slot (300pM) - - - 
At(l5opM)/SiOt(300gM) 11- - It 
At(300pM/90300pM 44 - It 
S104 (300pM)/At(300pIVO U - It 
Na$04 (500pgniF') I - t 
HEP(SOOpgnf')  
HS(Soopgmr)  
Hsw(soopgmñ - - - 
KS(soOpgmr) 4, - I 
I(500pgmr') - - - 
cS(SoOpgmr) - - - 
HS(500pgnf')/At(l5pMJ 4. - t 
HSPG(SUOpgmI1YAt(1.5pM) I - t 
I(500pgmF'yAt(13pM) I - I 
Hs(500pgmr'yQ?(lOpM) I - I 
HSPG(Soopgmr'yct(lOpM) 1- - I 
I(50Opgnf1yO?(10pM) 4, - tt 
HS(SOOpgmF'YCa(l6pM) 4,1' t It 
HSPG(500pgni'YCa(16gM) 44 - if 
S(5oOpgmr'yCa(16pM) 4,4, t It 
I(5oOpgmr1yCa(16pM) 4, - I 
tIS(SoOpgmr'YCa(l6pM) 4. - I 
HEP(SOOpgmr'YCa(l6pM) 4, - I 
Na$04(500pgmF'YCa(16pM) 44 4, tt 
Table 5.2a - Experiments with A13(l -40) (1 (>3%),  TT  (>6 	 (>10%) difference 
from the native peptides). 
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a helix 	 fi sheet 	 Random 
Q?(100,*b 1. - - 
zt(100pM) - - - 
th(1O0pMJ  
Mg(10011M) - - - 
- t 4. 
At(lSOpM) t 4- 
At(300pM) 44 tt 1' 
t(400pM) 44 if - 
S1044 (300pM) - - - 
300pMVSiO4 (100pM) if t 
At(30OpM)1SiO4 (300pM) if t 
SiO4'(100pM)/At(300pM) if - 
S104 (300pM)/At(300pM) t - 
Na$04(SOOpgmf) - - - 
HEP(SOOpgS) - - - 
HS(So0pgmr') t - 
HSPG(SOOpgmF') - 1' - 
KS(Soopgmr') I t - 
DS(SOOpgn&) 'I' I - 
CS (500pgmf) - - - 
HS(500pgnff')'At(tSpM) 4- 1 1 
HSPG(soOpgnff'yt(L5pM) 1. 1 - 
KS(SOOpgmI')I'At(LS pM) I 1 - 
Hs(500pgmr1yQ?(1otM) - - - 
HSPG(Soopgmr'YQ?(lopM) I I I 
U6(sOOpgniF'yQ?(lOpM) 1- 1 - 
ITS (500 pg mF'YZt (10 pM) I - 
)S(500pgniF1YZzt(10pM) 11 4. 
KS(SOopgmr'yZit(lOpM) It I 
HS(SOopgmr'yCa(l6pM) 41 It - 
HSPG(500pgmr'yca(16pM) 1 1 1 
KS(500pgmF'YCa(16pM) 14 It 1- 
I'(S00pgni'YCa(16pM) I Ii' 14 
CS(Soopgmr'yCa(l6pM) 4' t I 
HEP(So0pgmr')/Ca(16pM) 4- - I 
NaSO4/Ca(16pM) I4 It - 
Table Sib - Experiments with 132M (1 >3%), 
 if (>6%),  TTT (>10%) difference from 
the native peptides). 
Mir 
Random 
Zt(lOOpM) 	 - 	 - 	 - 
Ca(1OOpM 	 - 	 - 	 - 
A13 (5OpM 	 - 	 - 	 - 
At(lSUpM) 	 - 	 - 	 - 
At(300pM)  
	
Table 5.2c - Experiments with Afi( 1-43) (1 (>3%), 
 TT  (>q) 	 (>10%) difference 
from the native peptides). 
A(1-42) 	 a helix 	 Random 	 D sheet - 
ufllOopM) 4. T 4' 
Zt(lOOpM) 4. 1 4. 
Ca(lOOpM) 4. 1 4. 
At(SOsM) I - 
At(300pM) I - It 
At(400pM) 1 1. It 
Table 5.2d - Experiments with A13(I-43) (1 (>3%), TT (>6%), Itt (>10%) difference 
from the native peptides). 
Extract 	 cx helix 	 Random 	 0 sheet 
cit(lOOpM) 	 4' 	 4' 	 TTT 
Zt(loOpM) 	 I 	 t 	 1' 
Ca(lOOpiVb  
At(5OpM 	 - 	 - 	 - 
At(150p 	 - 	 - 	 - 
At(300pM) 	 - 	 - 	 - 
Table 5.2e - Experiments with AJ3 extract (t (>3%), TT (>6%), ttt (>10%) difference 
from the native peptides). 
PrionPmtein 	 a helix 	 Random 	 sheet 
Cantn1 4mouselPrY 	 - 	 - 	 - 
4nnise]Prr+Ptxtsmet 	 - 	 - 	 - 
r[mousejPrV+ Hiosmet 	 - 	 - 	 - 
Table 5.217 - Experiments with prion protein (1 (>3%), 
 TT (>6%), TTT (>10%) difference 
from the native peptides). 
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5.4 Discussion 
CD spectroscopy has been used to study the secondary structures of various amyloid 
peptides A13 ( 1-40), Af3(1-42), A13 ( 1-43), the A13  extract from Alzheimer's disease 
brain and 02M. CD spectroscopy has been previously used to study Af3( 1-40) and 
Af3(25-35) treated with A1 3, [289] and A13(l-42)  treated with A1 3 and Si044 , [289, 
314 & 320]. The present experiments extend the work of these studies by the use of 
other amyloid peptides, with various inorganic elements and GAGs. 
5.4.1 Comparison of secondary structural values in other CD studies. 
The secondary structural values obtained in various studies are shown in Table 5.3: 
Sampleand conditions 
Secondary structure (%) 
a Helix P sheet 	 Turn R Coil 
A13(1-40)(577 pMmTFE60%/tnslOmMpH7A) 369 176 168 294 
A13(1-40)(4OpMinTEE60%/tris)[289] 21 58 21 
A13(l -40)(FFE 70%/HEPESpH6.7)[278] 46 0 32 
AD(l-40)-A1(300pM)(FW60%/trsslOmMpH7.4) 	 >- A 155 266 169 403 
AJX14O)-M(350 pM) (FEE 70%/H20 pH 6.7) [278] 29 29 27 
A1)(1-40)-D-Asp-At (FEE 70%/H20 pH 6.7) [278] 	 I 13 27 47 
A(140)-L-Glu-At(FFE70%/H 2OpH6.7) [278] 	
) 
17 21 54 
A(1-4)(FFE67Mns1OmMpH7.4) 205 249 15.8 38.8 B A13(142)(60%TEEph7.4)[108] 	 J 38 3 35 
403 152 177 267 
AW23-35)(FFE6O%flhslQinM4iH7A) 10 50 153 239 
A(25-3 	 (0.23mM,TEE60%/tris) [289] 	 1> 5 61 34 c 
AP(25-35)(25 JMin5mMAcONapH40)[117] 	 [ 20 60 3 22 
A13(25-35)(60%TFEpH7.4)[108] 
	
..J 2.1 39 15.2 43.7 
AJ3(1-28)(60%TFEpH7.4)[108] 42 5 39 
AD(1-39)(60% TFEpH7.4) [108] 50 0 30 
Table 5.3 - The secondary structural values of the various amyloid peptides compared 
with other CD studies. The shaded values were obtained in the present studies. 
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The studies differed in terms of experimental conditions, the solvent environment, and 
the methods of data analysis. Several methods have been developed to analyse the 
secondary structures of peptides and proteins from CD data, to obtain secondary 
structural information from CD data [16-20]. Each method has been shown to have its 
own advantages and pitfalls; for example, the wavelength range of data acquisition 
and the precision of protein concentration determination have been shown to affect 
the reliability of each method. The differing conditions could account for the 
differences in the secondary structural values. Most alarming is a paper by Simmons 
et al. [125], which identified variation in results with amyloid materials from different 
suppliers as well as within the same batches from the same supplier. The method of 
analysis of the data could affect the way the results are interpreted. 
The following conclusions were made for the differences in the values obtained and 
the values quoted in various studies: 
A) Although, the native AJ3(l-40) peptide values differ from those in the literature, 
the values follow the general trends of decreasing a helix and increasing P sheet 
on addition of aluminium. 
B) The effects of solvents could alter the overall secondary structure, as is the case 
for Aj3(1-42). The secondary structural values differ in TFE (60%)! water (40%) 
showing more a helix and less 0 sheets. 
C) All the values show increased fi sheets for A13(25-35)  indicating that this peptide 
or peptide region may be involved in A13  aggregation. 
D) The PrPC 
 prion protein is predominantly a helix in nature. Conversion to the ppW 
results in an abolishment of the a helix with an increase in 13 sheets. 
5.4.2 Extracted Aji may contain different fragments of the AJ3 
protein. 
In the present study, the CD spectrum for the various A13 amyloid peptides clearly 
showed the diversity of secondary structures of the different fragments of the same 
protein. This suggests that certain fragments or residues within the A13 contribute to 
the overall structure. The secondary structural values for the A13 extract from brain 
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tissue were closest to that of AJ3(1-42) and Af3(25-35) but not the Afl(1-43). The a 
helical content for the A13  extract was too low compared with the Aj3( 1-43). 
Secondary structural values from the CD study are shown in Table 5.4. 
Amyloid protein Secondary structure (%) 
a Helix 13 sheet 13 Turn R Coil 
AD(140) 36.9 17.6 16.8 29.4 
AJ3(142) 20.5 24.9 15.8 38.8 
A43(1-43) 40.3 15.2 17.7 26.7 
AJ3(23-35) 30.0 50.0 15.3 23.9 
Extract 11.3 35.9 17.6 37.9 
36.9 15.2 15.8 31.4 
Control4mouse]prPC 42.5 18.2 13.0 28.2 
Table 5.4 
- The secondary values of the amyloid proteins obtained from CD spectra. 
The amyloid plaques are composed of 13 sheet aggregates and are formed as a result of 
a conversion from a helices to 13 sheets. Therefore, a large 3 sheet content was 
expected for the extracted protein. The extracted amyloid could also contain many f3 
amyloid protein fragments such as the AJ3(I-42) or A13(25-35).  The CD method is not 
able to distinguish between a mixture of proteins and the secondary structure from 
each protein within the mixture contributes to the overall spectrum. The secondary 
structural values for the extracted amyloid protein from Alzheimer's disease were 
between that of the A13(1-42) and the A13(25-35). 
The secondary structural values for the AJ3 extract from brain tissue were closest to 
that of AJ3(1-42) and A13(25-35) but not the AJ3(l-43). The a helical content for the 
Af3 extract was too low compared with the A13(1-43). The immunoblot detection with 
the antibody to A13(l-40) indicated that the extracted amyloid contains A13(l-40), but 
may also contain A13(1-42) andlor A13(l-43). It can be concluded that from both the 
immunoblot assay and the CD results that the AJ3 extract contained a mixture of 
amyloids, predominantly AJ3(1-40) but possibly also A13(I-42) and Af3(25-35). 
The 13-amyloid peptide has been shown to fold into two antiparallel 13-strands with a 
13-turn at residues 26-29 and with the nine N-terminal residues adopting a random coil 
configuration [118]. The synthetic Af3 peptide fragment having the same sequence as 
the N-terminal 28 residues, formed fibrils that share both antigenic and structural 
features with native AJ3 amyloid filaments [103 & 1041. The hydrophobic A13(29-42) 
peptide adopts exclusive intermolecular 0 sheet conformations in aqueous solution 
despite changes in temperature or pH. This peptide is derived entirely from the 
hydrophobic transmembrane domain and the ability of this peptide to form stable 13 
structure indicates that the C-terminal region could also be amyloidogenic [107]. Both 
A[3(1-40) and AI3(l-42)  have been widely studied, the A13(l-42)  forms 13  sheet structure 
and amyloid fibrils much more readily than does A13(1-40)  [112 - 115 & 329]. The 
Af3(1-43) formed stable a helices in solution indicating that the intact entire length 
peptide behaves differently to the other fragments. The Af3(25-35) undergoes a 
reversible 13 sheet - random coil transition at pH 4.0 and 5.5 [117]. 
5.4.3 The prion protein interaction with Phosmet. 
A truncated recombinant mouse, r[mouse]PrP' (90-23 1) was used in these 
experiments. The primary sequence of PrPC 
 has been determined for a number of 
species [100]. The human PrP exhibits 87.3% homology with hamster PrP that has 
over 94% homology with mouse PrP. The PrP has several definable regions within the 
primary sequence. The N terminus (region 7-69) contains a series of octa repeats of 
amino acid rich in prolines and glycines, which are known to bind to Cu 2t A 
hydrophobic cluster (residues 113-128) with a core domain (residues 125-228) 
consisting of three a helices and two short antiparallel [3 strands. The hydrophobic 
region (113-128) has been shown to be necessary for a to [3 conversion [152]. Studies 
with recombinant Syrian hamster PrP, r[SHa]PrP(29-23 I) compared to the 
r[SHa]PrP(90-23 1) show that they both exhibit identical core structures and similar 
backbone dynamics. The 29-124 residues of the r[SHa]PrP(29-231) displays a 
substantial amount of flexibility and little structure and indicates that the N terminus 
may be disordered in vivo [202]. Little information exists for the involvement of the 
N terminus region. It has been shown that the truncated PrP(121-231) without N 
terminal, caused cerebrallar disorders in transgenic mice. 
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The amino acids 1-22 of PrPC 
 comprise a single peptide that is removed during 
biosynthesis [330] and therefore not involved in the secondary structure of PrPC. 
Spectral data is available from the suppliers of the r[mouse]PrPC used in the 
experiments show the folding of the a helix from 0 pleated sheet form in reducing 
acid conditions. Therefore, the recombinant mouse PrP(90-231) is likely to refold in a 
similar manner to the intact mouse prion protein. It can also be used to detect changes 
in secondary structure on exposure to the Phosmet and its metabolites. The mouse 
prion protein has over 80% homology to the human prion and the region of interest 
which displays the ability to form P sheets lies within the hydrophobic cluster 
(residues 113-128). It was not possible to determine the conformational structure of 
isolated mouse PrPSC in these experiments because of its extreme insolubility in the 
buffers used. It would also be of interest to perform these experiments with the human 
full-length prion protein. 
In this experiment, the exposure of r[mouse]PrP' to Phosmet or its metabolites did not 
result in any changes in the conformation of the prion. A change from predominantly 
a helix to fi sheets would indicate that the PrPC 
 had been converted to PrP. This 
indicates that Phosmet does not act as a trigger factor for the initiation of mouse P rPW . 
The ectoparasiticide, Phosmet, was used to eradicate BSE in cattle in the '80s. This 
external treatment was applied as a liquid preparation, poured onto the back of the 
cattle. It was hypothesised that this method of application allowed the Phosmet to be 
absorbed into the spinal chord, entering the brain after a delayed period. One possible 
mechanism is the interaction of Phosmet with cellular PrPC 
 transforming it into P rPW 
and this would initiate the BSE disease [204]. The mechanisms for this proposed 
transformation of PrP can be divided into two distinct groups; those not involving a 
direct interaction with the Phosmet and those involving interaction between Phosmet 
and/or its metabolites with the prion protein. Indirect interaction is mechanistically 
diverse and could include esoteric cellular changes which result in altered cellular 
metabolism or altered immune responses or interactions between Phosmet and the cell 
membrane or prion anchor proteins, which might indirectly affect PrPC. 
 The direct 
interactions are perhaps the most likely mechanisms if Phosmet did play a role in the 
BSE epidemic. 
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However, the most likely cause was animal feed containing scrapie-infected bone 
meal [147]. Cattle that were fed on this infected bone meal then contracted BSE via 
cross species contamination. Exposure to BSE infected meat as a foodstuff is 
considered to be the likely cause of the new variant CJD (nvCJD) [197]. 
5.4.4 Amyloids treated with metals. 
The addition of copper, zinc, calcium and aluminium to Aj3(l-40),  AJ3(l-42), the Aj3 
extract and to 132M show some change with the exception of A13(1-43).  Addition of 
metals with the AJ%( 1-42) and A13  extract generally caused a decrease in the a helix. 
The effects of both copper and zinc were concentration dependent showing an almost 
complete abolition of a helices with a shift to f3 sheets with Af3(l-40). Aluminium has 
a concentration dependent effect on the secondary structure as seen with a decrease in 
a helices and an increase in 13 sheet for both AJ3(l-40) and 02M. Calcium also showed 
similar affects with the A13(l-40) but to a lesser extent. 
Iron, nickel and aluminium all caused amyloid to deposit to a degree whereas barium, 
silver, lead, magnesium and calcium had the least effect on A13(1-40) deposition 
[331). These metals may have similar effects on the other A13 fragments and indeed 
other amyloids such as 132M and the prion protein. Studies have reported metal-
induced aggregations of amyloid if the metals are present in a high enough 
concentration [331 - 333]. Bush et al. [331] found that at a concentrations of 25 tiM or 
less of zinc, less than 20% of amyloid 0 protein remained in solution. There is 
evidence that prolonged exposure to fragments of A13 can have toxic effects on 
neurons in vitro either directly or by calcium dependent mechanisms [254]. Calcium 
has been reported to cause the same effects on the structure of the A13 peptide as with 
aluminium [320]. 
5.4.5 Amyloids treated with copper and zinc. 
Addition of a mixture of copper and zinc to the A13(1-40) did not show a combined 
effect. In fact, the resultant changes were less than that of the metals on their own. 
Copper is able to displace of 65Zn from A13 when co-incubated with excess Cu 2 
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[319]. The Cu21_induced A13  aggregation at pH 7.4 is considerably less than that 
induced by Zn 2 
 [331, 332 & 3351. A13 has binding sites for both copper and zinc, but 
copper ions can displace zinc ions, hence a co-operative effect is not seen with the 
addition of both copper and zinc [331 & 336]. Af3(1-40) may be capable of binding 
Cu2 and Zn 2 
 simultaneously [331 & 335] and like the prion protein, A13 is able to 
bind multiple copper ions [319]. Clements et al. [319], reported that the binding of 
zinc to the peptide was dependent upon the amount of free zinc and the relative 
affinities of any competing proteins. Therefore, the overall binding and hence 
interaction of both the Zn 2 and Cu2 is actually decreased because of competition for 
the same binding sites. 
5.4.6 Amyloids treated with aluminium. 
The Afi( 1-40) and the 132M both showed similar results with the treatment of 
increasing concentration of A1 3 . There was a general decrease in a helix with an 
increase in 0 sheets. The results obtained for A13(1-40) are similar to, and a 
progression of, those previously reported by other workers. The peptide and 
aluminium results mirrored trends reported by Exley et al. [289] except for the 
addition of 400 pM A1 3t which they did not report. They also found that the addition 
of an increasing concentration of aluminium up to 300 RM caused a general decrease 
in a helices although there was also a decrease in the 13 sheets with an increase in 
random coil. In contrast there was a decrease in a helices and increases in both 13 
sheets and random coil, in this study. Experiments by Fasman et al. [314] also showed 
that on addition of upto 4 molar equivalents of A1 3 to rat Af3(l-42) caused a decrease 
in the a helix and an increase in 13 sheets. Thus, an increase in the J3 sheet content of 
the amyloid peptide A13(1-40) treated with A1 3 may indicate a possible mechanism 
for its aggregation. 
Exley et al. also reported that aluminium (50 RM) had a small effect on the A13(25-35) 
[289]. In the present study, the initial CD spectrum of the A13(25-35) showed that 
there was a significant amount of 0 sheet (>50%) and treatment of aluminium would 
not have any effect on the secondary structure. Although the solvent conditions were 
similar, the suppliers of the peptides differed. This may account for the differences in 
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the results as amyloid materials have been shown to vary from different suppliers 
[125]. 
5.4.7 Amyloids treated with aluminium and silicon. 
Addition of Si044 
 after the aluminium had the effect of reversing the changes in 
secondary structure caused by A1 3 
 for both the Af3(1-40) and 02M. This reversal was 
enhanced by the addition of the silicate before the aluminium. The effect of silicate on 
A13 (I -42) has previously been reported [314 & 320] but not for A13(l-40)  or 32M. The 
results presented here differ from those of Fasman et al. [314 & 320] with respect to 
(i) the amyloid peptide (ii) the matrix environment within which the peptide was 
analysed and (iii) the peptide concentration. The amyloid used by Fasman et al. was 
rat amyloid A13(l -42) whereas the amyloids used in the present study were all 
synthetic human amyloid peptides. The experiments by Fasman et al. were conducted 
in a 100% TFE environment. The solvent used in the current study consisted of 60% 
TFE/ 40% tris (pH 7.4, 10 mM) environment. This environment more closely 
resembles in vitro conditions than that of Fasman et al [314]. 
The effect of aluminium on the A13(1-42)  has been shown to be reversed on addition 
of silicate in a 1:2 ratio [314 & 3201, where as the above experiments show that there 
is a reversing effect with a 1:1 ration of Al 3 and Si044 . There was a greater reversal 
in the secondary structure with Si04 4 (300 mM) and with a lower concentration of 
Al3 (50 and 150 l.LM). The chemistry of aluminium also shows that it has a unique 
affinity for silicon forming insoluble aluminosilicates. Therefore, addition of Si0 44 
before the A1 31 , as above, could allow the formation of aluminosilicates thereby 
reducing the amount of soluble aluminium available to interact with the peptide [314]. 
5.4.8 Amyloids treated with GAGs. 
The f32M and Af3(1-40) peptides did not appear to undergo any significant 
conformational change on binding sulphates and GAGs. Even if sulphate did not 
influence fibrillogenesis via conformation changes, binding of the GAG could provide 
a high-affinity binding ligand that could then bind other factors such as metal ions. 
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Similar experiments by McLaurin et at. [315] show comparable results for the 
A13(l -40) treated with various GAGs using CD. In their experiments, the AJ3(1-40) 
showed little change on addition of the GAGs (heparin, heparan sulphate, keratan 
sulphate or chondroitin-4-sulphate and chondroitin-6-sulphate) at high concentration 
and at different pH (7.0 and 6.0). The concentrations of the GAGs they used ranged 
from 0.5-5 mg mF', the lowest was 10 times the concentration used in our 
experiments. 
They also looked at A13(1-42),  which is far more amyloidogenic than A13(l-40).  They 
showed it formed P sheets with the GAGs [315]. They used a phosphate buffer, and in 
the presence of phosphate (50 mlvi at pH 7.0 and pH 6.0), the chondroitin-4-sulphate 
was seen to induce a P sheet structural change in Af3(1-40) only after 4 hrs. They also 
showed that after 48 hrs at pH 7.0, the A13(1-40)  aggregated formed with or without 
either chondroitin 4 sulphate or heparin [315]. The interaction of the GAGs showed 
no time or pH dependence or effect from other molecules such as phosphate. 
Therefore çhe choice of buffer may influence the outcome of the GAG induced change 
in All Thus, the inability of GAGs to induce a 0 conformational switch in A13(1-40) 
may be as a result of specific shielding of charges by counter ions present in the 
buffer [315]. 
5.4.9 Amyloids treated with GAGs and metals. 
Aj3(l-40) and f32M peptide treated with physiological concentrations of A1 3 combined 
with the GAGs showed a synergistic effect. In the above experiments, it was observed 
that A1 3 
 had an effect on the secondary structure of both Af3( 1-40) and 132M but only 
at the higher concentrations. The levels of aluminium were lower (1.5 jiM) compared 
to previous experiments (50 jiM upwards). Neither the GAGs nor the aluminium on 
their own caused an appreciable change in the secondary structure. These results 
indicate that the highly sulphated GAGs were somehow enhancing the effects of the 
A131 
 . These changes seemed to occur with several types of GAG, which suggests that 
the highly negatively charged sulphate groups may be involved. 
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Similar effects were also seen with copper and zinc, although the Cu 2 and Zn 2 
initially alter the peptides at the concentrations used. The A1 3(l -40) peptide treated 
with combinations of Ca2 
 and various GAGs showed different effects depending on 
the GAG. Most notably, the combinations of heparin, HS, and Na2SO 4 with calcium, 
appears to increase the a helices and decrease the 13 sheets. For 132M, the combined 
calcium and GAGs generally decreased the a helices and increased the f3 sheets, with 
the exception of HSPG, HS, KS, and CS causing further decreases in a helices and 
13 sheets with increases in random coil. 
Highly sulphated glycosaminoglycans and proteoglycans are common constituents of 
amyloid deposits. The sulphate may represent an ideal distribution of sulphate groups 
for amyloid interactions. GAGs could affect the nucleation and propagation of these 
fibres by serving as an anchor for amyloid fibril organisation [315]. GAGs also 
possess substituent groups, which permits complex co-ordination with metal cations. 
These complexes could further interact with the amyloid fibrils. 
5.5 Conclusion. 
The present results show that metals with both A13(l-40) or 132M caused an increase in 
the peptide 13 sheets secondary structure and thus may accelerate amyloid deposition. 
It was seen that the effects on the amyloids of metals such as copper, zinc, aluminium 
and calcium are enhanced when combined with GAGs. The results for 132M are 
interesting because there is little work on 132M with metals in the literature. The work 
with the GAGs and Metals has not been previously reported. The similarity in the 
results for both the above amyloids indicates that common mechanisms are involved. 
Calcium under certain conditions with certain GAGs is seen to have increased or 
decreased effects on the amyloids. Abnormal metabolism of PGs including specific 
GAGs is closely involved in the production of amyloids. Though it is not known if 
elevated levels of PGs has any influence on amyloidosis. Given that in all amyloids 
highly sulphated GAGs are present, one can postulate that these highly negatively 
charged molecules may play a role in the presence of other factors, such as metals. 
155 
Chapter 6. Detection of secondary structural changes in amyloid 
proteins using attenuated total reflectance (ATR-tI'IR). 
6.1 Introduction. 
The technique of attenuated total reflectance Fourier transform infrared spectroscopy 
is a method widely used in the study of proteins. ATR-FTIR is more versatile than 
conventional transmission ETIR spectroscopy because the spectra of peptides can be 
obtained in such a wide range of matrices. ATR spectra can be collected of non-
transparent samples, and proteins can be detected in aqueous solutions. It is also 
possible to study proteins in the presence of strongly absorbing solutes (such as 
denaturants). A broad range of ATR-FTIR accessories is becoming available to 
overcome the problems of studying biological samples [337 -342]. Small amounts of 
sample are required and only very low protein concentrations (c 0.3 mg mr') are 
necessary. 
Traditionally AIR has been used for the analysis proteins as films and can be 
extended to study the orientation of molecules in thin films, such as lipids and 
peptides in bio-membranes. Such studies involve drying the protein as a hydrated thin 
film on the surface of an internal reflectance element (IRE) as in thin film 
ATR (IF-AIR). The other strategy for collecting AIR spectra is to allow proteins or 
peptides to adsorb to the surface of the IRE from solution as in adsorption ATR (Ads-
ATR). Significant structural disturbances may occur with drying of proteins onto the 
IRE. Proteins adsorb onto the surface will also interact with the IRE material. The 
structural distortion caused by protein-IRE interactions can be substantial; hence the 
secondary structure will be disrupted [23]. There are several factors that can affect the 
ATR spectra. A number of these parameters are fixed such as the angle of incidence 
of the infrared radiation and the length of the crystal. Other factors include the need 
for regular background spectrum and good contact between sample and the surface of 
the IRE, but this is not a problem with liquid samples, where the liquid is in direct 
contact with the surface of the IRE. 
Water-soluble protein samples are best analysed in adequately buffered aqueous 
solutions (in 21I20, 1
-I0 or preferably both) rather than as solids or as hydrated films. 
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Unfortunately, problems still remain when studying proteins dissolved in water or 
aqueous buffers due the high molar absorptivity of the 0-H bending vibrations of 
water (-1640 cm') and problems associated with non linearity. This limits the path 
length used in studies of proteins dissolved in water to 10 p.m or less. Longer path 
lengths result in significant distortions of water absoprtions, making background 
subtraction impossible. This can be overcome in ATR-FTIR as the germanium crystal 
used has an effective path length of 2.59 p.m (the internal critical angle is 22.02 0 with 
the external angle of 45 ° 
 giving the number of internal reflections as 12 and the depth 
of penetration as 0.664 Ltm). 
6.1.1 The use of FTIR in the study of amyloids 
FTIR has previously been used in the analysis of Alzheimer's disease amyloid 
proteins; changes in the S03 spectral region have been used to determine the binding 
of the congo red dye-protein complexes [343]. Other studies have used FTIR to detect 
changes in AD amyloid fragments in deuterated solvents and at various pHs [344]. In 
another study F1'IR was used in the correlation of the solubility and the 13 sheet 
structure formation of the amyloid proteins AJ3(26-33) and A13(34-42)  [107]. The 
solubility of the above fragments in various solvents such as 1,1,1,3,3,3 
hexafluoroisopropanol (HFIP), 2,2,2, trifluoroethanol (TFE) and deuterated water has 
been determined by Vf JR. The A13(26-33) in deuterated water and HFIP and 
A13 (34-42) in HFIP reveals a broader amide I band centred around 1650 cm 1 
indicative of a random coil or alpha helix formation. 
The formation of amyloid gel aggregates leads to a band at 1625 cm t , which is 
indicative of 13 sheets, demonstrating that precipitation is linked to the formation of 13 
sheets. Fragments Af3(34-42) in deuterated water also show positions of the amide I 
band at 1625 cm' and the weak absorption band at around 1700 cm 1 are 
characteristic of antiparallel 0 sheet structures, indicating that the amyloid fragments 
are predominantly 0 sheet. Solid state ETIR also reveals the A13(34-42) to be a P sheet 
structure [107]. The FTIR of A13(lI-25) shows that it exists as predominantly 13 sheet 
at pH 3 to 8 similar to the A13(1-40). A substitution of the histidines at position 13 and 
14 of the A13(1-28)  fragment showed less 0 sheets at all pHs indicating that histidines 
are involved in the 13 sheet formation or stabilisation [344]. Again, the different 
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peptide environments illustrate the difficulty in comparing the results between the 
various studies. A detailed discussion of the effects solvent and pH conditions on in 
vitro studies can be found in ChapterS, section 5.1.2.1. 
6.1.2 The present study. 
The present study investigated amyloid proteins treated with metals and 
glycosaminoglycans using a novel ATR-FTIR method. The synthetic amyloid 
peptides used were synthetic A13(l -40) , A13 (l -42) and  Al3 (l -43 ) peptides, as found in 
senile plaques in the brains of Alzheimer's disease sufferers. The extracted amyloid 
protein from Alzheimer's disease brains and the synthetic 02 microglobulin, as found 
in dialysis related amyloidosis, were also investigated. The changes in the protein 
secondary structure were detected using ATR-FTIR spectroscopy. 
The system developed here used an acetate 'cover-slip' to minimise the sample 
volume needed to cover the germanium crystal surface. The system is 'open' and the 
sample may be prone to evaporation. The total time for each analysis was 
approximately 10 minutes, which was short enough so as to prevent evaporation of 
the sample in the tris buffer. The solvent used in the ATR study contained only tris 
buffer (10 mM, pH 7.4), where as, tritluoroethanol would evaporate during the short 
sample analysis time. Again, we are measuring the changes in the secondary structure 
from the initial conformation in the isis buffer. Further spectral deconvolution was 
necessary for the determination of the percentages of secondary structures, but this 
was not possible with the current system. However, much information can be obtained 
by monitoring changes within the spectra for individual peptides. The tris buffer itself 
would have a different effect on the overall ratios of a helix and 0 sheet secondary 
structures of the proteins compared to the tris/TFE buffer used in the CD experiments. 
Therefore, the overall changes in the amyloid secondary structure, rather than absolute 
values were compared between the results of the CD studies and ATR studies. 
6.1.3 Method. 
Experimental methods, instrumentation and reagent details are given in Chapter 2, 
section 2.5. 
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6.2 Results. 
The developed ATR method used a strip of acetate that covered the sample on the 
germanium crystal. The sample was sandwiched between the acetate and the IRE 
surface much like a cover slip on a glass slide, thus reducing the sample volume to 15 
M1 • It is necessary to obtain regular buffer spectra as the subtraction of the sample 
spectra from the buffer spectra is prone to discrepancies due to the presence of air and 
water vapour as the system is 'open'. The tris buffer (10 mM, pH 7.4) used was not a 
deuterated buffer as the small path lengths of the ATR system meant that water was 
not totally absorbing. 
6.2.1 Validation of the ATR system. 
Cleaning of the ATR element is also important as protein may adsorb onto the surface 
of the crystal and add to successive spectra. Figure 6.1 shows that cleaning with 10% 
SDS was necessary to remove all the adsorbed protein. The protein may adsorb onto 
the crystal surface and this would contribute to the next spectrum. After several 
sample runs the protein may not be removed by cleaning with ethanol and rinsing 
with water, but is completely removed with a detergent. The total time for each 
analysis was approximately 10 minutes and the protein concentration (I mg mF') was 
low enough so as to prevent adsorption onto the crystal surface within this time. 
The validation of any technique is important for quantitative work. Figure 6.2 shows 
the reproducibility of the method. Running four replicate samples of bovine serum 
albumin (BSA, I mg mr') in tris buffer (10 mM, pH 7.4) to test the reproducibility. 
The spectra were obtained independently and on different days. The buffer spectrum 
were subtracted and the spectrum were normalised to the maximum peak intensity of 
amide 1(1600 - 1700 cm'). The overall standard deviation was calculated to be 
0.0035 absorbance units. It is necessary to take into account the overall error; 
therefore, any changes must be greater than 0.003 absorbance units. 
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Figure 6.1. 
- Spectra of BSA (1 mg ml'), after cleaning with ethanol and after 
cleaning with SDS (10% w/v) and ethanol. Cleaning the AIR crystal with 10% SDS 
and with ethanol is necessary is to remove all traces of protein adsorbed onto the IRE. 
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Figure 6.2.- The reproducibility of the ATR system was determined by independently 
running four replicate samples of bovine serum albumin (BSA, I mg mId). 
 Spectra 
were normalised to the maximum peak intensity of amide I bands of BSA. 
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6.2.2 Second derivative spectra. 
AIR-FUR has been shown to be useful for studying the secondary structure and other 
properties of proteins in a variety of matrices [27, 337 - 342]. The secondary structure 
of these proteins can be determined by infrared. Bands can be assigned in accordance 
with the particular physical arrangements of the amide bonds within the protein 
backbone. For example, the major amide I bands of 3 pleated sheets contain an 
intense absorption at 1620 to 1630 cm and a weaker high frequency band at 1685 
cm4 , while random structures display broader spectra with a maximum centred 
around 1640 cm* These bands contribute to the overall spectral envelope. 
Most of the absorption band positions are easily found in second derivative spectra. 
Some difficulty arises in absorption bands showing as shoulder peaks in the second 
derivative. Information about frequency position, width, maximum intensity can be 
obtained from second derivative spectra but in practice are inaccurate due to 
neighbouring absorption bands. However, the second derivative spectra are more 
useful to assign absorption bands, as the derivative spectra will exactly show the 
positions of all the true absorption bands. The downward peaks corresponding exactly 
to the wavenumber of the component absorption band. 
The second derivative spectra for each of the proteins are shown in Figure 6.3. The 
frequency range for the secondary structures as calculated by second derivative is 
given in Table 6.1. The ranges shown next to the secondary structural types are the 
values that are quoted in the literature [23 & 24]. 
Structure and amide I frequency Aj3(1.40) A(1.42) A(1-43) Extract I3M 
Anhiparallel3sheets (1675.1695) 1683 1685 1678 1680 1684 
cihelix (1648.1660) 1650 1649 1648 1648 1655 
Random (1640.1648) 1638 1640 1638 1635 1644 
sheet (1625.1640) 1628 1630 1630 1627 1634 
Aggregateclstrands (1610.1628) 1611 1615 1610 1612 1616 
Table 6.1 
- The wavenumber of the absorption bands corresponding to the secondary 
structural features as calculated by the second derivative spectrum of amyloid 
proteins. 
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The second derivative spectrum of amyloid proteins of (a) AJ3(1-40), (b) AJ3(1-42), 
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/ 	 (0 	 (0(00(0 	
'. 	
U) 	 01 	 00") 
0.12 
0.1 
0.08 
0 
U 
0.06 
n 
0.04 
0.02 
0 
1800 	 1750 	 1700 	 1650 	 1600 	 1550 	 1500 
Wavenumber (cm) 
0.12 
0.1 
0.08 
0.06 
0.04 
0.02 
0 
1800 	 1750 	 1700 	 1650 	 1600 	 1550 	 1500 
Wavenumber (cm 4 ) 
1800 	 1750 	 1700 	 1650 	 1600 	 1550 	 1500 
Wavenumber (cm 4 ) 
U) t tO (e) 	 o OOO 
0.12 
0.1 
o 0.08 
a 
0.06 
0.04 
I 
1800 	 1750 	 1700 	 1650 	 1600 	 1550 	 1500 
Wavenumber (cm-1) 
	 162 
1800 	 1750 	 1700 	 1650 	 1600 	 1550 	 1500 
Wavenumber (cm 1 ) 
The main absorption bands corresponding to the various secondary structures are 
present. There are small shifts in the positions of the absorption bands comparing all 
the proteins. There was a maximum shift of about 5 cm, which maybe accounted for 
by effects such as side chains of the peptides and solvent interactions. 
The second derivative spectra can give some indication of relative peak intensities of 
the individual absorption bands within the spectral envelope. Both the absorption 
bands at 1680 cm and 1610 cm 1 are difficult to assign. The antiparallel P sheets at 
1680 cm4 are weak as seen in the second derivative spectra in Figure 6.3. This 
component is normally weak and is often overlapped by absorption from f3 turn and 
unordered structures. The absorption bands around 1610 cm 4 correspond to denatured 
aggregated strands but the range is also within the P sheet assignment and is difficult 
to interpret. 
The precise percentages of secondary structure have not been calculated as this would 
require the use of curve fitting programs such as Gaussian curve fitting, which was 
not possible with the current system and software used. It should be noted that due to 
overlap of the secondary structural envelope, the direct calculation of secondary 
structures is not possible by absorbance measurements alone. A change in one 
component may cause an overall change in the spectral envelope and may mask 
changes of other secondary structure. Therefore, the absolute absorbance values 
assigned to particular secondary structures should be treated with caution without 
analysis by curve fitting programs. However, monitoring of the changes in position 
and intensity of the amide I bands gives an indication of the conformational changes 
within the protein. Spectra of peptides treated with metals can be directly compared 
with the native peptide spectra. The changes in the peak intensities within the base 
spectra can be used to empirically follow any changes in the secondary structures due 
to interaction with the metals. 
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6.23 Amyloid peptides. 
The comparison of ATR spectra of amyloid proteins A1 3 ( 1-40), A13 (l -42) ,  A(1-43) 
and AO extract from Alzheimer's disease brain and 02M are shown in Figure 6.4. The 
table shows the relative intensities of the amide I absorption bands corresponding to 
the secondary structural features. Little can be said about the various ratios of 
secondary structure between the different amyloid peptides. Further spectral 
deconvolution is necessary for the determination of the percentages of secondary 
structures, but this was not possible with the current system. However, much 
information can be obtained by monitoring changes within the spectra for individual 
peptides. 
6.2.4 Amyloid proteins treated with metals. 
The amyloid proteins treated with metals are shown in Figure 6.5. AJ3(l-43) treated 
with Cu 2 caused a decrease in a helix and 3  sheet and an increase in random 
structures (Figure 6.5a). A13( 1-42) treated with both Cu 2 and Zn2 showed a decrease 
in a helix and P sheet with an increase in random structures, albeit small changes 
(Figure 6.5b). The extracted protein treated with zinc caused a decrease in a helix 
and an increase in both random coil and fi sheet (Figure 6.5c). Afl( 1-40) treated with 
Cu2t Zn2 and Ca2 show a decrease in a helix and random structures with increases 
in 13 sheet. There was also a shoulder developing at about 1660 cm 1 that may be 
associated with 0 turns (Figure 6.5d). 02M with Cu 2 , Zn2 show a decrease in a 
helix but an increase in both 13 sheets and random structures. Whereas calcium caused 
an overall decrease in 13 sheet and increases in both random and a helix structures 
(Figure 6.5e). 
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Figure 6.4 
Comparison of AIR spectra of; A3(I-40), AJ3(1-42), Af3(I-43), Af3 extract and W. 
The relative intensities of the amide I absorption bands corresponding to the 
secondary structures are shown below. 
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Figure 6.5a 
The Af3(l-43) peptide treated with CaCl2, Cud2, and ZnCl 2 (tOO jiM). The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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Figure 6.5b 
The Aj3(1-42) peptide treated with CaCl2, Cud2, and ZnCl 2 
 (100 jiM). The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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Figure 6.5c 
The A13  extract treated with CaCl2, CuCl2, and ZnCl2 (100 piM). The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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Figure 6.5d 
The AJ3(1-40) peptide treated with Cad2, Cud2, ZnCl2, and MgC12 (100 jiM). The 
relative intensities of the amide I absorption bands corresponding to the secondary 
structural features are shown below. Shaded values are changes greater than 0.003 
absorbance units. 
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Figure 6.5e 
The 132M peptide treated with CaCl2, CuCl2, ZnCl2, and M902  (100 j.M). The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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6.2.5 Amyloid proteins treated with aluminium. 
The effect of increasing A1 3 on the Aji(l-43), A13(l -42) and Au extracted peptides 
are shown in Figure 6.6. A1 3 
 seems to have little effect on A13(l -43 ), A13 (l -42) and 
the extracted amyloid as indicated by small changes in the peak intensities. There was 
a small increase in 0 sheet with both Af3(1-42) and AI3 ( 1-43) treated with 300 plY! 
A1 3 (Figure 6.6a and Figure 6.6b). Af3( 1-40) with increasing concentration of A1 3 
caused an overall increase in random and P sheet with a decrease in a helix (Figure 
6.7a1). 32M, on the other hand, showed similar changes to that of the AJ3(l-40) but to 
a lesser extent. Addition of increasing concentration of A1 3 caused a small increase in 
P sheet and decreases in a helix (Figure 6.7b1). 
6.2.6 Amyloid proteins treated with both aluminium and silicon. 
A13 (l -40) with increasing concentration of A1 3 caused an overall decrease in a helix 
and increases in both random and f3 sheet. Addition of silicate with the A1 3 treated 
peptide caused a slight reversal in the changes due to AI 3 (Figure 6.7a2). 32M also 
showed similar changes with A1 3 with small increases in 3  sheet and decreases in a 
helix. Addition of silicate seemed to have little effect on the treated peptide (Figure 
6.7b2). 
6.2.7 Amyloid proteins treated with glycosaminoglycans and calcium. 
Treatment of peptide with GAGs combined with calcium is shown in Figure 6.8. 
A13(l -40) treated with HSPG and HS caused a small decrease in a helix. Calcium had 
the effect of increasing 0 sheets and decreasing random structures (Figure 6.5d) but 
combination of the GAGs with calcium had the effect of reducing the P sheet but 
increasing the random coil structures (Figure 6.8a). The GAGs with 132M caused 
small increasing in the a helix and 0 sheet. As shown in Figure 6.5e, calcium had the 
effect of increasing random structures but when combined with GAGs caused an 
increase in 0 sheet and a decrease in a helix (Figure 6.8b). 
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Figure 6.6a 
The A3(1-43) peptide treated with AId3 (50, 150, 300 and 400 .tM); The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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Figure 6.6b 
The Af3(I-42) peptide treated with AId3 (50, 150, 300 and 400 jiM). The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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Figure 6.6c 
The AJ3 extract treated with AICI3 (50, 150, 300 and 400 jiM). The relative intensities 
of the amide I absorption bands corresponding to the secondary structural features are 
shown below. Shaded values are changes greater than 0.003 absorbance units. 
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Figure 6.7a1 
The AJ3(1-40) peptide treated with AId 3 
 (50, 150, 300 and 400 p.tM). The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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Figure 6.7a2 
The A3(1-40) peptide treated with AId3 (150 and 300 tM) with Si04 4 (300 1.tM). The 
relative intensities of the amide I absorption bands corresponding to the secondary 
structural features are shown below. Shaded values are changes greater than 0.003 
absorbance units. 
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Figure 6.7b1 
The 132M peptide treated with AId3 (50, 150, 300 and 400 jiM). The relative 
intensities of the amide I absorption bands corresponding to the secondary structural 
features are shown below. Shaded values are changes greater than 0.003 absorbance 
units. 
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Figure 6.7b2 
The 02M peptide treated with AId3 (150 and 300jiM) with Si04 4 (300 IIM). The 
relative intensities of the amide I absorption bands corresponding to the secondary 
structural features are shown below. Shaded values are changes greater than 0.003 
absorbance units. 
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Figure 6.8a 
The Af3(l-40) peptide treated with heparan sulphate (HS) (500 ig ml') and heparan 
sulphate proteoglycan (HSPG) (500 ig ml') also combined with CaCl2 (100 j.M) The 
relative intensities of the amide I absorption bands corresponding to the secondary 
structural features are shown below. Shaded values are changes greater than 0.003 
absorbance units. 
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Figure 6.8b 
The 13 2M peptide treated with heparan sulphate (HS) (500 gig mY') and heparan 
sulphate proteoglycan (HSPG) (500 gig mY') also combined with CaCl2 (100 jiM). 
The relative intensities of the amide I absorption bands corresponding to the 
secondary structural features are shown below. Shaded values are changes greater 
than 0.003 absorbance units. 
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6.3 Summary of results. 
The following tables show a summary of all the results. 
A(1-40) a helix Random sheet 
Qj(lOOuM) 
 
Zn(lOOpM) 
 
Ca(lOOpM) 
 
M90001M - - - 
M(SOiM 
 
M(I5OMM 
 
Al(300piM) U tt t 
A1(400pM) 
 
Si(30001) - - - 
Si(300IJMYAI(lSOuM) - - - 
Si(3OOMjA1(3OOpM) 
- I - 
HSPG(SOOpgml) - - - 
HS(SOOpgml4) - - - 
HSPG(SOOjigniF'YCa(lOOpM) 
 
HS(5OOgniF'Ca(10OM) 
 
Table 6.2a - Experiments with A13 ( 1-40), the differences from the native peptide are 
indicated by: t (>0.03 absorbance units), 11' (>0.06 absorbance units) and TTT (>0.1 
absorbance units). 
a helix Random sheet 
cucloottM) I tt 'F 
Zn(lOOuM) 
 
Ca(1OOM) 
 
Mg(1OO - - - 
M(5OpM - - - 
M(15OpN - - - 
M(30OMM 
 
M(4OOjM I 'F I 
Si(300pM) - - - 
Si(3OOjaMA1(I5OpM) - - - 
Si(3OOpMA1(3OOjaM) - - - 
HSPG(50Oagmr') - 
- 'F 
HS(500pgmF') - 
- 'F 
HSPG(SOOpgmF')/Ca(lOOjjM) U - 'Ft 
HS(Soopagp(yCa(lOOgM) 
- t 'Ft 
Table 6.2b - Experiments with 132M, the differences from the native peptide are 
indicated by: 'F (>0.03 absorbance units), 'F (>0.06 absorbance units) and TTT  (>0.1 
absorbance units). 
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AB(1-43) 	 a helix 	 Random 	 B sheet 
Qz(lOOpM) 14 t 14 
Zn(lOOpM) 1 - - 
Ca(lOOpM) t It I 
A1(SOpM) - 4. - 
M(15OpM - 4. - 
M(300pM - 14 t 
Al(400pM) t II. t 
Table 6.2c - Experiments with Af3(1-43), the differences from the native peptide are 
indicated by: T (>0.03 absorbance units), tt (>0.06 absorbance units) and TTT (>0.1 
absorbance units). 
AB(1-42) 	 a helix 	 Random 	 B sheet 
cu(loOpM) 	 - 	 4. 	 - 
Zn(lOOpM) 	 14 	 1 	 It 
Ca(10OpM  
M(SOp1'U 	 - 	 - 	 - 
M(15OpM 	 - 	 - 	 1 
A1(3ooe 	
- 	
- 	 I 
M(400pM 	 It 	 - 	 - 
Table 6.2d - Experiments with A13(1-42),  the differences from the native peptide are 
indicated by: T (>0.03 absorbance units), TT (>0.06 absorbance units) and TTT (>0.1 
absorbance units). 
Exind 	 a helix 	 Random 	 B sheet 
ui(1ooixrv - 	 1- 	 - 
Zn(lOOpM) .14 	 1 	 Ii' 
Ca(1OOpM  
Al(SUpM)  
M(I50pM - 	 - 	 - 
AJ(3OOxM) - 	 - 	 - 
Table 6.2e - Experiments with Afi extract, the differences from the native peptide are 
indicated by: I (>0.03 absorbance units), II (>0.06 absorbance units) and TTT (>0.1 
absorbance units). 
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6.4 Discussion 
The novel use of ATR-FTIR in the analysis of metals with amyloids has been 
demonstrated for the different amyloid peptides Af3(l-40), A1 3(l -42), Af3(l-43), the 
AJ3 extract from Alzheimer's disease brain and 02M. The developed method used an 
acetate 'cover-slip' to reduce the sample volume. The technique of ATR-FTIR has not 
been previously used to detect changes in the secondary structure of the amyloids 
treated with metals. Further spectral deconvolution is necessary for the determination 
of the percentages of secondary structures. However, much information can be 
obtained by monitoring changes within the spectra for individual peptides. 
It should be noted that the buffer used in the ATR experiments only contained tris (10 
mM, pH 7.4). The buffer used in the CD experiments contained trifluoroethanol, 
which stabilises a helices. Therefore, any changes in the secondary structures are 
more pronounced in CD especially if the a helices are altered. Also, the ATR method 
is less sensitive because of the inherent high absorbance of water. The different 
protein environments between the ATR and CD studies could account for any 
differences in the results or it may be the case that the ATR method is not sensitive 
enough to detect these changes. 
6.4.1 Amyloid proteins treated with metals. 
Most of the metals had the effect of decreasing a helices in all of the amyloids except 
A13 (l -43 ). The changes are small for the treatment of metals with A13(1-43).  With 
Cu2 and Zn 2 
 with the Af3(l-40) and the 02M, there was a redistribution of a helices 
to 3  sheets and random coil secondary structures. These results are similar to those 
obtained in the CD spectra in Chapter 5, section 5.2.3, where there was also a 
decrease in a helices and an increase in 0 sheets with A(l-40) and 132M treated with 
Cu2 and Zn2t 
Zn 2 and Cu2 ions have been implicated in both Aj3 aggregation and neurotoxicity 
and have both been shown to cause aggregation of A13  peptide in vitro [333 & 333]. 
Aj3 preferentially and saturably binds Zn 2 [3311, and induces synthetic A13 
aggregation in a pH-dependent and reversible manner [238, 332, 333, 345-347]. 
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Copper is able to stabilise the formation of dimers of A13(l-40) as observed with 
affinity gel chromatography [331]. The A13(l-40) has both Cu 2 and Zn 2 binding sites 
and both can simultaneously bind [331 & 336]. Metal mediated radical damage of Afi 
has been suggested as a causative agent for A1 3  neurotoxicity [348-350]. 
6.4.2 Amyloid proteins treated with aluminium and silicon. 
Addition of A1 3 increased the 0 sheets with a decrease a helix with both the A13(1-
40) and f32M and similarly there were no significant changes with both the A1 3(l -43 ) 
and Af3( 1-42). In the CD work in Chapter 5, section 5.2.4., there was also a general 
decrease in a helices with an increase in 13 sheets with both the A13(l-40) and I32M. 
Similar changes to that of the CD results (Chapter 5, section 5.2.5) were also 
observed with the A13(l-40) with A13* and Si0 44 . Addition of the silicate caused a 
reversal in the changes due to A1 3 itself. Therefore, interaction of Si0 44 and A1 3 to 
form aluminosilicates may mean less available soluble aluminium for interaction with 
the proteins. 
It has been suggested that the binding of A1 3 to A13 peptide [351] and tau proteins 
[352] results in the formation of senile plaques and neurofibrillary tangles as observed 
in AD brains. [264] Aluminium can promote the phosphorylation and aggregation of 
tau proteins and also induce the aggregation of conformationally modified Af3 peptide 
in vitro [353]. Amino acid-Al complexes such as D-Asp-Al and L-Glu-Al induce a 
larger random coil conformation in the A13 peptide than the free A1 3 [278]. The 
putative toxicity of amyloids can be mediated by aluminium, aluminium silicates, 
and/or metal catalysed oxidative damage resulting in increased risk for premature 
amyloid deposition [94]. 
6.4.3 Amyloid proteins treated with GAGs and calcium. 
There were some slight differences in the ATR results compared to those from the CD 
work in Chapter 5, section 5.2.6-5.2.9. The A13(l-40)  with HSPG or HS and Ca2 
caused decreases in a helices and a redistribution to both random coil and 0 sheet, 
which was also seen in the CD. For 02M, the CD showed that with combined calcium 
and HSPG and HS, there were further decreases in a helices and 13  sheets with 
increases in random coil. The ATR showed that these combinations of GAGs and 
Ca2 
 with 02M caused a decrease in a helices but with an increase in 3 sheets and 
random coil. There was, however, a common decrease in a helices as seen in both 
studies. This still highlights the fact that combinations of GAGs and metals had 
additive effects compared to the GAGs or Ca 2 on its own. 
Very specific high affinity interactions have been shown to occur between the HSPG 
and the various forms of the Alzheimer amyloid precursor protein [354]. The GAGs 
may bind to the region of Hisl3-Lysl6 of AP between two neighbouring filaments. In 
this way, the ultrastructure of the fibres would be maintained and the stability 
enhanced. GAGs could affect the nucleation and propagation of these fibres by 
stabilising the tertiary structure and inter-sheet interactions [355] and may serve as an 
anchor for fibril organisation [315]. 
6.5 Conclusion. 
A novel technique for reducing the volume of sample required for the ATR-FTIR 
system has been demonstrated. The detection of amyloid treated with metals as seen 
with ATR-FT'IR was similar to the results of the CD work. In the ATR study, the 
addition of copper, zinc, calcium and aluminium (>100 jiM) to the amyloid proteins, 
in particular the Af3(1-40) and 132M, showed some changes with a general decrease in 
a helix and an increase in 0 sheet, though the results with the P2M  were smaller. 
Although no interaction between GAGs and the amyloids was seen, the binding of the 
GAGs could provide an anchor for the assembly of the fibrils or could allow binding 
of other factors such as metal ions leading to subsequent aggregation and amyloidosis. 
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Chapter 7. Polyacrylamide gel electrophoresis of amyloid 
proteins treated with metals. 
7.1 Introduction. 
Polyacrylamide gel electrophoresis (PAGE) is a useful technique for the separation 
of proteins with a net charge by the differential movement of the protein gel under an 
electric field. The polyacrylamide gel consists of uniform sized 'pores' formed from 
the polymerisation of acrylamide and methylenebisacrylamide. The mixture of 
proteins is denatured by first dissolving it in a solution of sodium dodecyl sulphate 
(SDS), that disrupts nearly all non-covalent interactions in native proteins, treatment 
with dithiothreitol to break disulphide bonds. The SDS coats the protein giving an 
overall negative charge, which is much greater than the charge of the native protein; 
thus separation is solely due to mass under denaturing conditions. The mobility of 
most polypeptide chains under these conditions is linearly proportional to the 
logarithm of their mass. 
7.1.1 The use of PAGE in the study of amyloids. 
SDS PAGE has been used extensively for the analysis of various amyloids and the 
determination of extracted amyloid proteins. It is an indispensable analytical tool for 
purification, detection, characterisation and determination of the molecular weight of 
the isolated amyloid protein [356]. SDS PAGE has been used in the extraction of 
Alzheimer's disease fi amyloid [294, 356-359] and also in the extraction of 132M 
from amyloid laden tissues [157, 167, 360-362]. The proteins are usually run on the 
polyacrylamide gels of uniform concentration (15-17%) or of linear gradient 
concentration (from 5% to 20%), using a continuous buffer system containing 0.025 
M tris, 0.192 M glycine and 0.1% SDS [363]. Other techniques including the use of 
continuous buffers such as Ens phosphate [363], and tricine (instead of glycine) and 
the use of discontinuous buffers systems such as tris-glycine [364], tris-tricine [365], 
trisbicine [366] and urea [367 & 368] have all been used in different amyloid studies. 
Western blotting has also been extensively used for the immuno-detection of 
amyloids and has been shown to be effective for the determination of the type and 
size of amyloid proteins when using the appropriate antibodies raised against 
different amyloid fibril proteins and their precursor proteins [356]. Two-dimensional 
PAGE has also been used to detect the presence of two or more acidic isoforms of 
02M with p1 coordinates (5.3-5.7) [157 & 356]. More specifically SDS PAGE has 
been used in the study of amyloids treated with aluminium. Aluminium was revealed 
to promote the aggregation of synthetic amyloid 3-protein Aj3(l-40) using 
immunoblotting and centrifugation [369 & 370]. Aluminium also caused aggregation 
of human recombinant amyloid precursor protein (APP) as investigated with SDS-
PAGE [370]. 
7.1.1 The present study. 
The present study investigated amyloid proteins treated with metals and 
glycosaminoglycans. Experiments showing the effect of metals on the charge and 
electrophoretic mobility of the amyloid peptides were carried out using gel 
electrophoresis. Any changes such as aggregation, fibril formation etc were detected 
using SDS PAGE. The synthetic amyloid peptides used were A1 3 ( 1-43 ), A13 ( 1-42), 
A13 ( 1-40) peptides, as found in senile plaques in the brains of Alzheimer's disease 
sufferer. The A13 extracted peptide and the synthetic 132 microglobulin, as found in 
dialysis related amyloidosis, were also used. 
7.1.2 Method. 
Experimental methods, instrumentation and reagent details are given in Chapter 2, 
Section 2.6. 
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7.2 Results. 
7.2.1 Af3(1-40) treated with metals. 
The SDS-PAGE results of A13(l-40)  amyloid protein treated with AICI3 0  mM), 
Cud2 (1 mM), ZnC12 0  mM), CaCl2 0  mM) and MgCl2 (1 mM) are shown in 
Figure 7.1. The A13(l-40)  was seen at 4.3 kDa corresponding to the monomer. The 
addition of the metals, with the exception of aluminium, did not affect the 
electrophoretic mobility of the A13(I-40)  as seen in SDS PAGE. Aluminium caused 
a smearing of the band with a possible formation of the dimer of A13(  1-40). 
7.2.2 A13(1-40)  treated with aluminium. 
The A(1-40) amyloid protein treated with increasing concentrations of Al 3 (12.5, 
25, 50, 150, 300 and 400 j.tM) are shown in Figure 7.2. These concentrations are 
lower than the concentration used in the previous experiment with A13(  1-40). These 
samples were run both with SDS and natively with no SDS. The SDS PAGE in 
Figure 7.2a show that treatment with increasing AI 3 did not have any affect on the 
A13 ( 1-40). The non SDS treatment of the samples gave a PAGE as shown in Figure 
7.2b. The bands show an elongation with a greater degree of smearing with higher 
concentration of A1 3t 
7.2.3 A13(1-40)  treated with GAGs and metals. 
The Figures 7.3 and Figure 7.4 show the SDS PAGE of A(l-40) treated with 
various GAGs and combinations of GAGs with metals. There were no visible 
changes in the mobility of A(l-40) with any of the combinations of GAGs and 
metals. 
Figure 7.1 
The A13(l-40)  amyloid protein treated with A1 3 (1 mM), Cu 2 (I mM), Zn 2 (1 mM), 
Ca2 (l mM) and Mg 2 (1 mM). The molecular weight markers are shown in the left 
lane. 
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-H irb 
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1 	 2 	 3 	 4 	 567 
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1 MW markers 
2 Af3(l-40) 
3 Af3(1-40) + A1 3 (l mM) 
4 AF3(1-40)+Cu2(l mM) 
5 A3(1-40) + Zn 2 (l mM) 
6 A13(l-40) + Ca2 (l mM) 
7 Aj3(I40)+Mg2 (1 mM) 
IM 
Figure 7.2 
The A13(l-40)  amyloid protein treated with increasing concentrations of AI 3 (12.5, 
25, 50, 150, 300 and 400 jtM). These samples were run both (a) with SDS and (b) 
non SDS, i.e. natively run. Both the gels were processed with silver staining. The 
molecular weight markers are shown in the left lane. 
(a) Gels run in (b) 
this direction 
26,600kDa 
S 	 17,000kDa  
14,200kDa 
 
6,500kDa 0 
OS S S 
1234567 	 1234567 
Lane Sample 
1 A13(1-40) 
2 A13(1-40) + Al (12.5 MM) 
3 A13 ( 1-40)+Al(2SMM) 
4 A13(1-40) + Al (50 MM) 
S A13(1-40) + Al (ISO MM) 
6 A13(1-40) + Al (300 jiM) 
7 A3(I-40) + Al (400 MM) 
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Figure 7.3 
The AJ3(I-40) amyloid protein treated with (a) heparan sulphate, (b) heparan 
sulphate proteoglycan and (c) dermatan sulphate with Ca 2 (100 jiM), Cu2 (100 
jiM), A1 3 (300 jiM), Si044 (300 jiM) and A1 3 (300 jiM) with Si044 
 (300 IIM). 
TLe- 
(c) 
	
r n 	 M± 
2 	 3 	 4 	 5 	 6 	 7 	 8 
Lane 	 Sample 
1 	 A13(1-40) 
2 	 A(1-40) + GAG (500 jig mF') 
3 	 A3( 1-40) + GAG (500 jig mF') 
4 	 Aj3(1-40) + GAG (500 jig mr') + Ca2 (100 jiM) 
5 	 A13(1-40) + GAG (500 jig m1') + Cu 2 (100 jiM) 
6 	 Af3(1-40) + GAG (500 jig mF') + A1 3 (300 jiM) 
7 	 A13(1-40) + GAG (500 jig mF') + A1 3 + Si044 (both 300 jiM) 
8 	 A13(1-40) + GAG (500 jtg mF') + Si044 (300 jiM) 
(a)  
(b)  
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Figure 7.4 
The AI3(  I -40) amyloid protein treated with heparan sulphate, heparin and Na 2SO4 
with Ca2 (100 RM). The molecular weight markers are shown in the left lane. 
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7.2.4 132M treated with metals. 
The 132M amyloid protein treated with AI 3 , Cu2t Zn 2t Ca2 and Mg2 (1 mM) are 
shown in Figure 7.5. The 132M was seen as a band at 12 kDa corresponding to the 
monomer. The addition of the metals, with the exception of A1 3t did not affect the 
32M in SDS PAGE. A1 3 
 caused a smearing of the band with a possible formation of 
the dimer (24 kDa), and higher aggregates of 13 2M. This result is similar to that of the 
A13 ( 1-40 ) (Figure 7.1). There were no effects with Cu 2t Mg2 , Ca2 or Zn 2t 
7.2.5 02M treated with aluminium and with aluminium and silicon. 
The 132M peptide treated with increasing concentrations of A1 3 (25, 50, 150, 300 and 
400 RM) and mixtures of A1 3 with silicate are shown in Figure 7.6. These samples 
were run both (Figure 7.6a) with SDS and (Figure 7.6b) natively. The SDS PAGE 
in Figure 7.6a show that treatment with increasing A1 3 did not have any affect on 
the 132M and may indicate a concentration as well as a time dependent effect. There 
were feint high molecular weight bands near the top of the gel, which may be related 
to the 32M samples or may be due to artefacts in the experiment. There was no other 
high molecular weight protein in any of the samples, which indicates that the bands 
may be very high molecular weight polymers of the f32M or aggregates. 
Non SDS treatment of the samples gave a PAGE as shown in Figure 7.6b. Lanes 3, 
4, 5, and 6 show two bands with Al 3 (50, 150, 300 and 400 jiM) which correspond 
to dimers of the P2M. There was a greater conversion of monomer to dimer with 
increasing A1 3 
 as seen by increasing intensity of the higher molecular weight bands 
and decreasing intensity of the monomer band. Addition of a higher concentration of 
silicon abolished this higher molecular weight band with a reversion back to the 
monomer as seen in lane 9. 
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7.2.6 Two dimensional PAGE of 02M treated with aluminium. 
A further experiment was performed with the aluminium treated J32M sample. A two 
dimensional electrophoresis gel was run with the 132M treated with aluminium (300 
jiM). The 02M peptide (85 j.tM) was treated with aluminium (300 jiM) and allowed 
to incubate at room temperature for 1 hour. The first dimension was run as an 
isoelectric focused gel. In 2 dimensional, the first tube gel was carefully removed 
and was laid on top of the second dimension gel and was run as an SDS PAGE gel. 
The two dimensional gels showed no bands except one spot corresponding to the 
13 2M itself indicating that no dimers or other isoforms were present (results not 
shown). 
7.2.7 32M treated with GAGs and metals. 
The Figures 7.7 and 7.8 show the SDS PAGE of W  treated with various GAGs 
and combinations of GAGs with metals. There were no visible changes in the 
mobility of 02M with any of the combinations of GAGs and metals. This may be due 
to the fact that the samples have not been allowed to incubate long enough. 
7.2.8 A3(1-42) and A(1-43) treated with metals and with silicon. 
The Figures 7.9 and 7.10 show the SDS PAGE of A3( 1-42) and AJ3( 1-43) treated 
with various metals and combinations of aluminium and silicon. There were no 
visible changes in the mobility of the amyloids with either the metals or any of the 
combinations of aluminium and silicon. 
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Figure 7.5 
The 132M  amyloid protein treated with AId3 0  mM), Cud12 (1 mM), ZnCl2 (1 mM), 
CaCl2 (1 mM) and M902 (1 mM). The molecular weight markers are shown in the 
left lane. 
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7 32M+Mg2 (1mM) 
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Figure 7.6 
The 02M treated with increasing concentrations of A1 3 (25, 50, 150, 300, and 400 
MM) and with Si0 44 (100 and 300 MM) run (a) with SDS and (b) natively. Gels were 
processed with silver staining. 
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132M+ A1 3 (150 MM) + Si044 (lOOjiM) 
8 132M+ A1 3 (300 jiM) + Si044 (lOOjiM) 
I3M+ A13 (300 jiM) + Si044 (300pM) 
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Figure 7.7 
The 02M amyloid protein treated with (a) heparan sulphate, (b) heparan sulphate 
proteoglycan and (c) dermatan sulphate with Ca 2 (100 tM), Cu 2 (100 MM), A1 3 
(300 MM),  Si044 (300 .tM) and AI 3 (300 .tM) with Si044 (300 jiM). 
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6 	 132M + GAG (500 Mg  mY') + A1 3 (300 MM) 
132M + GAG (500 Mg  mY') + AI 3 + S1044 (both 300 riM) 
S 	 32M + GAG (500 Mg  mY') + Si044 (300 jiM) 
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IT 
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Figure 7.8 
The f32M amyloid protein treated with heparan sulphate, heparin and Na2SO4 with 
Ca2 (100 jiM). The molecular weight markers are shown in the left lane. 
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Figure 7.9 
The A13(1-42)  amyloid protein treated with A1 3, (1 mM), Cu 2 (1 mM), Zn2 (1 
mM), Ca2 (l mM) and with A1 3 and Si044 (1 mM). The molecular weight markers 
are shown in the left lane. 
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Figure 7.10 
The A13(1-43)  amyloid protein treated with A1 3 (1 mM), Cu 2 (1 mM), Zn2 (I mM), 
Ca2 (1 mM) and with Al 2 and Si044 0  mM). The molecular weight markers are 
shown in the left lane. 
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7.3 Discussion 
Metals have been shown to induce aggregations of amyloid and accelerate amyloid 
deposition. With the exception of A1 3 , the treatment of the amyloids, including 
A13(l -42) and A13(l -43), with most of the metals and GAGs showed no change in 
mobility as determined by SDS PAGE. Incubation time is very important for the 
experiments described in this chapter. The techniques of CD and ATR-F1'IR as used 
in the previous chapters are more sensitive to the changes in the secondary structure. 
SDS-PAGE can only measure changes in the electrophoretic mobility or size of 
proteins. Therefore, these experiments were designed to have a short incubation 
period and any change in the mobility of the amyloid peptides would be due to the 
addition of metals and GAGs. It may simply be the case that a longer incubation 
period is necessary, but this may simply cause the spontaneous aggregation of the 
amyloid itself. 
7.3.1 Aged amyloid. 
The AJ3 aggregation requires conformational changes that include the formation and 
stacking of j3 sheet structures. The lag phase of the initial nucleation process could 
account for the apparent delay in onset of Alzheimer's disease. It is possible that a 
soluble toxic A13  conformation triggers a slow degenerative process that does not 
become apparent until after the peptide has proceeded to the stable aggregate stage. 
At a peptide concentration of 25 RM the solution contains essentially monomers with 
random coil structure, as evidenced by analytical ultra-centrifugation and CD 
spectroscopy. Solutions with higher peptide concentrations are characterised by 
equilibrium between random coil monomers and P structured aggregates [127]. 
Ageing may stabilise andlor accelerate this conformational change. Aggregation of 
A13  protein, has been observed in aged peptides. Incubation of A3 for 2-4 days at 
37 °C [80], and storing at 4 °C for I week [316] have been reported to cause 
spontaneous aggregation. In fact, the self-assembly into fibrils by A13  peptide 
analogues has been a major criticism of the role of GAG [371] and other factors in 
amyloidosis. 
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Therefore, since the amyloid proteins have been shown to self aggregate with time, 
the incubation period is very important for the present experiments. All the 
experiments were designed to have a short incubation period of 1 hour so that any 
changes in the peptide would be due to the added metals or GAGs rather than aged 
amyloid. It may be the case that a longer incubation period is necessary for a 
maximal effect, but this may simply cause the spontaneous aggregation of the 
amyloid itself. High concentrations of metals [369] and GAGs [315] may also cause 
greater aggregation within the short incubation time, but the physiological relevance 
of these concentrations may be questionable. The apparent ageing of synthetic 
amyloid in vitro may also be accounted for by a lag time, if the spontaneous 
formation of fibrils is via a nucleation dependent mechanism. 
7.3.2 Amyloid peptides treated with metals. 
The metals, copper, zinc calcium and magnesium (1 mM) did not appear to have any 
effect on the electrophoretic mobility of the amyloid peptides Af3(l-40), A13(I-42), 
AJ3(I-43) and 132M. A13(I -42) and AJ3(1-43) treated with combinations of aluminium 
and silicate also showed no changes in the PAGE gels. A13(I-40)  treated with 
aluminium (1 mM) was shown to cause an elongation of the SDS PAGE band with 
the possible formation of the dimer. The 132M in SDS PAGE also showed similar 
results to the A(1-40). AI 3 
 caused a smearing of the band with a possible formation 
of the dimer (24 kDa), and higher aggregates of 132M. The results for the A13(l-40) 
were similar to that of Kawahara et al. [369] although they did not test other peptides 
such as the 132M. They also found that AJ3(l-40) treated with AI 3 (1 mM) caused an 
elongation of the band with the formation of higher molecular weight bands up to 94 
kDa relating to higher order polymers of the A(1-40). 
The SDS treatment will break non-covalent bonds hence any ionic bound Al 3 will 
be removed. Therefore, the higher concentration of A1 3 (1 mM) must have 
interacted with both the A1 3(l -40) and the P2M  to form partial aggregates within the 
1 hour incubation time. It can be assumed that a high concentration of aluminium has 
altered the electrophoretic mobility of the amyloid peptides by the formation of 
dimers and trimers. Since the SDS treatment is extremely thorough, any loosely 
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bound aluminium will be stripped off the protein. The high concentration of 
aluminium in solution may interact with the SDS coated protein, thus causing the 
streaking effect. 
7.3.3 Amyloids peptides treated with an increasing concentration 
aluminium. 
The SDS PAGE of the AD(1-40)  and 132M with increasing concentration of Al 3 (up 
to 400 jiM) did not show any effects after a 1 hour incubation. This is in contrast to 
the 1 mM concentration of aluminium in the previous experiment. Kawahara et al 
[369] showed that addition of aluminium immediately before the electrophoresis did 
not alter the mobility of peptide, but caused the formation of higher molecular 
weight markers with incubation of the sample for 24 hours [369]. 
The additional incubation time may be necessary for aggregation or the formation of 
oligomers in the samples treated with lower concentrations of aluminium. Samples 
that had been left for more than one day did not run on the PAGE, they were retained 
at the top of the gel indicating, the formation of aggregates. The feint high molecular 
weight bands near the top of the gel in Figure 7.6 could be due to higher molecular 
weight aggregates of P2M. These bands could also be due to artefacts in the 
experiment. Too large a sample volume in the loading wells may mean that some of 
the protein sample runs into neighbouring wells and may give erroneous bands. 
Similar high molecular weight bands were seen in a study by Burdick et al. with 
A0(1-42) but they were attributed to gel artefacts [305]. 
The non SDS treatment of the amyloid peptide samples showed a concentration 
dependent effect with the aluminium. For the A13(  1-40), a greater degree of smearing 
was seen with the addition of higher concentrations of A1 31 . This indicates that the 
A131 directly binds the A13(l-40).  As the concentration of A1 3 increases, then the 
extent of Al 3 bound to the protein becomes greater. PAGE run under native 
conditions with no SDS treatment may be used to separate proteins according to 
charge as well as with size much like 2 dimensional electrophoresis. The smearing 
phenomena may be explained by the fact that, as the current passes through the 
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sample the aluminium was successively stripped off the protein, thereby changing 
the electrophoretic mobility of the protein. The smearing/tailing indicates that the 
A1 3 
 directly binds the Af3(l-40). The amount of AI 3 bound to the protein is 
concentration dependent, with more AI 3 being bound at a greater concentration of 
A1 3 
 (400tM). With a lower concentration of A1 3 (50 p.tM) the streaking effect was 
minimal as less aluminium was initially bound to the A3(l-40). 
With 13 2M, the non SDS treatment of the samples showed two discrete bands with 
increasing A1 3 which correspond to dimers of the P2M. Again there is a 
concentration effect with a greater conversion of monomer to dimer with increasing 
A1 3 
 as seen by the lower intensity of the monomer band with a corresponding 
increase in the intensity of dimer band. Addition of a silicate abolished this higher 
molecular weight band with a reversion back to the monomer as seen by the loss of 
the dimer band. Silicon has previously been shown to reverse the effect of AI 3 
treated A( 1-40) and 02M (see previous chapters). 
7.3.4 Two dimensional PAGE of 132M treated with aluminium 
The two dimensional PAGE of the P2M treated with Al (300 RM) only showed one 
spot corresponding to the 132M itself indicating that no other isoforms were present 
(results not shown). Reports of immunoblot analysis of SDS PAGE gels of partially 
solubilised amyloid fibrils extracted from tissue deposits have shown them to be 
composed of monomer, dimers, and higher polymers of 132M. Two-dimensional gels 
show the presence of two or more isoforms of 132M with p1 coordinates (5.3-5.7) 
[157]. Acidic forms of 132M have also been found, the presence and relevance of 
acidic 32M isoforms in the pathogenesis of 132M amyloidosis have been reported 
[167]. This is important because the above experiment was performed using 132M 
isolated from urine (Sigma, UK) and treated with metals in vitro. Other reported 
studies have shown 32M isolated from amyloid laden tissues and that may have 
already been subject to physiological processes such as proteolysis in vivo which 
leads to altered 132M. 
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7.3.5 Amyloid peptides treated with GAGs and metals. 
The combinations of GAGs with Ca 2 and Al3(1-40)  showed no visible changes in 
the mobility of A13(l -40) with either heparan sulphate or heparan sulphate 
proteoglycan. As with the A1 3(l -40), 02M treated with various GAGs and 
combinations of GAGs with metals showed no visible changes in the mobility of 
13 2M. This may be due to the fact that the samples had not been allowed to incubate 
long enough. The incubation time was 1 hour, with a longer incubation the A13(l-40) 
may aggregate as the aggregation process is time dependent. Therefore, these GAGs 
may function by enhancing the structural features that favour a 3 sheet conformation 
or by accelerating the formation of the nucleation centre. 
7.4 Conclusion. 
With SDS PAGE, aluminium was seen to cause the aggregation of both AJ3( 1-40) 
and 132M as seen by a smearing of the bands. Again this was similar to the results of 
the CD and ATR studies. With 32M, addition of a high concentration of silicate 
appeared to stop the formation of higher weight molecular with a reversion back to 
the monomer. The treatment of the amyloids with GAGs showed no change in SDS 
PAGE, as with the CD and ATR. Even if sulphate did not influence fibrillogenesis 
via conformation changes, binding of the GAGs could provide an anchor for the 
assembly of the fibrils. The high-affinity binding sites on the GAGs could then bind 
other factors such as metal ions altering the conformation and reducing the solubility 
of the peptide leading to aggregation and deposition. Highly sulphated species such 
as GAGs and the addition of sulphate ions have been reported to promote the 
aggregation of amyloid 13 protein [354]. 
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8 General discussion 
The present study involved the investigation of the effects of inorganic elements on 
the secondary structural integrity of amyloid proteins leading to aggregation and 
deposition. There is evidence in the literature for metals as trigger factors in the 
deposition of the Alzheimer's disease Af3 peptides, but not for the 02M. The current 
results show that metals with both Af3(l-40) or 132M caused an increase in the peptide 
fi sheets secondary structure and thus may accelerate amyloid deposition. Therefore, 
the data on Aji and the new data on 02M peptides indicates that metals may have an 
underlying role in the general process of amyloidosis independent of the type of 
amyloid protein involved. 
The interaction of metals in the presence of GAGs as a possible trigger factor for 
amyloid deposition has not been previously reported in the literature. The treatment of 
metals and GAGs with A13 ( 1-40) or 02M showed a synergistic interaction indicating 
that GAGs may be acting in conjunction with metals leading to the aggregation of 
amyloid peptides. The fact that similar changes occurred for the interaction of metals 
and GAGs with metals, with both the AJ3(l-40) and 132M, suggest similar mechanisms 
of interaction. 
8.1 Common features of amyloids. 
Amyloid deposits are associated with several human diseases, for example the prion 
diseases, Alzheimer's disease and dialysis-related amyloidosis. The major factor for 
amyloidosis appears to be an increase in the amount of amyloidogenic proteins, 
resulting in the deposition of aggregated amyloid. There are several suggested trigger 
factors for amyloidosis, for instance a genetic pre-disposition leading to enhanced 
susceptibility of an individual. GAGs are present as free chains and/or as intact PG 
and may be involved in the initiation or propagation of these deposits. An 
environmental component has been implicated and could involve damage from 
chemical agents such as metals [332]. Where these trigger factors interact in the 
amyloidosis pathway, and whether they act on their own or together are largely 
unknown. Although there might be various critical triggering events in the early 
stages of the disease, they seem to converge on a few characteristic final pathways in 
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the late stages of the disease. It appears that a possible common mechanism involves a 
nucleus formation with subsequent seeding. External factors may be important as they 
may accelerate the initial formation of fibrils necessary for seeding to occur and/or 
promote the subsequent polymerisation. 
The characteristic feature of the amyloid deposits is a large quantity of intra- or inter-
crossed 13 pleated sheets. The secondary structural values for the 132M and Af3(l-40) 
and the prion PrPC 
 were similar (37-42% (x helices and 15-18 % 3  sheets). All the A13 
amyloids including the 02M and PrPC 
 prion protein showed a common structural 
feature of f3 sheets. The amyloid deposits in Alzheimer's disease [94 & 1001, in the 
13 2M [164 & 165], and the prion PrPW [50, 196, 198 & 201], all have predominantly 
13 sheet structures (>50 %). The A13 extract was shown to contain A13(l-40) from the 
immunoblot assay but may also contain A13(1-42). It was shown to consist of a greater 
degree of 0 sheets than the AJ3(l-40) or Af3(l-42) indicating that it could be an 
aggregated state. All the amyloids undergo a conformational change to adopt a new 
amyloidogenic conformation [318]. The P sheet formation and aggregation are closely 
coupled events that are difficult to separate suggesting that the transition to 13 sheets is 
critical for amyloid formation. 
8.2 Metals as a possible trigger factor for amyloidosis. 
A large number of studies of metal interaction and A13 have shown that metals can 
induce aggregations of amyloid [332], others have suggested that the aggregation of 
amyloid may be accelerated by various metals [372]. In the present study, the addition 
of copper, zinc, calcium and aluminium (>100 jiM) to the amyloid proteins, in 
particular the A13(1-40) and 02M, showed some changes with a general decrease in a 
helix and an increase in P sheet. The CD and ATR spectrum of A13(l-40) amyloid 
protein treated with copper or zinc (10, 50 &lOO j.tM) showed a shift from the a helix 
to the P sheet and that these effects in both copper and zinc were concentration 
dependent. There was no additive effect from the addition of combined copper and 
zinc, which may indicate competition for binding sites. The addition of aluminium 
(50, 150, 300 & 400 jiM) was shown to have a concentration dependent effect on both 
the A13(1-40) and f32M peptides as seen with an overall increase in 13 sheet and a 
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corresponding decrease in a helix. The changes with the 132M peptide were smaller 
than that of the AJ3(l-40) peptide. 
Aluminium (I mM) caused the aggregation of both A(l-40) and 02M as seen by a 
smearing of the bands of the SDS PAGE indicating the formation of dimers and 
oligomers. Feint high molecular weight bands that were observed near the top of the 
gel for the 32M treated with aluminium, which may relate to high molecular weight 
132M aggregates. Two distinct bands corresponding to the monomer and the dimer 
were observed with aluminium treated 02M under non-denaturing conditions. 
Addition of a high concentration of silicate abolished this higher molecular weight 
band with a reversion back to the monomer. In the CD, addition of Si0 44 (300 MM) 
before the aluminium (300 MM) had the effect of reversing the changes in secondary 
structure caused by A1 3 
 for both the A(l-40) and 32M. Silicon may have no direct 
biological function other than to reduce the bioavailability of aluminium by the 
formation of a hydroxyaluminosilicates [279 & 3731. This property could be exploited 
as a therapeutic agent to reduce aluminium levels. 
It may be argued that the concentrations of metals needed to elicit the above changes 
do not relate to physiological concentrations. The fact that the GAGs combined with 
physiological concentrations of metals enhanced this interaction, suggests that they 
could play a role in conjunction with metals. There has been considerable controversy 
as to the concentration of metals, such as zinc, that are required for AO aggregation 
[209 & 374]. Because the behaviour of A13 is highly dependent on its concentration, 
and the concentration of the metals, the results can be viewed in two respects; the 
concentrations used can be extrapolated back to physiological concentrations or the 
levels represent an accumulated concentration from chronic exposure to low levels of 
metals in vivo [94]. 
Rapid, pH-sensitive aggregation has been shown to occur at low nanomolar 
concentrations of both AJ3(l-40) and A13(l-42)  with sub-micromolar concentrations of 
Cu2 [334] and Zn 2 [331 & 334]. The concentration of Cu 2 required for A13 
aggregation (-5 MM) [334] is well within the concentration range for copper found in 
the synapse (--15 MM) [375]. Concentrations of 25 jiM or less of zinc are able to cause 
the aggregation of amyloid fi protein [331]. Extrapolation to physiological 
concentrations (10 - M) from data gathered at >106 
 M, indirectly indicates that Zn 2 
[334 & 3351, and Cu2 [334] at physiologically relevant concentrations will also cause 
aggregation of A13 
High concentrations (0.15 to >3001iM) of zinc have been found in neurons in regions 
of the brain that are vulnerable in AD such as the cortex and the hippocampus during 
neurotransmission in the hippocampus up to 300 RM Zn 2 is released into the 
extracellular space [252 & 257]. This increase in zinc levels may be sufficient to 
induce aggregation of A13.  Although aluminium salts have been shown to precipitate 
soluble A13  in vitro [289, 314, 320, 351 & 353], the concentrations of aluminium 
(> 50 RM) required to precipitate Aji are far above those that are physiologically 
possible [331]. However, accumulation of aluminium from long term exposure to low 
levels of aluminium could increase the risk for premature amyloid deposition [94]. 
8.2.1 Metal binding sites in amyloids. 
Although the mechanisms of aluminium interaction are still unclear, it has been 
shown that aluminium directly binds to the peptide and changes its conformation 
[289], and that silicate can reverse both the binding and conformational changes 
[320]. The capacity of aluminium to form polynuclear species acting as cross-linkers 
may play a role [376]. AP has six acidic amino acids that may be involved in metal 
binding [377]. At least two classes of metal binding site on A13  exist; a Cu2 /Ni 2 site 
that is responsible for significant Au  assembly only under mildly acidic (pH 6.6-7.0) 
conditions and a Zn 2 /Co2 site that mediates significant AP assembly at pH 7.4 
[334]. The binding of metal ions with exposed binding sites resulting in a change in 
the protein structure. They could facilitate aggregation of amyloid filaments through 
cross-links, or seeding of amorphous amyloid into fibrils. Common metal binding 
sites may lead to an overall mechanism in the amyloidogenesis of these proteins. 
Evidence of copper interaction with Af3(l-40) was first observed by the stabilisation 
of an apparent A13(1-40)  dimer by Cu 2 on gel chromatography [331]. Copper is also 
able to displace 65 Zn 2 from AJ3 when co-incubated with excess Cu 2 [319] 
Subsequently aggregated A13  was shown to exhibit multiple specific binding sites for 
FM 
Cu2 
 presented as a chelate, with both low and high binding affinity sites on At 3 ( 1-40) 
(0.025-I nM and 16-40 nM) respectively. The stoichiometry of Cu 2 binding to 
soluble A13 was <= I, but it increased upon aggregation to 3 at both p1-i 7.4 and 6.6 
[334]. Zinc also specifically and saturably binds AJ3 itself, manifesting high binding 
affinity (K = 107 nM) with a 1:1 (zinc:A) stoichiometry and a lower affinity 
binding of (Kr,ssoc 
 = 3.2-5.2 jiM) with a 2:1 stoichiometry [331 & 320]. Zinc binding is 
histidine mediated [334] and has been mapped to a stretch of contiguous residues 
between positions 6 and 28 of the AP sequence [331]. Iminodiacetate (IDA) - Zn 2 
affinity columns retain A(1-40) at a pH of 7.0 and suggests that histidine (pKa —6.6) 
residues are involved in this binding. [378]. Zinc binding to A13  at the 16 Lysine 
position inhibits the a-secretase proteolysis leading to abnormal proteolysis [331]. 
8.2.2 Evidence for a histidine binding site. 
The mechanism of AJ3 modification appears to involve the oxidation of histidine, 
tyrosine, and methionine residues [379]. The 02M contains six tyrosine residues, all 
located within the two 13 sheets of the immunoglobulin sandwich structure [168]. 
Tryptophan, tyrosine and methionine residues are likely to be important in the protein 
folding of 02M [163]. The histidine, tyrosine, and methionine residues are associated 
with metal ion binding to amyloids [334]. One or more histidines are probably 
involved in binding [334 & 380] and they appear to be between residues 6 and 28 of 
the A13 sequence [331]. The metal is likely to co-ordinate to histidine at position 13 
and tyrosine at position 10 and may direct the aggregation of A13(l-40)  [381]. Similar 
A0 amyloid deposits has been detected in aged monkeys, dogs, and polar bears [383], 
but rarely have they been found in rats and mice [384]. Cerebral A1 3  deposition is not 
a feature of aged rats [385]. The rat A13 lacks the single tyrosine and one of the three 
histidine residues of human A0 (Arg-5, Tyr-lO and His-13 modifications). The rat A13 
and a histidine-modified human A13 were not aggregated by Zn 2t Cu2t or Fe3t 
indicating that histidine residues are essential for metal-mediated A13 assembly [386]. 
The modulation of Af3 aggregation is commonly regulated through the affinities of 
many neurochemical factors such as zinc, copper, transthyretin, apolipoprotein E, and 
pH for the histidine residues of Au [334]. Both the rate and the extent of assembly are 
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much higher at lower pH in comparison with pH 7.4. Based on its measured 
isoelectric point A13 (l -40) has a zero overall charge at a pH of 7.1 ± 0.2, based on its 
measured isoelectric point [243]. The loss if solubility at a pH of approximately 7.2 is 
consistent with the experimentally determined isoelectric point. The amphiphilic 
nature of the residues in a peptide is essential to the secondary structural conformation 
and the solubility of the protein [382]. Histidine has a pKa near neutrality and 
frequently serves as a controllable element of protein conformation, so slight changes 
in pH close to physiological conditions may protonate or deprotonate some or all of 
the histidines, altering the conformation or solubility of a protein [243]. It may be 
significant that abrupt change in solubility with pH occurs close to physiological pH. 
At pH values above the isoelectric point, some of the three histidine residues of Af3( 1-
40) are deprotonated. 
8.3 GAGs as a possible trigger factor for amyloidosis. 
The current work showed that 32M and A(1-40) peptides did not appear to undergo 
any significant conformational change on binding suiphates and GAGs when analysed 
by CD, ATR-FTJR and SDS PAGE. Even if sulphate did not influence fibrillogenesis 
via conformation changes, binding of the GAGs could provide high-affinity binding 
ligands that could then bind other factors such as metal ions. They may; (i) initiate 
fibrillogenesis by promoting amyloidogenic protein conformation and structural 
transitions [107, 118 & 387]; (ii) enhance the stability of pre-formed fibrils [55, 354, 
388 & 389]; (iii) decrease amyloid susceptibility to proteolysis; and (iv) direct the 
anatomical distribution of amyloid deposition. 
Highly sulphated glycosaminoglycans and proteoglycans are common constituents of 
amyloid deposits. Immunohistochemical localisation of GAGs to regions containing 
neurofibrillary tangles [390], diffuse [391] and senile plaques have been reported 
[392]. Heparan sulphate, keratan sulphate, dermatan sulphate and chondroitin sulphate 
are associated with AD senile plaques and neurofibrillary tangles [393 - 395] and with 
articular connective tissue where P2M  amyloid is most often found [396 - 398]. An 
unusual feature of the fibrils of haemodialysis-associated amyloid is the presence of a 
peripheral layer composed of chondroitin sulphate proteoglycan (CSPG) rather than 
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of HSPG. CSPG is not tightly bound to the 132M amyloid fibrils themselves, but may 
be involved in regulation of the amyloid deposition [372]. Abnormally high levels of 
HSPG are also associated with most types of PrP pathology including all plaque types 
and diffuse neuro-anatomically targeted forms [56, 399 & 400]. 
The presence of HSPG or other GAGs in a range of amyloids [57 & 389] suggests a 
common function or role [55]. It is unclear when GAG involvement with amyloid 
begins, although the association of HSPG with early diffuse A13 plaque in the brains 
of young Down's syndrome patients suggests an early role [315 & 392]. In the latter 
stages of the amyloid pathway, GAGs may act by enhancing lateral aggregation of 
small fibrils. The acceleration of fibril formation induced by GAG-A13 binding [54, 
354, 387 & 389] may be particularly relevant at low nanomolar A13  concentrations 
found in vivo where the nucleation lag is predicted to be extremely slow. 
8.4 The interaction of both GAGs and metals with amyloids. 
It appears that the GAGs do not illicit any confoi -mational change on their own but 
can have a synergistic effect when combined with either Zn 2 , Cu2 , A1 3 or Ca2 at 
physiological concentrations. Both the A13(l-40)  and P2M  peptides treated with 
physiological concentration of A1 3 combined with the GAGs showed that they had a 
synergistic effect. Neither the GAGs nor the A1 3 (1.5 piM) on their own cause an 
appreciable change in the secondary structure. Similar effects were also seen with 
Cu2 and Zn2 (10 jiM), although the Cu 2 and Zn 2 initially alter the peptides at the 
concentrations used. These changes seemed independent of the type of GAG, which 
may suggest that it is the highly negatively charged sulphate groups on the GAGs that 
may exacerbate this interaction. 
The importance of the sulphate groups in AP aggregation has been confirmed by a 
decrease in Af3 fibril formation in the presence of de-suiphated heparan sulphate 
[392]. Chondroitin suiphates are suiphated on a single face of the polymer and may 
represent an ideal distribution of sulphate groups for Af3 interactions [334]. GAGs 
possess substitucnt groups, which permits complex co-ordination and chelation of a 
range of inorganic and organic cations. Several cation-heparin interactions putatively 
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affecting the activities of either or both of the participants have been described. Zinc 
binds to heparin more readily than to other glycosaminoglycans [401] and such 
binding may have a role in A13 deposition. Other metals that have high binding 
affinities with the GAGs [401] such as copper and aluminium may have similar 
effects on these amyloids. 
The amyloidogenic peptides have been demonstrated to show a variation in their 
ability to interact with GAGs. In the present study, GAGs with calcium seemed to 
have interactions with the amyloids dependent on the type of GAG. The ability of 
GAGs to induce an amyloid-related structural transition may reflect variation in 
binding specificity of the GAGs to the amyloids and the metals to the GAGs. For 
example, the nucleation of Af3( 1-42) is greater for heparan sulphate at pH 7.0 than for 
heparin, though heparin is more highly charged than heparan sulphate. Heparin shows 
a higher binding activity compared with heparan sulphate [402], but both are known 
to have tighter binding properties compared to other GAGs [373 & 403]. 
Heparan sulphate with Serum AA causes an increase in its 0 sheet configuration [147 
& 404]. Although serum amyloid A (SAA) analogues bind to both heparan and 
chondroitin sulphate, the effects on the SAA secondary structure vary greatly [59]. It 
may be that certain metals have different binding affinities with the various GAGs 
[401]. Zinc partially activates the binding serum amyloid protein (SAP) whilst other 
cations (Ba2t Mg2 , Mn2 , Fe2 , Fe3t and A1 3 ) are ineffective [406]. 
In the CD study, certain combinations of GAGs with calcium further decreased the a 
helices and increased the 0 sheet secondary structures of the A13(l-40) and P210, 
indicating that these combinations enhance the effects of Ca 2t The A13(1-40)  with 
either HSPG and CS combined with calcium caused further decreases in a helices 
compared to Ca2 but only the CS and Ca 2 caused a further increase in 0 sheets. The 
132M treated with the combinations of HSPG, CS, KS or HS and calcium further 
enhanced the changes compared to calcium with a decrease in the a helices and an 
increase in the 3 sheets. Heparan sulphate in the presence of calcium has been found 
to increase the 3  sheet structures of certain amyloids [114]. Ca 2 and GAGs have been 
shown to cause changes in the secondary structure of mouse SAA, which is an acute 
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phase protein precursor of the AA amyloid [59]. This increase in 0 sheets caused by 
HSwith Ca2 was only detected at high concentration of Ca 2 (1-2 mM) [59]. SAP in 
affected vessels, bind in a calcium dependent manner, to amyloid fibrils and heparan 
sulphate, dermatan sulphate and heparan sulphate proteoglycans [405] but it is unclear 
if this is important for fibril formation. SAP is also seen to self aggregate in calcium 
free solutions, and forms small aggregates in 2 mM calcium and at 25 mM calcium, 
forms larger crystalline aggregates [406]. It has been reported that SAP has 2 calcium 
binding sites on each subunit and that 2 calcium ions form the binding site for the 
known ligands such as 0 D-galactose [405]. 
Most notably in both the CD and AIR studies, the treatment of the A13( 1-40) peptide 
with combinations of heparin, HS, and Na2504 with calcium, appears to reverse the 
effect of calcium on its own with increases in the a helices and decreases in the 13 
sheets. Since P sheets are a pre-requisite for aggregation, then this also indicates that 
addition of heparin/heparan sulphate with the calcium prevents aggregation due to 
calcium itself. A similar phenomena was seen with calcium induced aggregation of 
SAP. One study showed that SAP aggregation was enhanced by calcium but on 
addition of heparin or heparan sulphate to SAP before calcium completely prevented 
formation of aggregation but distribution of SAP fibrils was not evenly spread [406]. 
Serum amyloid P component plays a crucial role in amyloid fibril formation, directly 
influencing either the processing of a precursor proteins or protein folding rather than 
being deposited coincidentally as an innocent bystander [407]. Since SAP is an 
integral component of the amyloid deposits, metal interaction with or without the 
presence of GAGs could be important in the amyloidogenic process. 
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8.5 Conclusions. 
The main aspects of the work presented in this thesis are highlighted below: 
1. The novel use of ATR-FTIR for the analysis of metals with amyloids, and the use 
of CD for the detection of the protein secondary structure of amyloids treated with 
both metals and GAGs. 
2. The present study indicates that metals may be involved in the amyloidogenesis of 
Af3 and 132M amyloid. A change in the secondary structure of the amyloids 
A13 ( 1-40) and 32M with both metals and GAGs has been demonstrated. 
3. There are many studies in the literature relating to the involvement of metals in 
the deposition A13 peptides, in comparison, there are relatively few for the 32M. 
The results showed that 32M treated with metals displayed similar interactions to 
that of the Afi peptides indicating that similar mechanisms maybe involved. 
4. The interaction of both metals with GAGs as a possible trigger factor has not been 
previously reported. The treatment of metals and GAGs with A( 1-40) or 32M 
shows a synergistic interaction indicating that metals in the presence of GAGs 
may play a role in the amyloidogenic process. 
5. The similarity of the results as seen with both 02M and A13(l -40) suggests similar 
modes of interaction, and hence may lead to mechanisms of amyloid deposition. 
It is clear that conformational changes in amyloidogenic proteins lead to fibril 
formation and aggregation. Several trigger factors may be involved in the initiation 
and propagation of these amyloid deposits. Metals have been shown to induce 
aggregations of both the Af3(1-40) and 02M amyloid in vitro and may accelerate 
amyloid deposition. The binding of GAGs could provide an anchor for the assembly 
of the fibrils. The high-affinity binding sites on the GAGs could then bind other 
factors such as metal ions altering the conformation of the peptide leading to 
aggregation and deposition. A transition from a helix to 0 sheet structures is critical 
for amyloid formation. The fact that similar changes occurred for the interaction of 
metals and GAGs with both the Af3(l-40) and f32M, suggest that similar mechanisms 
may be involved. Therefore, a mechanism for this conversion to P sheet secondary 
structures may provide an insight into the deposition of amyloid. 
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8.6 Future work. 
Possible future work could include: 
I. A trace element survey to determine an empirical link between metal levels and 
disease state. A study of trace element levels in tissues in which amyloid is 
deposited from various amyloid diseases. A more extensive study to include other 
organs and tissues to identify an overall change in element status of an individual. 
Emphasis on the disease state, tissue location, other factors such as diet, age, 
gender etc should be taken into account as these can affect metal levels. 
2. Further development of the ion chromatography system to enable the detection of 
metals at physiological levels. A rapid and simple method should be adopted to 
avoid contamination and sample degradation. Other methods of metal detection 
should be used to enable comparison of results. Techniques such as inductively 
coupled plasma spectrometry and graphite furnace atomic absorption spectroscopy 
could be employed. Although sample size and detection limits will be a 
controlling factor in sensitivity with ICPOES. 
3. Further CD studies of amyloid proteins and metals including the use of other 
amyloids, to elucidate a common mechanism of metal interaction and amyloid 
deposition. The use of other amyloid fragments and other factors such as serum 
amyloid P component and amyloid enhancing factor should be investigated. A 
study of metals with the amyloid precursor proteins should determine whether 
metals interact at this early stage of the deposition process. 
4. The combination of ATR-FTIR with deconvolution and curve fitting techniques 
will allow the determination of secondary structural values. Current techniques for 
protein structure analysis include mass spectrometry, CD, FTIR, NMR, peptide 
mapping etc. Many of these techniques could be adopted for the analyses of 
amyloid proteins and with real time analysis. 
5. There are now at least half a dozen mouse transgenic lines that develop one of the 
pathological characteristics of AD, amyloid plaques. An animal model for 
Alzheimer's disease would be extremely useful for basic research and for drug 
development. Therefore, animal models could be used for the investigation of 
amyloid deposition in relation to trace elements. 
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Appendix 
Reagents and their suppliers 
Ammonium sulphate 
Acetic acid 
Acrylamide stock solution 
Aluminium chloride hexahydrate 
Aluminium nitrate nonahydrate 
Alcohol dehydrogenase 
Ammonium acetate 
Ammonium hydroxide 
Ammonium persulfate 
Ampholytes (pH 3-10) 
APP(125-135) 
Atomic absorption standards 
A13 ( 1-40) 
A13(1-43) 
AJ3(25-35) 
A13(l-42) 
02 Microglobulin 
Bisacrylamide stock solutions 
Bovine serum albumin 
Bromophenol blue 
Calcium chloride dihydrate 
Calcium nitrate tetrahydrate 
Carbonic anhydrase, 
Chloroform 
Chondroitin sulphate 
Coomasie Brilliant Blue R250 
Coomasie brilliant blue 0 
Copper chloride dihydrate 
Copper nitrate 
Cytochrome C 
Dermatan sulphate 
Dithiothreitol 
Ethanol 
Filters 0.45 jiM 
Formic acid 
Glucose-6-phosphate 
Glucose-6-phosphate dehydrogenase 
Glutaraldehyde 
Glycerol 
Sigma, UK 
BDH, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Fisher, UK 
Sigma, UK 
MRC Neurochemicalpathology 
Unit, Newcastle, UK. 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
BDH, UK 
Millipore, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
Sigma, UK 
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Glycine Sigma, UK 
Heparan sulphate Sigma, UK 
Heparan sulphate proteogylcan Sigma, UK 
1,1,1,3,3,3 hexafluoroisopropanol Sigma, UK 
Hydrochloric acid BDH, UK 
Iso-butanol Sigma, UK 
Immuno-Blot immunoassay kit (protein G 
- Bio-Rad, UK 
horseradish peroxidase) (Cat no.170-6467) 
Keratan sulphate Sigma, UK 
Lithium hydroxide BDH, UK 
Molecular weight markers (1,060-26,600 kDa) Sigma, UK 
Methanol BDH, UK 
Magnesium chloride hexahydrate Sigma, UK 
Magnesium nitrate hexahydrate Sigma, UK 
NADPH Sigma, UK 
NADP Sigma, UK 
Nickel chloride hexahydrate Sigma, UK 
Nitric acid BDH, UK 
Nitro-cellulose membrane Schleicher & Schuell 
NP-40 Sigma, UK 
Orthophosphoric acid BDH, UK 
Oxalic acid BDH, UK 
4-(2-pyridylazo) resorcinol Dionex, UK 
Phenyl methyl sulphonyl fluoride Sigma, UK 
Recombinant human prion protein Imperial College London, UK 
SDS Sigma, UK 
Sephadex G75, 0150 Sigma, UK 
Sodium carbonate Sigma, UK 
Sodium chloride Sigma, UK 
Sodium Citrate Sigma, UK 
Sodium heparin Sigma, UK 
Sodium hydroxide Sigma, UK 
Sodium metasilicate Sigma, UK 
Sodium sulphate Sigma, UK 
Sulphuric acid BDH, UK 
TEMED Sigma, UK 
Tiron Sigma, UK 
2,2,2-Trifluoroethanol Sigma, UK 
Tris (hydroxymethyl) aminomethane Sigma, UK 
Urea Sigma, UK 
Vitamin B12 Sigma, UK 
Zinc chloride Sigma, UK 
Zinc nitrate hexahydrate Sigma, UK 
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Ion chromatography was used to detect levels of copper and zinc in blood plasma from renal dialysis patients on 
continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis (I-ID). The developed method used cobalt as 
an internal standard and when combined with the standard additions method improved the overall precision of the 
results by between -0.3 and 6-0% and -0.8 and 5.7% for copper and zinc, respectively. The method was 
compared with inductively coupled plasma optical emission spectrometry (ICPOES) and the results indicated no 
significant difference between the two methods with or without an internal standard. Without an internal standard, 
t,,,. was 0,869 with a t. rj, of 2.201 (n = 12, p = 0.05) and with an internal standard, tcatc  was 0.189 compared to 
a tcrjl of 2.201 in = 12, P = 0.05). The copper and zinc levels in blood plasma in both dialysis groups were not 
significantly different to the copper and zinc levels in blood plasma of the control patients. A convenient method 
of analysis of trace elements in blood such as ion chromatography with UV/VIS detection is useful for 
determining whether inorganic elements may be disrupted in the body due to changes in the state of health. 
Introduction 
The trace elements copper and zinc serve chiefly as key 
components of proteins and of enzyme systems in the human 
body and are vital for their proper functions.' Zinc is involved 
in the synthesis of nucleic acids and proteins and is necessary 
for growth.' The majority of these enzymes act as antioxidants 
in biological systems [e.g.. Cu, Zn in superoxide dismutase 
(SOD) and Cu in caeruloplasmin]. Deficiencies or excess of the 
trace elements may have a detrimental effect on the function of 
these enzymes. 23 Levels of many trace elements are disturbed 
in various diseases, e.g., abnormal levels of copper and zinc 
have been found in patients on renal dialysis, 44 lowered copper 
levels are associated with Wilson's disease and hypocupremia is 
observed with leukaemia and with a number of acute diseases. 
The detection of trace elements in blood is an important 
factor for determining any disruption in trace element status of 
the body. The method used to determine elemental levels needs 
10 be sensitive enough to detect the amounts present in blood 
(levels of Cu and Zn - I mg dm -3 ) in an all too often limited 
sample volume. 3 Analysis of trace elements in biological 
samples requires: precise and accurate separation of the analyte 
from the bulk matrix for some measurements, a suitable means 
of detection which is of the appropriate sensitivity and to be free 
of contamination. Careful consideration of factors such as diet 
and disease state are critical in the assessment of the results 
before any conclusions can be made about cause-effect 
relationships for the disruption of metal status. 3 
Atomic absorption spectrometry (AAS) is widely used for the 
detection of many elements. Techniques such as flame atomic 
absorption spectrometry (FAAS) and electrothermal atomic 
absorption spectrometry (ETAAS) are suitable for the detection 
of Zn and Cu in blood serum and plasma. With the development 
of such routine methods often samples only require dilution. 9 
Detection limits for flame AAS have been reported to be as low 
as 9.4 tg dm -3 for zinc 10 and 0.2 pig dm 3 for copper when 
preconcentration techniques have been employed.'' Detection  
limits for ETAAS are typically 0.4 pig dm -3 and 0.1 pig dm 3 
for Cu 12 and Zn, 13 respectively. However, for most of the AAS 
techniques, only one element can be determined at a time in 
many routine laboratories, although the relatively new Perkin-
Elmer SIMAA 6000 method of simultaneous multi-element 
ETAAS is able to detect up to six elements with the same 
detection limits as conventional ETAAS analysis due to the 
very low noise of the solid-state detector.' 4 Inductively coupled 
plasma optical emission spectrometry (ICP-OES) and mass 
spectrometry (ICP.MS) can be used in the direct analysis of 
biological fluids. The advantages include simultaneous detec-
tion of several elements in the one sample and its ability to 
overcome matrix interferences.' 5 The sample is efficiently 
desolvated. vaporised. excited and ionised. Many chemical 
interferences are greatly reduced by the high temperature of 
7000-8000 °C. Typical levels of detection range from <0.5 to 
100 mg dm -3 for most metals. One of the major advantages of 
ICP-MS over ICP-OES is a three orders of magnitude higher 
sensitivity for metal detection although there may be problems 
due to the matrix. 15 Ion chromatography has been increasingly 
used for the determination of metals and is becoming an 
alternative to conventional spectrometric methods)6.17  The 
main advantage is that multiple elements can be simultaneously 
determined in one sample using similar sample pre-treatment 
methods. Ion chromatography can separate a mixture of ions by 
their net charge according to the principles of ion exchange. 
Several detection methods are available including conductance 
and detection by UV by the use of a post column derivatisation 
reagent. Ion chromatography is suitable for small sample 
volumes, with injection volumes of 25 pil per analysis. 
Detection limits of less than 13 pig dm 3 have been reported by 
a number of workers 1819 
The current study involved the development of an ion 
chromatography (IC) method which would enable the determi-
nation of copper and zinc in the same aliquot of a sample. The 
final method made use of a cobalt internal standard which was 
used to minimise errors due to sample loading and fluctuations, 
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which occurred during the running of the column. The peak area 
results for the copper and zinc peaks were expressed as a ratio 
of the peak area result from the cobalt peak. Hence, if a varied 
volume of sample was injected or there was a variation in the 
flow rate of the mobile phase or the detector did not respond in 
a uniform manner throughout all the chromatography runs, then 
the results could still be used. The cobalt peak would be affected 
in the same manner as the copper and zinc peaks and so the ratio 
of the peak areas would remain the same although the raw peak 
area data values would change according to the inconsistencies 
within the instrument. Hence the use of an internal standard in 
analyses allows the use of data which may otherwise be deemed 
worthless. The method of standard additions was also used. To 
test the developed method a number of blood plasma samples 
from patients on haemodialysis (liD) and continuous ambula-
tory peritoneal dialysis (CARD) as well as control samples were 
analysed. 
Materials and methods 
Specimens 
Blood samples from eight renal dialysis patients, four on HD 
and four on CARD, plus four control samples were obtained 
from the Royal Preston Hospital, The blood samples were 
collected from patients on renal dialysis in S-Monovette LU-
Metall-Analytik tubes (Sarstedt Ltd., Leicester, UK) which 
contained lithium—heparin as an anticoagulant. These tubes are 
recommended by the suppliers for the collection of blood 
plasma which is to be analysed for analytes such as copper, zinc. 
lead, manganese. cadmium, iron, aluminium, nickel, selenium. 
chromium and mercury. The plasma was removed from the 
blood sample by centrifugation and the samples stored in the 
refrigerator at 4 °C before use. The time between sample 
collection and centrifugation was between 1-2 h because of the 
staggered collection time on the hospital ward. The dialysis 
subjects ranged in age (35-60 years) and in the number of years 
that they had received dialysis (2-25 years) (Table I). The 
control samples were age matched where possible. 
Reagents 
All chemicals were of analytical-reagent grade and where 
possible all analyses were carried out in plasticware to reduce 
the risk of contamination during storage, transport and analysis. 
All containers were acid washed by soaking in 10% nitric acid 
(BDFI-Merck, Poole, Dorset, UK) overnight and then in 
deionised water (Barnstead E-Pure, Fisons, Loughborough, 
Leicestershire, UK, 17.6 mQ cm_t)  overnight. Stock standard 
solutions containing 1000mg dm 3 of copper, zinc and cobalt 
were diluted to 5 mg dm 3 working solutions. All these 
solutions were prepared daily from copper, zinc and cobalt 
atomic absorption spectrometric standards (Fisher, Lough-
borough. Leicestershire, UK). 
Table t Details of the patient sample used in each dialysis and control 
group 
Dialysis 	 Years on 	 Years on 
type 	 Male 	 dialysis 	 Female 	 dialysisysis 
CAPD 	 38 I 50 	 2 
73 10 52 	 II 
I-ID 	 54 I 33 	 3 
70 4 52 
Control 	 34 N/A 69 	 N/A 
50 N/A 
61 N/A 
Instrumentation 
A I cm3 sample of the blood plasma sample was digested with 
70% rittric acid in a ratio of 1:3 in pressure sealed Teflon bombs 
(150 cm3 CEM, Buckingham, UK). An MDS SD microwave 
(CEM) was used at 70% power for a total of 60 min in 3 X 20 
min periods allowing the samples to cool for 10 min between 
each 20 min period. The digested material was diluted to 10cm 3 
with deionised water. For the standard additions method, four 1 
cm 3 aliquots of the plasma digest were spiked with increasing 
amounts of copper (0, 0.2, 0.4. 0.8 cm 3 from the working 
solution) and zinc (0, 0.2, 0.4, 0.8 cm 3 from the working 
solution). A 0.6mg dm 3 cobalt internal standard (0.6 cm 3 from 
the working solution) was also added to each sample. The 
solutions were made up to 5 cm 3 with deionised water. 
Measurements were performed in triplicate on a Dionex 
DX500 ion chromatography system. A 25cm HPIC-CSS cation 
exchange column (Dionex. Camberley. Surrey, UK) with a 5cm 
HPIC-CG5 guard column (Dionex) and a 25 r1 sample loop was 
used. The column packing consisted of a cross-linked styrene 
and vinylbenzene polymer with sulfonic functional groups. The 
eluent was 50mM oxalic acid and 95 mM lithium hydroxide at 
pH 4.8 (BDH-Merck) at a flow rate of 1 cm 3 min'. The post-
column reagent used was 0.3 mM 4-(2-pyridylazo) resorcinol 
(PAR) (Dionex) in I M acetic acid and 3 M ammonium 
hydroxide solution at a flow rate of 0.7 cm 3 mm — '. The 
detection was at 520 nm using a Dionex A20 absorbance 
detector (Dionex). 
An inductively coupled plasma optical emission spectrome-
ter (ICP-OES) (Spectro, 1-lalesowen, Worcestershire, UK, 
Analytical Model I') was used to detect copper and zinc. Copper 
was detected at 324.8 nm and zinc at 213.9 nm. The sample was 
introduced into the plasma at a flow rate of I cm 3 mir' through 
silicone tubing via a peristaltic pump. Five replicate measure-
ments were made and approximately 0.5 cm 3 of sample was 
required per sample. The system was flushed with deionised 
water between individual solutions. 
Result.s and discussion 
Copper, zinc and cobalt were easily separated by ion chroma-
tography with elution times of 2.9. 4.8 and 6.6 mm, re-
spectively, as shown in Fig 1. With the oxalate eluent used it is 
reported that only cations lead, copper, zinc, manganese, cobalt, 
cadmium and nickel are detected. It was hypothesised that either 
iron(Il) or iron(ttt) may interfere with the analysis of zinc or 
copper but preliminary experiments suggested that this was out 
the case. The cobalt internal standard was subjected to the same 
conditions as the sample, hence any fluctuations in the running 
conditions would be eliminated by plotting the absorbance ratio 
between copper and cobalt against the concentration of spiked 
copper. Similarly for zinc, the absorbance ratio between zinc 
0 90000 
j40000 
30000 
0 	 I 	 2 	 3 	 4 	 5 	 6 	 7 
Time/mm 
Hg. I Chromatograms of spiked blood plasma. Copper, cobalt and zinc 
eluted at 2.9. 4.8 and 6.6 mm, respectively. Each of the three samples was 
spiked with cobalt (0.6 mg dm 3) and with increasing concentrations of 
copper and zinc (0. 0.4, 0.8 mg dir'). 
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t thCO ratio for standards 
2 1 	
. Qrco ratio for plasma 
0.5 
(b) 
and cobalt against the concentration of spiked zinc was plotted. 
By using cobalt as an internal standard it is suggested that the 
ratio of the analyte to the internal standard provides a more 
accurate determination than the use of the analyte response 
alone. The precision was further improved by combining the 
internal standard method with the method of standard additions. 
This produced an overall improvement in the correlation 
coefficient of between -0.3 and 6% for copper and between 
-0.8 and 5.7% for zinc (Fig. 2 and Table 2). For this method to 
be reliable, the chosen internal standard must be well separated 
from the components but must appear close to the peaks of 
interest. Cobalt can be used as an internal standard as it is found 
in serum at very low levels (<0.05 lAg dm 3),' well below the 
detection limit of IC with VIS detection and ICP-OES. The 
detection limit was calculated as three times the signal to noise 
ratio. The signal to noise ratio was calculated by measuring the 
concentration of the baseline noise in comparison with a peak of 
a 0.5 rng dm 3 
 sample of the analyte. The detection Limits were 
calculated as 0.09 mg dm -3 for Cu and 0.03 mg dm for 
Zn. 
The results obtained from the ion chromatography analysis 
were validated by comparing the results with those obtained 
from ICP-OES. The I-test (at 95% confidence limit) revealed no 
significant differences between the values obtained by the two 
methods. There was reasonable agreement between both 
methods, although more samples would indicate if a better 
correlation was possible. The correlation coefficient for copper 
was 0.88 with an equation ofy = I .04x - 0.019 In = 12) (Fig. 
3) and the con -elation coefficient for zinc was 0.89 with an 
equation ofy = 1.08 .v - 0.022 (ii = 12). A Bland-Altman plot 
is where the difference between the results from the two 
methods is expressed as a percentage of the mean of the two 
results for each sample, plotted against the mean concentration 
of the two measurements. If there is no systematic difference in 
the results from the two techniques then the data points would 
oscillate about the zero line on the y-axis. The Bland-Altman 
(a) 
500000 1 	 . copper standards 
t 4000001 
C 
i-i 
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l000c 
0 	 02 	 0.4 	 0.6 	 0.6 
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400000 	 A Plasm tue 
300000 - 
I Hi, < 200000. 100000 
-, 
0 	 01 	 0,4 	 0.6 	 0.8 
COnc.ntrstjon/mg dnf  
	
0 	 0.2 	 0.4 	 0.6 	 0.8 
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2.5 	 d) 
* 	 A Zn.Co ratio for pfasn 
2 
11,5 
i 
01 
05!. 
021 - - - -- - 
	
0 	 0.2 	 0.4 	 0.6 	 0.8 
Conc.ntration/rng dm" 
Fig. 2 Comparison of calibration and standard addition graphs of plasma from one haeniodialysis patient (tin Table 2) for Cu (a) and (b)l and Zn ((c) and 
(d)1 with [(b) and (d)] and without f(a) and (c)1 the use of an internal standard. 
Table 2 Comparison of the correlation coefficient for each patient group when samples were analysed with and without an internal standard (IS). Results 
marked (1 correspond to data presented in Fig. 2 
Copper 	 Zinc 
Dialysis 	 Improve. 	 Improve- 
type 	 No IS 	 With IS 	 ment (%) 
	
No IS 	 With IS 	 ment (9b) 
CAPD 0.917 0.976 6.05 0.951 0.943 -0.83 
0.922 0.954 3.35 0.907 0.951 4.64 
0.944 0.991 4.76 0.950 0.977 2.70 
0.954 0.991 3.75 0.921 0.976 5.64 
MD 0.923 0.943 2.14 0.945 0.954 0.93 
0.943 0.951 0.82 0.928 0.932 0.43 
0.951 0.977 2.61 0.897 0.942 4.78 
* 0.925 0.976 5.23 0.922 0.951 3.05 
Control 0-931 0.954 2.41 0.944 0.977 3.33 
0.921 0.932 1.18 0.954 0976 2.25 
0.945 0.942 -0.33 0.932 0.954 2.31 
0.914 0.951 189 0.934 0.991 5.77 
Average 2.98 ± 1.89 2.92 ± 2.07 
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plot is used as Pollock eral. 20 
 suggested it to be more sensitive 
to potential bias within techniques than the standard regression 
techniques which can be used. In Fig. 4 if the difference 
between the results is 10%, this represents that one of the results 
is 1.1 times the value of the other, if the difference is 66%, then 
one result is twice the other and if the difference is 100%, one 
result is three times the other. Using the results from this work 
the Bland-Altman plot (Fig. 4) demonstrates that there is an 
overall positive bias for both copper and zinc of 0.006 mg dm' 3 
(0.35%) and 0.128 mg dm 3 (7.07%). respectively. This 
suggests that the results for zinc obtained from the ICP-OES 
method are higher than those obtained with IC-VIS analysis. 
This could result from matrix effects in either the IC-VIS or 
ICP-OES methods. Teixeira Cr a/. 21  reported that the use of 
ICP-OES for the determination of zinc at low concentrations in 
(I co>ck<s!. 
0.34 	 0.44 	 0.54 	 0.64 	 0.74 	 0.84 
Mean of IC.VtS vaIuea/mgdm" 
2 
2.40 
a 
2.00 
.60 
2 1 .20 
0.80 
0 
0.40 
0.40 
	
0.80 	 1.20 	 1.60 	 2.00 	 2.40 
Mean of tC-VIS vatun /mg din" 
Hg.) The correlation between samples run on both ICP-OES and IC-VIS: 
(a) the correlation coefficient for copper values was r = 0.88 and the 
equation of the line is v = 1.04 .r - 0.019 (n = 12); (b) the correlation 
coefficient for zinc was r = 0.89 with an equation of the line y = 1.08 .t - 
0.022 (a = 12). 
matrices containing high concentrations of copper was difficult 
because of the interference by copper in the main emission 
wavelength of zinc at 213.856 nm. 
There were no significant differences in both the copper and 
zinc levels between CAPD patients and HD patients and there 
was no significant difference when dialysis groups were 
compared to the control patients (Tables 3 and 4). It must be 
stressed that these individual values represent the levels of 
copper and zinc indifferent patients and thus the concentrations 
of copper and zinc may vary from patient to patient due to 
factors such as sex, age, and time on dialysis. The normal range 
for copper in serum is 0.8-1.5mg dm 3 and for zinc it is 0.6 
-1.3 mg dm 3 . Overall, the average control copper levels were 
lower than the normal levels expected in the blood. The 
measured copper concentration for this study was 0.501 ± 0.05 
mg dm 3 for copper and was 1.350 ± 0.05 mg dm 3 for zinc in 
the control samples. This paper is concerned with the develop-
ment of an alternative analytical method to conventional 
spectrometric methods for the determination of copper and zinc 
in biological samples and as such the levels of copper and zinc 
reported in this study should not be used exclusively as the 
measured concentration of the zinc in the samples was probably 
affected by the lapse time between collection and centrifugation 
as suggested by English and Hambridge. 12 They reported that 
2) 0 
20 0 
25 A 00 
0 A 
____.___.S_. ___ ..__................_. - 	 - 0 
o 
8 	 4copper 
a 	 ozrnc 
-15 0 Moan of data 
0.0 	 0.5 	 1.0 	 1.5 	 2.0 	 2.5 
Mean of the two methods, tC-VIS and ICP-OES /mg dm' 
Fig. 4 The Bland-Altman plots for copper and zinc which compares the 
two methods IC-VIS and ICP-OES. The plots show a small positive bias 
indicating that the results obtained with ICP-OES are higher than those 
obtained using IC-VIS. 
0,84 
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Table 3 Concentrationsofcopperaod zinc in acid digested blood plasma as detected by ion chromatography with VIS detection using the standard additions 
method with a cobalt internal standard and with ICP.OES 
Copper/mg dm 
	
Zinc/mg dni" 
Dialysis 
Method 	 type (a = 4) 	 Average 	 Range 	 Average 	 Range 
lC.VtS 	 Control 0.501 ± 0.05 0.45-0.67 1.350±0.05 0.73-1.83 
CAPD 0.549 ± 0.05 0.33-0.68 1.576 ± 0.06 0.89-1.95 
RD 0.594 ± 0.05 0.46-0.78 1.348 ± 0.06 0.98-1.79 
ICP-OES 	 Control 0.534 ± 0.03 0.31-0.62 1.417 ± 0.02 0.79-1.95 
CArD 0.597 ± 0.02 0.51-0.70 1.789 ± 0.03 0.91-2.28 
HD 0.575 ± 0.02 0.43-0.73 1.481 ± 0.02 0.93-2.02 
Table 4 One tailed I-test for unequal variances was used to compare between the means of the dialysis group with the control groups and between the two 
methods (P <0.05) 
Copper 	 Zinc 
Comparison 	 fl 	 44 	 1cnI 	 tcak 	 610 
IC-VIS (with IS) vs. tCP-OES 12 0.189 2.201 0.265 2.201 
IC-VIS (no IS) vs. lCP-OES 12 0.869 2,201 1.170 1201 
CAPD is, control 4 0.448 3.182 0.747 3.182 
I-ID vs. control 4 0.938 3.182 0.007 3.182 
CAPD vs. HD 4 0.427 3.182 0.747 3.182 
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the level of Zn determined in plasma and serum increased by 6% 
for the first 2 h after collection which was thought to be 
attributed to the release of some erythrocyte membrane zinc. A 
similar effect was not found for copper. 
Many factors are involved in determining blood and tissue 
levels of individual elements in patients with renal failure. The 
processes involved in renal disease itself can result in either 
excretion or retention of individual elements whilst dialysis 
treatment can cause either removal or exposure to these 
elements. Trace metal disruption causes chronic renal in-
sufficiency in dialysis patients that have been studied but many 
of these studies are contradictory due to different techniques 
that have been used. For instance, copper levels have shown 
conflicting results with high, low and normal levels with some 
evidence that the levels increase with age and the female sex but 
not with dialysis duration. Hypozincaemia is also common in 
patients with end stage renal disease and those on dialysis 
(haemodialysis and CAPD). 
In haemodialysis the blood is pumped at 200-400 cm 3 mm — ' 
into an artificial kidney where it is filtered by a semi-permeable 
dialysis membrane against the dialysate solution at a flow of 
500 cm 3 mm', Transfer occurs across the membrane of waste 
products into the dialysate which is drained away. The dialysate 
solution is made from combining a concentrate with a filtered 
and reverse osmosis treated tap water. 
In CAPD the dialysate (typically 2dm 3 ) is introduced into the 
abdominal cavity via a catheter and remains there for 4-6 hours. 
During this time, excess fluid and waste products are transferred 
into the dialysate solution from the blood across the peritoneal 
membrane and subsequently drained out to be replaced by fluid 
dialys ate. 
Dialysis tluid (CAPD, haemodialysis concentrate and reverse 
osmosis treated tap water) has a role in contributing to trace 
element abnormalities in renal patients. Metal contaminants in 
dialysis fluid such as copper and zinc should be eliminated by 
the manufacturing process. Other sources of contamination such 
as dialysate tubing could be a possible source of metal 
contamination. 23 Further factors may he important in determin-
ing blood and tissue levels, in particular the ongoing ageing 
process with poor dietary intake and decreased gastrointestinal 
absorption of zinc, whilst copper absorption in the small 
intestine is facilitated by zinc deficiency owing to the loss of 
absorption competition. 
Ion chromatography is an attractive alternative to the usually 
more conventional spectrometric methods for the determination 
of metals. Ion chromatography offers a more cost effective 
choice as the running expenses of ion chromatography often are 
cheaper than those faced by ICP-OES users. The most obvious 
advantage of this technique is that multiple elements can be 
determined in one sample of 25 R1  volume and complete 
analysis can be performed when coupled with a suitable 
detection system or systems. Generally, the sample requires 
minimal sample pre-treatment. 16 Although it is accepted that 
microwave digestion seems laborious when compared to the 
simple dilution methods used with some atomic spectrometric 
methods, the use of acid digestion to totally breakdown the 
matrix of a sample in order to ensure all the analyte is recovered  
offers its own advantages. The selectivity and peak sharpness in 
IC can be enhanced by the use of complexing agents such as 
PAR for the detection of cations followed by spectrophoto-
metric detection giving a highly sensitive method. The use of 
the standard additions method and of an internal standard can 
improve the precision of the results. 
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